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The mammalian heart is a complex multicellular organ which undergoes many critical 
changes during development and under pathological conditions. Cardiac fibroblasts 
(cFBs) represent the predominant non-myocyte population in the adult heart and play 
essential roles in heart muscle development and homeostasis. The mechanisms how 
cFBs communicate with cardiomyocytes (CMs) in contributing to the formation of a 
cardio-instructive environment remain unclear. In this study, we hypothesized that the 
mechanical and paracrine effects of cFBs and its secreted extracellular matrix (ECM) 
influence cardiac tissue formation and CM maturation. We utilized the 3D Engineered 
Heart Muscle (EHM) model of heart muscle development to investigate the role of 
cFBs in cardiac muscle formation in mouse and human systems. As collagen type I 
produced by cFBs comprises the main ECM protein in the heart, we furthermore 
investigated the influence of the collagen-specific molecular chaperone Heat Shock 
Protein 47 (HSP47) on CM maturation and assembly into functional syncytia, 
utilizing HSP47 knockout (KO) mouse FBs on 2D and 3D EHM culture platforms. By 
use of genetically engineered mouse and human embryonic stem cell (ESC) lines, we 
were firstly able to successfully generate by directed differentiation highly purified 
CMs to exclusively define the cellular constituents (CMs to non-myocytes) in EHMs. 
The generation of mature compact cardiac tissue with organotypic morphology and 
functionality was only feasible with the supplementation of FBs to EHMs. These 
observations can be explained by several identified mechanisms: FBs facilitate (1) 
cardiac tissue formation via integrin mediated signalling, (2) the secretion of a cardio-
instructive ECM environment, important in mediating heart muscle maturation. 
Utilizing HSP47 KO FBs, we demonstrated the absence of HSP47 in FBs impairs 
both ECM-collagen deposition and CM morphology and functionality in both 2D and 
3D EHM mouse culture systems. We were able to furthermore recently establish the 
generation of two mutant HSP47 human ESC lines via the CRISPR/Cas9 system. In 
conclusion, FBs play a prerequisite role in controlling and inducing cardiac tissue 
formation and maturation. Furthermore, we identified HSP47 to be an important 
regulator of cardiac tissue maturation. 
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1.1 Structure and cellular components of the heart 
 
The mammalian heart is a complex multicellular four chambered pumping organ 
which developmentally undergoes a series of crucial structural and functional changes 
leading to a mature and highly organized organ, capable of providing an optimal 
continuous blood flow to the rest of the body. The main cellular constituents of the 
heart include: cardiomyocytes (CMs) and non-myocytes (including; fibroblasts [FBs], 
endothelial cells and vascular smooth muscle cells), which are all surrounded by the 
extracellular matrix (ECM) environment (Figure 1). In addition, there are other 
transient cell types present in the heart which include: macrophages, lymphocytes and 
mast cells (Howard and Baudino, 2014). Our understanding of the developmental 
processes underlying the complexity of myocardial tissue and processes that maintain 
it have advanced over the recent years. 
 
 
               
 
Figure 1. Intercellular communication in the heart. The complex interaction of cardiomyocytes, 
non-myocytes (including; fibroblast, smooth muscle cells, endothelial cells, macrophages and other 
cells of leukocytic orgin) and the surrounding extracellular matrix (ECM) are critical in maintaining 
homeostasis in the mammalian heart. Cells can interact through integrin receptors, cell surface 
molecules, gap junctions and through growth factors, cytokines and hormones, which can act in both an 
autocrine and paracrine manner (Taken from Howard and Baudino, 2014). 
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CMs constitute approximately 20-30% of cells in the human heart (Jugdutt, 2003), 
50% in mouse heart (Banerjee et al., 2007) and 30% in rat heart (Banerjee et al., 
2007). The non-myocytes thus constitute the main cellular components of myocardial 
tissue (Pinto et al., 2016). These cells communicate with each other directly or 
indirectly via autocrine or paracrine signalling (Souders et al., 2009) and both the 
organization and the relative proportions of these cellular components play critical 
roles in heart development, physiology and pathology.  
 
CMs are the key force-generating constituents of the myocardium and their 
maturation during development seems to be orchestrated in a temporal-specific 
manner from an embryonic elongated, ovoid shape, into a postnatal rod-shaped 
phenotype (Chacko, 1976). Each CM has a bundle of myofibrils divided into 
contractile units, or sarcomeres, which consist of a range of different contractile 
proteins including actin and myosin (Gregorio and Antin, 2000). The complex cellular 
components in the heart and their dynamic interactions are likely to collectively 
constitute a unique cardio-instructive environment, which can ultimately influence 
CM structure and function.  
 
During the mammalian developmental stages of cardiac commitment and 
morphogenesis, CMs organize their structure by undergoing myofibrillogenesis (Du et 
al., 2008; Guan et al., 1999; Van der Loop et al., 1996). This results in the precise 
formation and arrangement of CM shape, assembly of the cardiac contractile 
apparatus and sarcomeric proteins, which is critical for normal cardiac growth and 
maturation. Disturbances of CM organization or contractile performance in the 
dynamic cardio-instructive environment during cardiac development usually have 
fatal consequences leading to cardiac malformations or prenatal lethality (Sussman et 
al., 1999). Moreover within the adult heart, rod-shaped CMs are anisotropically 
aligned in order to facilitate the propagation of electrical signals in directions parallel 
to the long axis of myocardial fibres (Kléber et al., 2011), which is necessary for 
efficient contraction, force transduction and electrical transmission in the heart to 
sustain effective cardiac output. At the cellular level, the mechanical and molecular 
signals which guide the orientation and alignment of myofibrils are not clearly 
understood, however, studies have identified that the formation of focal adhesions and 
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cell-cell adhesions play a critical role in CM development (Petit and Thiery, 2000; 
Kovacic-Milivojevic et al., 2001). 
 
The regulation of the heart requires the integration of various complex cellular 
mechanical, chemical and electrical signalling networks which are carefully 
orchestrated in order to sustain normal cardiac function and homeostasis. Alterations 
in any of these signalling networks can thus lead to disruption in other signals and 
ultimately result in cardiac dysfunction and disease (Howard and Baudino, 2014).  
 
1.2 Heart disease 
 
Heart disease is the leading cause of disability and mortality worldwide according to 
the World Health Organization (http://www.who.int/mediacentre/factsheets/fs317/en/) 
characterized by a loss or dysfunction of CMs (e.g., during and after a myocardial 
infarction). Heart failure is a progressive disease which has generally been 
characterized by the imbalance between cardiac output and the metabolic demands of 
the body. This usually results from reduced contractility of the heart (systolic 
dysfunction), insufficient filling of the heart (diastolic dysfunction) or more often a 
combination of both dysfunctions.  
 
The mammalian heart is one of the least regenerative organs in the body and adult 
CMs have very little intrinsic capacity to regenerate following cardiac injury (Xin et 
al., 2013). Upon injury, the heart undergoes a series of initial morphological and 
function changes in order to compensate for CM loss at the aim to restore cardiac 
output. Over time however, chronic cardiac stress results in maladaptive responses, 
involving CM hypertrophy, cardiac fibrosis, ventricular dilation, chronic 
inflammation, and increased cellular apoptosis (Hill and Olsen 2008; Patton et al., 
1998). Cardiac fibrosis is an integral component of most cardiac pathological 
conditions and is characterized by the excessive deposition of ECM proteins in the 
cardiac interstitium. Following acute myocardial infarction, the sudden loss of CMs 
triggers inflammation and thus ultimately leads to the replacement of dead 
myocardium with increased collagen-deposited fibrotic scars in the cardiac interstitial 
space (Frangogiannis, 2012), which is associated with increased mechanical stiffness 
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and thus can contribute to both systolic and diastolic cardiac dysfunction (Janicki and 
Brower, 2002; Berk et al., 2007). These consequences above result in a vicious cycle 
towards pathological cardiac remodelling, further cardiac dysfunction and 
decompensated heart failure (Hill and Olsen, 2008; Patton et al., 1998). 
 
Our understanding of cardiovascular disease has evolved over the last decade, leading 
to our current standard therapeutic interventions, which include β- adrenergic receptor 
blockers, angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor 
blockers, ARBs), aldosterone antagonists and/or diuretics to treat heart failure patients 
(Abraham et al., 2008; Bristow, 2000). However, despite improvements in the 
management of symptoms and overall mortality rates, these therapeutic interventions 
are only able to indirectly target heart failure and are not able to stimulate 
cardiomyocyte proliferation and regeneration, and can thus only delay heart failure 
progression with limited clinical benefits on preventing or reversing the onset of late 
stage heart failure (Packer et al., 1996; Lechat et al., 1998; Liu et al., 2010; Dhawan et 
al., 2007).  
 
At present, the lack of ability to reverse the diseased cardiac phenotype is most likely 
due to our limited knowledge of the molecular mechanisms underlying cardiovascular 
disease pathologies. Most research has focused on malfunctions in CMs, disregarding 
the complex cellular composition of myocardial tissue. There has however been more 
of recent attention to the „non-myocyte‟ cell populations in the heart, which compose 
the major cell population of it and are believed to play essential roles in CM 
development and function, hypertrophy (Brutsaert et al., 1996; Harada et al., 1997), 
and cardiac remodelling in heart diseases (Souders et al., 2009). 
 
1.3 Cardiac Tissue Engineering 
  
Cardiac tissue engineering based approaches focus on providing an artificial tissue 
mimic with natural organ structure and function. These aim to provide innovative in 
vitro research models for studying cardiac (patho) physiology, drug development and 
for use in therapeutic applications in order to restore the function of the damaged 
myocardium (van Spreeuwel et al., 2014; Christalla et al., 2012). The progress in this 
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field however critically depends on the use of stem cell technologies and a greater 
understanding of biological processes which can govern these cells towards a desired 
phenotype, which may support the improvement of cardiac regeneration therapies and 
further facilitate the discovery of new possible targets to treat heart disease. 
Understanding the processes in driving CMs towards maturation in an organotypic 
manner or towards a pathological phenotype will be a pre-requisite to ultimately 
provide realistic cardiac tissue models (Christalla et al., 2012). 
  
The process of creating functional three dimensional cardiac tissue constructs relies 
on the combination of cardiac cells with scaffolds or devices that facilitate cell 
growth, organization and differentiation (Griffith and Swartz, 2006). Despite our 
increasing understanding of developmental processes governing cardiac development, 
there is still a lack of understanding concerning the complex interplay of cellular and 
extracellular factors, which are most likely to constitute a unique cardio-instructive 
environment and control cardiogenesis and maturation of the myocardium (Christalla 
et al., 2012). 
 
1.3.1 Engineered heart muscle (EHM) to study cell interactions 
 
Tissue models reconstituted from specified cell types and ECM components provide 
simplified 3D biological systems to study cell-ECM interactions in several different 
biological processes, including tissue homeostasis and development (Bell et al., 1979; 
Grinnell, 1994). Several groups including our own have previously demonstrated that 
CMs from neonatal rats and embryonic chicken can be reconstituted to 3D cardiac 
tissue-like constructs (Eschenhagen et al., 1997; Akins et al., 1999; Bursac et al., 
1999; Carrier et al., 1999; Li et al., 1999; Leor et al., 2000; Li et al., 2000; 
Zimmermann et al., 2000; Kofidis et al., 2002; Krupnick et al., 2002; Shimizu et al., 
2002). Studies in our lab use a novel simplified in vitro 3D model of heart muscle 
development termed „Engineered Heart Muscle‟ (EHM). EHMs are collagen-hydrogel 
based constructs comprising of the most abundant cellular and ECM components of 
native heart muscle, which resemble morphological and functional properties of the 
native myocardium (Tiburcy et al., 2011; Zimmermann et al., 2002) and can be used 
to address the importance of cell-ECM interactions in the myocardium. The 
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development of our EHM model was originally influenced by a method developed to 
measure the functional and mechanical properties of tissue constructs assembled with 
chicken embryonic FBs (Kolodney and Elson, 1993).  
 
Several lines of evidence suggest that non-myocytes both support the growth of CMs 
in culture, and are essential for the generation of cardiac tissue constructs. Our group 
has previously demonstrated the importance of the non-myocyte cell fraction in the 
heart for being essential in maintaining a cardiogenic environment in EHMs (Naito et 
al., 2006). EHMs comprised of mixed heart cell populations (CMs and non-myocytes) 
showed advanced tissue structure and displayed increased contractile and passive 
forces, when compared to EHMs comprised of an enriched CM cell population (Naito 
et al., 2006). Furthermore, Vunjak-Novakovic and colleagues demonstrated that poly 
(glycerol sebacate) constructs seeded with both cardiac FBs and CMs developed much 
better tissue structure and function compared to those cultured with pure CMs 
(Radisic et al., 2008). In addition, several other studies using other bioartificial 
cardiac tissue-based models have demonstrated the importance of FBs for CM 
survival and coupling, and the formation of well structured, functional myocardial 
tissue (Kensah et al., 2012; Liau et al., 2011; Pfannkuche et al., 2010). Finally, the 
addition of endothelial cells and stromal cells to human embryonic stem cell-derived 
CMs has been demonstrated to improve both cardiac tissue structure and function 
(Lesman et al., 2010; Stevens et al., 2009; Tulloch et al., 2011). The mechanisms 
underlying how FBs or other non-myocytes are able to promote CM maturation in 
these models of heart muscle development are however not clearly understood. 
 
It is becoming increasingly recognised that cardiac fibroblasts (cFBs) are the most 
abundant cell type in the myocardium and contribute importantly to multiple aspects 
of myocardial function and pathophysiology (Souders et al., 2009). FBs are able to 
interact with CMs via paracrine and mechanical signalling mechanisms. The 
utilization of this EHM model to study the functional and mechanistic roles of cFBs 
may thus provide further insight to how these cells may control cardiogenesis and CM 





1.4 Cardiac fibroblasts in the heart  
 
FBs are found in all vertebrate organs and are usually defined as cells of 
mesenchymal origin (Souders et al., 2009). cFBs are key components of the 
myocardium and have been found to play critical roles in cardiac development, 
maintaining normal cardiac function, as well as cardiac remodelling during 
pathological conditions, such as myocardial infarction and hypertension (Souders et 
al., 2009).  
 
Morphologically, these cells are flat and spindle-shaped in culture and lack a 
basement membrane (Souders et al., 2009). Although a lot of research focus has paid 
attention to FBs, there is no truly definitive cell-specific marker to characterize these 
cells. Three proteins primarily used in studying FBs are the collagen receptor 
Discoidin Domain Receptor 2 (DDR2) and Vimentin, present in the fibroblasts 
intermediate filaments, and Fibroblast Specific Protein 1 (FSP-1; also known as 
S100A4), a filament associated calcium-binding protein in fibroblasts (Zeisberg and 
Kalluri, 2010; Fan et al., 2012). These proteins however lack fibroblast specificity 
(Vimentin and DDR2) or are only specific for a subset of cFB populations (FSP-1). 
There is thus emerging evidence that cFBs are not a homologous cell type, but highly 
heterogenous cell populations existing in the myocardium (Krenning et al., 2010; 
Zeisberg et al., 2007). 
 
1.4.1 Origins of cardiac fibroblasts 
 
During cardiac development, epicardium-derived cells over the embryonic heart 
undergo epithelial-mesenchymal transformation (EMT) and consequently differentiate 
into fibroblasts (Lie-Venema et al., 2007). EMT has been shown to be induced 
primarily by periostin (Norris et al., 2008) and Transforming Growth Factor β (TGF-
β) (Olivey et al., 2006). In addition, FBs have also been shown to derive from 
endothelial cells from the endocardium via endothelial mesenchymal transformation 
(EndMT) (deLange et al., 2004). Both epicardium- and endothelial- derived cells 
however become quiescent after embryonic development. Following myocardial 
injury, hematopoetic cells derived from the bone marrow can be recruited to the site 
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of injury and transform to cFBs or myofibroblasts (Fan et al., 2012). Myofibroblasts 
play critical roles in remodelling processes in cardiac pathology (Calderone et al., 
2006; Brown et al., 2005). 
 
1.4.2 Function of cardiac fibroblasts in the heart 
 
cFBs are involved in numerous functions in the heart including primarily the secretion 
and remodelling of the ECM. In addition, cell-to-cell communication with 
neighbouring CMs, endothelial cells, other FBs and smooth muscle cells, can impact 
cellular events such as: angiogenesis, CM hypertrophy, cell proliferation, and 
apoptosis (Fan et al., 2012). FBs are able to exert mechanical force on CMs by 
contracting the collagen network that forms the ECM (Howard and Baudino, 2014). 
FBs also produce various growth factors and cytokines (Souders et al., 2009). It is 
becoming more appreciated that FBs furthermore support the electrical activity of the 
heart, as they are conductors with high membrane resistance (Kohl, 2003) and are 
responsible in electrically separating the atria and ventricle by forming an insulating 
layer to facilitate in proper sequential contraction of the heart (Liu et al., 2008). cFBs 
are coupled to CMs via gap junctions through connexins (Cx40, Cx43 and Cx45) 
which are necessary in maintaining an optimal electrical conduction in the heart 
(Camelliti et al., 2004a; Gaudesius et al., 2003). Many studies have termed these cells 
as „sentinel‟, as they can both sense and respond to changes in mechanical, chemical 








Figure 2. Roles of cardiac fibroblasts and their impact on different aspects of cardiac structure 
and function (Adapted from Souders et al., 2009; Fan et al., 2012). 
 
 
It is thus becoming clearer that cFBs play a key role for constructing a cardiogenic 
environment and contribute to structural, biomechanical, biochemical and electrical 
properties of the heart, thus maintaining appropriate form and function of the 
myocardium (Chilton et al., 2007; Kohl, 2003; Louault et al., 2008; Camelliti et al., 
2004b). Since most cardiac diseases are associated with an increase of fibrosis in the 
heart (Boudoulas and Hatzopoulos, 2009), it is clear that FBs and its derived ECM 
play significant roles during cardiac pathological remodelling.  
 
1.5 Cardiac fibroblasts and the ECM 
 
cFBs are the key cell type in the heart responsible for the deposition and maintenance 
of ECM homeostasis during cardiac development, normal physiology, and during 
remodelling in heart disease (Fan et al., 2012). The ECM is a complex, heterogeneous 
network of soluble and insoluble protein, which provides a structural framework and 
support for CMs and other cell types in the myocardium. This mechanical framework 
permits cell-to-cell interactions for healthy tissue formation and maintenance (Bowers 
et al., 2010). The cardiac ECM under normal conditions provides an anisotropic 
structural scaffold to guide CM alignment and has been shown to be essential in 
supporting the efficient contraction and relaxation of CMs (Li et al., 2014), and thus 
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proper myocardial structural integrity and pump function (Curtis and Russel, 2011). 
The ECM scaffold enables optimal force transduction for mechanical work, electric 
transmission and chemical signals within the myocardial environment during 
development and homeostasis, as well as in response to physiological stress or injury 
(Li et al., 2014; Bowers et al., 2010).  
 
The major component of the ECM is primarily collagen, and to a lesser extent a wide 
array other different proteins including; fibronectin, laminin fibrillin, elastin, 
proteoglycans and glycosaminoglycans (GAGs). Both collagen and elastin have been 
considered as the „bricks‟ of the ECM due to their contribution to its mechanical 
properties, and GAGs are thought to contribute to the „gel-like‟ characteristics of the 
ECM (Fernandes et al., 2009). The ECM is very dynamic as numerous studies have 
revealed that both the structural organization and composition of the ECM differs 
during distinct physiological states. For instance, during cardiac development and 
disease, a number of growth factors such as platelet-derived growth factor (PDGF) 
and TGF-β can induce the activation of a wide array of different ECM proteins in 
cFBs (Butt et al., 1995). In addition to the synthesis of ECM proteins, cFBs also 
produce a variety of different ECM-degrading proteins including; matrix 
metalloproteinase (MMPs) and tissue inhibitors of matrix metalloproteinase (TIMPs), 
which are all critical in maintaining ECM homeostasis and can impact cardiac 
function. Furthermore, the ECM contains a number of growth factors and cytokines 
than can also impact CM function (Fan et al., 2012).  
 
 
1.5.1 ECM remodelling in the developing and pathological heart  
 
The different ECM microenvironments present during cardiac development, 
homeostasis and pathological conditions display unique biochemical niches. These 
different microenvironments can thus influence cardiac form and function, which are 
primarily driven by cell-cell and cell-ECM interactions (Bowers et al., 2010). 
Numerous studies have collectively identified differences in specific ECM 







Figure 3. Schematic overview of the changes in ECM composition during different physiological 
states in heart. The changes in cellular (grey boxes) and ECM components (black boxes) during 
different cardiac physiological states (white boxes) (Taken from Bowers et al., 2010).  
 
 
The critical roles of ECM in tissue formation and homeostasis have been 
demonstrated in a number mouse models for certain ECM proteins as well as some 
human disorders (Aszódi et al., 2006). Diseases such as Osteogenesis Imperfecta (OI), 
Ehler-Danlos (ED) syndrome and epidermolysis bullosa caused by mutation in genes 
encoding for structural proteins in collagens, can result in fatal outcomes (Fernandes 
et al., 2009). Within the context of heart diseases, the ECM initially undergoes 
dynamic changes in order to restore function of the myocardium. Over time, sustained 
ECM deposition (primarily collagens) results in a stiffer myocardium, which impairs 
mechanical function and electrical dynamics of the heart (Li et al., 2014; Bowers et 
al., 2010). 
 
The knowledge of the role of the ECM during cardiac development is however still 
limited and it is not clearly understood which ECM factors are on the one hand; 
supporting CM growth, maturation and physiological hypertrophy, and on the other 




1.6 Collagens in the heart 
 
The most abundant proteins in the ECM are members of the collagen family, which 
are centrally involved in the formation of fibrillar networks of the ECM, basement 
membranes, as well as structures of the ECM (Gelse et al., 2003). More than 28 
different collagen types in various vertebrate tissues have been identified. These can 
be divided into two major classes; the fibrillary and non-fibrillar collagens (Jugdutt, 
2003). Among the collagen family, five collagen types (I, II, III, V and XI) form 
fibrils which provide the structural framework of tissues (Jugdutt, 2003).  
 
Fibrillar collagen types I and III are the most abundant components in the cardiac 
ECM (De Jong et al., 2012; Fan et al., 2012) with collagen type I making up 85% and 
collagen type III 11% of total collagen in the myocardium (DeSouza, 2002; Jugdutt, 
2003). Collagen fibres in the myocardium are able to form collagen networks that 
provide cardiac strength during contractile forces (Jugdutt, 2003). In addition, these 
collagen fibres play a role in connecting neighbouring CMs (Eghbali and Weber, 
1990). In the context of heart diseases, the myocardium is characterized by excessive 
collagen type I deposition, collagen fibril disruption, structural ECM remodelling and 
loss of CMs via apoptosis and necrosis (Swynghedauw, 1999).  
 
During cardiac development, fibrillar collagen I is initially expressed throughout the 
developing leaflets of the atrioventricular valves, but this gradually becomes restricted 
to the ventricular sides of the valve leaflets after birth (Kruithof et al., 2007; Lincoln 
et al., 2004). Collagen I is additionally expressed in the aortic walls. Studies have 
shown the disruption of the Col1A1 gene in mice, are more susceptible to aortic 
dissection and rupture. Furthermore, Mov13 mice possessing an insert mutation in the 
Col1A1 gene are embryonic lethal at 12-14 days postcoitus (dpc), due to rupturing of 
developing blood vessels (Lohler et al., 1984; Rahkonen et al., 2004).  
 
Many more animal studies have revealed that different collagen types are important 
during cardiac development (Metsaranta et al., 1992; Lincoln et al., 2004; Hinton et 
al., 2006; Liu et al., 1997; Polschl et al., 2004; Kruithof et al., 2007; Favor et al., 
2006; Wenstrup et al., 2004; Bonaldo et al., 1998; Klewer et al., 1998), however 
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currently little work has been performed to elucidate the roles of collagens in early 
stages of cardiac development. 
 
1.6.1 Structure and biosynthesis of collagen 
 
Knowledge into the molecular structure, biosynthesis, assembly and turnover of 
collagens is essential in order to understand both the developmental processes, as well 
as the pathological processes linked with cardiac disorders and many other human 
diseases (Gelse et al., 2003). 
 
All collagens are right-handed triple helix structures which are composed of three α-
chains (Figure 4). Each α-chain contains domains with repetitions of proline-rich 
amino-acid tripeptides (Gly-X-Y)n, in which X and Y are usually proline and 
hydroxyproline residues respectively, and flanked by N- and C- propeptide globular 
domains. These triple-helical structures can be either homotrimeric or heterotrimeric, 
depending on the collagen type (Canty et al., 2005; Gelse et al., 2003).  
 
 
       
 
 
Furthermore, depending on the collagen type, the proline- and lysine specific residues 
can be modified by post-translational modifications by enzymatic hydroxylation 
(Gelse et al., 2003). The Gly-X-Y helical repeats are the major motif present in 
fibrillar forming collagen types (I, III and V), which can result in triple helical 
structures of 300 nm in length (Von der Mark, 1999). Fibrillar collagen type I is the 
Figure 4. Molecular structure of 
collagen type I. Procollagen consists of 
two α1- and α2- chains which are 
wounded into a triple helix.  Once 
procollagen is processed in the ER, pro-
peptide domains at the N- and C-
terminals are cleaved, resulting in the 
formation of mature collagen. When 
collagen is degraded, telopeptides (from 
the N- and C- terminals) are cleaved and 
released (Taken from Fan et al., 2012). 
1. Introduction 
14 
most abundant collagen in the body and the most extensively characterized (Gelse et 
al., 2003). The mechanisms involved in the biogenesis of collagen type I are described 




Figure 5. Schematic representation of processes involved in the folding and assembly of 
procollagen in the endoplasmic reticulum (ER) during collagen biogenesis. Newly synthesized 
collagen α1- and α2- chains are inserted into the ER and undergo hydroxylation and post-translational 
modifications. All 3 α-chains assemble at the C-propeptide region, are covalently linked by disulphide 
bonds, and triple helix formation then proceeds from the C- to N-terminus with the aid of several 
folding enzymes and molecular charperones. Triple helix procollagen is then transported out the ER 
and secreted out into the extracellular space. N- and C- propeptides are then cleaved off by N- and C- 
propeptides to form mature collagen. Mature collagen is then assembled laterally with other 
neighbouring molecules to form collagen fibrils (Adapted from Nagata, 2003).    
 
 
This initially starts with transcription of collagen genes within the nucleus of FBs 
and/or other collagen-producing cells. The regulation of the transcriptional processes 
involved in collagens depends largely on the cell type, but activities may also be 
controlled by various growth factors and cytokines (Von der Mark, 1981). The 
collagen type I triple helix is heterotrimeric and comprises of two identical α1 (I) 
chains and one α2 (I) chain, which are synthesized as large precursor pro-α-chains. 
Subsequently, these individual α-chains are co-translationally transported into the 
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lumen of the endoplasmic reticulum (ER), where they undergo multiple steps of post-
translation modifications by a large number of molecular chaperones and enzymes to 
assist folding and trimerization (Gelse et al., 2003; Canty et al., 2005) (Figure 5).  
 
Hydroxylation of specific proline (particularly at the Y position of the Gly-X-Y 
triplet) and lysine residues of the triple-helical domains are catalyzed by prolyl 3-
hydroxylase (P3H), prolyl 4-hydroxylase (P4H) and lysyl hydroxylase, during co-
translational transport into the ER (Gelse et al., 2003). All the three enzymes require 
the provision of ferrous ions, ascorbate, 2-oxogluterate and molecular oxygen as 
cofactors (Gelse et al., 2003). In procollagen, these hydroxyl groups are thought to 
form interchain hydrogen bonds that help stabilize the triple helix. Conditions 
preventing proline hydroxylation, such as the deficiency of ascorbic acid (vitamin C), 
have severe consequences. In scurvy, the disease caused by a dietary deficiency of 
vitamin C, the defective pro-α chains that are synthesized fail to form stable triple 
helices and are thus immediately degraded within the cell (Alberts et al., 2002). 
 
After hydroxylation, these 3 pro-α-chains assemble at their C-propeptide regions. The 
globular structures of the C-propeptide regions present in all 3 pro-α-chains are then 
covalently linked by inter-chain disulphide bonds (Doege and Fessler, 1986) by 
protein disulphide isomerase (PDI) (Koivu et al., 1987) and triplex helix formation 
then proceeds from the C-terminus to the N-terminus in a zipper-like manner. In the 
procollagen molecule, glycine residues located in the inner-most region of the triple-
helix and the hydroxylated proline residues (at the Y position) contribute to the 
stabilization of the triple helix (Nagata, 2003).  
 
A number of folding enzymes and molecular chaperones including; glucose-regulated 
protein 78 (GRP78; or BiP), GRP94, peptidyl-prolyl cis-trans-isomerase (PPIase) 
(Lang et al., 1987) and the collagen-specific chaperone Heat Shock Protein 47 
(HSP47) (Clarke et al., 1991) have been shown to associate with newly synthesized 
procollagen in the ER and assist in facilitating efficient formation and correct folding 
of procollagen chains (Nagata, 2003; Gelse et al., 2003; Canty et al., 2005). HSP47 
has been shown to be critical for collagen molecular maturation in the ER (as further 
discussed in Section 1.6.2). After processing and procollagen assembly, only the 
triple-helical form of procollagen is transported from the ER in the Golgi apparatus, 
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where these procollagen trimers are packaged into secretory vesicles and transported 
out of cells into the extracellular space (Gelse et al., 2003; Nagata, 2003). Following 
secretion, the N- and C-propeptides are cleaved off by N- and C- propeptidases, 
respectively, to form mature collagen. The resulting triple-helical collagen molecules 
assemble laterally and intermolecular covalent cross-links occur within and between 
adjacent structures to form a stable fibrillar network, which contributes to the 
mechanical stiffness of collagen fibrils.  
  
1.6.2 HSP47 in the biogenesis of collagen 
 
Heat shock protein 47 (HSP47) is a 47 KDa collagen-specific glycoprotein molecular 
chaperone residing in the ER of collagen-producing cells and has been shown to be 
essential for embryonic development and maturation of collagen types I and IV 
(Ishida and Nagata, 2011). This protein is a member of the serpin (serine protease 
inhibitors) superfamily and possesses a unique characteristic as it specifically binds to 
procollagens in the ER. HSP47 exclusively binds to collagen, recognizing an arginine 
at the Y position of a procollagen Gly-X-Y helical repeat (Widmer et al., 2012). In 
contrast to many other ER chaperones involved in collagen processing and 
maturation, HSP47 preferentially recognizes the folded triple-helical conformation of 
its client (Widner et al., 2012). 
 
Furthermore, HSP47 expression patterns in different cells and tissues always correlate 
closely with collagen expression (Nagata and Hosokawa, 1996; Nagata, 1998). HSP47 
synthesis has not been observed in cells which do not synthesize collagen (Nagata and 
Hosokawa, 1996). Furthermore, evaluated expressions levels of HSP47 have also 
been observed in several fibrosis models (Nagata et al., 1986; Taguchi and Razzaque, 
2007; Takechi et al., 1992). Several roles have been suggested for HSP47 in collagen 
biogenesis. These include assisting the correct folding and stabilization of triple-
helical procollagen (Tasab et al., 2000; Nagata et al., 1996), and the control and 
prevention of unfolded procollagen aggregates in the ER. HSP47 has been shown to 
be associated with triple-helical procollagen rather than unfolded α-procollagen 
chains (Tasab et al., 2002; Koide et al., 2006; Thompson et al., 2003), and also assists 
during its export into the cis-Golgi, where it then dissociates from procollagen in a 
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pH-dependant manner and is recycled back to the ER (Lamande and Bateman 1999; 
Satoh et al., 1996). 
 
The importance of HSP47 in embryonic development and collagen maturation has 
been demonstrated previously from gene ablation studies from the lab of Kazuhiro 
Nagata. Studies showing the disruption of murine HSP47 using homologous 
recombination caused embryonic lethality in mice at 11.5 dpc. These mouse embryos 
displayed impaired defects in the formation of collagen fibres and basement 
membrane (Nagai et al., 2000), caused by aberrant procollagen folding in the ER 
(Figure 6). At 10.5 dpc, the embryos from HSP47 knockout (KO) mice showed 
developmental retardation and cardiac hypertrophy (Nagai et al., 2000; Ishida and 




Figure 6. Schematic representation of the possible function of HSP47 in the folding and assembly 
of procollagen in the ER. Collagen forms trimers in the ER and triple helix formation proceeds from 
the C- to N- terminus in a zipper-like manner. (A) In the presence of HSP47, correctly folded collagen 
is exported out the ER and secreted into the extracellular space, and rigid collagen fibrils are formed by 
assistance of HSP47. (B) In the absence of HSP47 (in HSP47 
-/-
 [KO] fibroblasts), collagen folding is 
impaired and is retained in the ER. Aggregate formation and the induction of ER stress are observed, 
finally triggering ER stress induced apoptosis. Note that N-propeptides of procollagen secreted from 
HSP47 KO fibroblasts are not cleaved/processed due to improper folding of the procollagen triple 





Furthermore, collagen type I secreted from HSP47 KO FBs was markedly decreased 
and displayed abnormal and misaligned fibrillar structures with thin and branched 
fibrils (Ishida et al., 2006).Triple helix formation, secretion, and processing of the N-
terminal propeptide of procollagen type 1 was impaired, which thus resulted in the 
failure to accumulate collagen fibres into the ECM. The secretion of collagen type I 
and IV (Matsuoka et al., 2004) was delayed leading to the intracellular accumulation 
of procollagen in the ER. The secretion and deposition of other ECM proteins 
including fibronectin and laminin were however shown to be unaffected (Ishida et al., 
2006), indicating that HSP47 disruption specifically altered procollagen maturation.  
 
Since HSP47 is essential for mouse development, mutations in human HSP47 would 
thus be expected to be lethal. The ECM is required for both bone and tissue formation, 
and additional studies have revealed that point mutations in the SERPINH1 gene 
(encoding for human HSP47) are present in one of the subtypes of the recessive 
Osteogenesis Imperfecta (OI) bone disorder in humans (Christiansen et al., 2010) and 
dog, i.e. in Dachshunds (Drogemuller et al., 2009; Lindert et al., 2015). These results 
further highlight the importance of HSP47 as a collagen-specific molecular chaperone 
which is necessary for the formation of procollagen triple helices in the ER. 
 
HSP47 is closely related with collagen-related diseases, including fibrosis in various 
organs. It has been shown to be over expressed in various human and experimental 
fibrotic diseases which include; glomeruloscerosis pulmonary fibrosis, liver cirrosis 
and fibrosis following myocardium infarction (Sauk et al., 2005). Furthermore, 
studies have shown that suppression of HSP47 expression can reduce the 
accumulation of collagens in order to delay the progression of fibrotic diseases in 
experimental animal models (Taguchi and Razzaque, 2007). HSP47 thus provides a 
selective target to manipulate collagen production in the ECM, which may thus have 
enormous clinical impact in controlling a wide range of fibrotic diseases. 
 
Although HSP47 is essential for embryonic development and collagen maturation, it 
is not known with respect to the heart whether its influence in collagen processing and 
maturation can impact the functionality and maturation of CM during development, 




1.7 Cell-ECM communication via integrin receptors 
 
Increasing evidence suggests that mechanical interactions between the ECM and 
CMs, as well as physical interactions transmitted between other neighbouring cells 
play important roles in regulating signalling pathways, which can thus influence the 
form and function of the myocardium during development (Sheehy et al., 2012). Cells 
are able to sense external mechanical cues primarily through interactions with the 
ECM via integrin binding and from neighbouring cells through intracellular junctions 
(Chen et al., 2004). 
 
Integrins are a diverse family of heterodimeric, transmembrane receptors composed of 
18 α and 8 β heterodimeric subunits (Hynes, 1987; Giancotti and Ruoslahti, 1999) that 
mediate the attachment of cells to the ECM, as well as in mediating cell-cell 
interactions (Barczyk et al., 2010). In total, there are 24 integrin heterodimeric 
receptors (formed from one α and one β subunit) which can specifically bind to a wide 
range of different ECM molecules/ligands with overlapping binding affinities (Alam 
et al., 2007). Additional complexity is further presented by the numerous splice 
variant isoforms of individual α and β subunits, including some expressed in the heart 







Figure 7. Representation of the integrin 
family. This includes the classification of 
integrin receptors based on their ligand 
binding ability. Four different categories 
have been presented; 1) Collagen binding, 2) 
RGD binding, 3) Laminin binding and 4) 
Leukocyte-specific receptors. In vertebrates, 
the integrin family contains 24 heterodimeric 
receptors that mediate attachment of cells to 




Integrin signalling impacts the physiological function of all cells and tissues in the 
body. These receptors bind to ECM protein ligands via short amino acid sequences, 
such as the GFOGER motifs found in collagens (Knight et al., 2000), and the Arg-
Gly-Asp (RGD) tripeptide sequence motifs present in several ECM proteins 
including; fibronectin, vitronectin and fibrinogen, in addition to collagens and 
laminins (Barczyk et al., 2010; Bellis, 2011). Furthermore, a single ECM ligand can 
have the ability to bind to one or more integrin heterodimer. The wide range of 
integrins that are expressed on a particular cell type and in different subcellular 
regions can be unique and can vary in a temporal manner.  
 
Integrins function as mechanotransducers, transforming mechanical forces created by 
the ECM or the intracellular actin-cytoskeleton into biochemical signals (Larson et al., 
2006). These receptors can function in a bi-directional manner across cell membranes. 
ECM ligands binding to integrin receptors can mediate intracellular signalling 
processes, which are termed as „outside-in‟ signalling. In addition, intracellular 
signals originating within the cell cytoplasm can control integrin function, which can 
then be transmitted to the ECM ligand-binding domain; a process which is termed as 
„inside-out‟ signalling. In „inside-out‟ signalling, both an increase in integrin binding 
to ECM ligands, as well as the clustering of multiple integrin receptors in close 
proximity within the cell membrane occurs. It is understood that integrin clustering in 
both CMs and cFBs in the heart is associated with biochemical and mechanical 




















                    
 
 
Figure 8. A simplified schematic of bi-directional ECM-cell signalling interfaces in the 
myocardium. (A) External mechanical cues are transmitted in a bi-directional manner from the ECM 
to intracellular compartments via transmembrane integrin receptors. These signals activate a number of 
biological responses, and in turn these biological responses can feed information back to the ECM via 
the same mechanical pathways. (B) Integrin receptors form a direct physical link between the ECM and 
the cytoskeleton through focal adhesions that translate mechanical signals directly into intracellular 
compartments such as the nucleus to regulate gene transcription. (C) Mutual bi-directional signalling 
between the ECM (exogenous tension can regulate endogenous cellular tension) and intracellular 
compartments (endogenous tension can directly or indirectly control ECM rigidity) through integrin 
receptors are necessary to regulate and maintain tension in the cellular microenvironment (Adapted 




This integrin bi-directional signalling is essential for cells to sense and respond to 
surrounding environmental changes with precise timing and kinetics, in order to 
maintain tissue integrity and homeostasis. Both cells and the ECM are able to 
mutually interact to regulate exogenous tension (ECM rigidly) and endogenous 
tension (cell actomyosin contractility) in the cellular microenvironment (Berrier and 
Yamada, 2007) (Figure 8C). 
 
Mechanical forces are transmitted across the integrin-ECM interface to the cellular 
cytoskeleton, where they activate mechano-sensitive signal transducers. The 
signalling events critical in cell-ECM adhesion complexes involve a wide range of 
different cytoplasmic proteins (Lo, 2006). These include an array of different 
intracellular proteins such as: a) integrin-binding proteins; b) adaptor/scaffold proteins 
and c) enzymes. Integrin-binding proteins such as Talin directly bind to integrin-
cytoplasmic domains and play a role in regulating integrin activation and signalling 
processes (Calderwood, 2004). Adaptor/scaffold proteins connect integrin-associated 
proteins with the actin-cytoskeleton, or an array of different other proteins including; 
paxillin, vinculin and α-actinin. Finally, enzymes include non-receptor tyrosine 
kinases, such as focal adhesion kinases (FAK). Mechanosensitive signal transducers 
such FAK are able to translate a mechanical cue from the ECM environment into a 
biochemical response (Sheehy et al., 2012; Samarel, 2005; Schwartz and Ginsberg, 
2002; Burridge and Chrzanowska-Wodnicka, 1996; Li et al., 2005). This transmitted 
information has been shown to activate a wide array of different downstream 
intracellular pathways, including PI3K, ERK, Src and MAP kinase pathways, which 
can modulate transcriptional activity and direct important cellular activities such as; 
cellular adhesion dynamics, the induction of apoptosis, cell cycle entry and regulate 
gene expression (Sheehy, 2012; Chen et al., 1997; Hynes, 2002; Schwartz et al., 1995; 
Fletcher and Mullins, 2010; Ingber, 2006).  
 
The detailed understanding of these complex signalling pathways and networks is thus 
the ultimate goal to define the molecular basis of specific patterns in cardiac 





1.7.1 Integrin-mediated signalling in the myocardium 
 
Several studies have addressed the roles of integrins in the myocardium by genetic 
and biochemical approaches. The essential role of integrin-mediated signalling 
became apparent in integrin β1 transgenic mice. Cardiac cells from chimeric mice 
constructed with a β1 integrin-null allele exhibited delayed development and 
differentiation of cardiac lineage, as well as abnormal myofibrillogenesis (Fässler et 
al., 1996). Moreover, using integrin β1 deficient embryonic stem cells for the in vitro 
differentiation of CMs, severely disrupted cardiomyogenesis and defective 
myofibrillogensis was observed (Fässler et al., 1996).  
 
Furthermore, when integrin β1 was inactivated exclusively in ventricular CMs, this 
resulted in myocardial fibrosis and heart failure (Shai et al., 2002). In addition, the 
disruption of integrin β1 function in CMs by a high level of dominant-negative 
integrin β1 mutant under the control of the CM-specific α-myosin heavy chain 
(αMHC) promoter, displayed a more severe pathological phenotype. These transgenic 
mice die perinatally and display fibrotic replacement of the myocardium (Keller et al., 
2001). More recently, it was demonstrated that during embryonic development 
embryonic cFBs produce a complex ECM environment (including collagens and 
fibronectin) which stimulated the proliferation of immature CMs through integrin β1 
signalling (Ieda et al., 2009). In addition, Ieda et al., were able to identify other FB-
secreted growth factors which were involved in inducing CM proliferation; including 
heparin-binding epidermal growth factor-like growth factor (HB-EGF) (Ieda et al., 
2009). 
 
In summary, these studies indicate that cell–ECM interactions via integrin signalling 









1.8 Effects of the mechanical ECM environment on cardiomyocytes 
 
Cardiac organogenesis and pathogenesis are both characterized by changes in CM 
shape, cytoskeletal architecture, and the ECM. It is clear that mechanical forces of the 
ECM play critical roles in cardiac development of the embryonic heart, where 
mechanical forces are imposed on maturing CMs over the course of development 
(Jacot et al., 2010; Taber, 2001). These interactions between CMs and the ECM cause 
changes in cell shape that direct actin filament orientation, sarcomere organization 
and myofibrillogenesis in vitro (Sheehy et al., 2012; Bray et al., 2008). The ability of 
cells to move directionally towards areas of stiffer ECM via a process termed as 
„durotaxis‟ is thought to be critical in influencing cellular phenotype and tissue 
morphogenesis (Plotnikov and Waterman, 2013). Studies on embryonic CMs when 
seeded on ECMs with different rigidity associated with normal cardiac development 
and fibrotic remodelling dramatically affected rhythmic contractility of the cells 
(Engler et al., 2006; Tobita et al., 2002). 
 
It is clear that the mechanical properties of the cellular environment from the ECM 
contribute to the functional maturation of the myocardium. Our current knowledge of 
how changes in ECM organization and composition can influence structure and CM 
function is still limited. Obtaining mechanistic insights and understanding of how 
CMs respond to different ECM microenvironments may thus shed light into new 
targets which can support the improvement of cardiac regeneration therapies to treat 













1.9 Aims of Thesis 
 
It has been recognised that cFBs play an essential role in heart muscle development 
and homeostasis by establishing a supportive cardiac-microenvironment. We 
hypothesize that the mechanical and paracrine mediated effects of cFBs and its 
secreted ECM influence cardiac tissue formation and maturation. The underlying aims 
and objectives of this thesis were the following: 
 
(1) To determine the mechanistic role of cFBs in mediating cardiac tissue 
formation and maturation by utilizing the established in vitro EHM model of 
heart muscle development. 
(2) To identify the influence of cFB-derived ECM in controlling organotypic CM 
maturation. 
(3) Elucidating the importance of collagen type I as a mediator of cardiac tissue 
formation and maturation by investigating how collagen processing HSP47 
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2. Materials and Methods  
 
2.1 Cells  
All handling and experiments with cells were performed according to institutional 
regulations and good laboratory practice rules. 
 
2.1.2 Primary cell isolation and culture 
 
Mouse and human cells were utilized for all subsequent experiments. Mouse cells 
were isolated from primary tissue and human primary cells were purchased from 
commercially available sources. 
 
2.1.2.1 Mouse primary cells 
 
2.1.2.1.1 Mouse embryonic fibroblast isolation   
 
Mouse embryonic fibroblasts (MEFs) were isolated from 10.5 to 13.5 postcoitum 
(dpc) mouse embryos (NMRI and C57B6/J) according to a modified cell isolation 
protocol (Conner, 2001). Briefly, pregnant mice were euthanized by cervical spine 
dislocation. Laparotomy was performed and uteri were harvested. The embryos were 
subsequently dissected from the uteri. The embryonic internal organs, including the 
head and liver were removed from the abdominal cavity. Embryos were rinsed in 
sterile 1X PBS and thereafter cut into 1-2 mm pieces using a sharp sterile pair of 
scissors. Minced embryos were transferred into a clean sterile Erlenmeyer flask 
containing glass beads (Pyrex 4 mm; VWR, #13782-554) and incubated in 25 ml (per 
mouse) of pre-warmed 0.25% trypsin (Trypsin-EDTA) for 30 mins at 37 °C, under 
gentle agitation on a magnetic stirrer. Trypsin was then deactivated by adding x2 
volumes of MEF medium (see appendix A2) and allowed to stand for 3-5 mins at 
room temperature (RT) to allow the large tissue pieces to settle to the bottom of the 
flask. The cell suspension was removed (avoiding large tissue pieces) and 
subsequently transferred into fresh polypropylene tubes. Cells were centrifuged at 300 
x g for 5 mins at RT, pelleted and resuspended in fresh pre-warmed MEF medium. 
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Cells were finally plated into 15 cm culture plates (approximately one embryo per 
plate). MEF medium (20 ml) was changed every second day and maintained in culture 
until the specific confluency had been reached. MEFs from passages 1-5 were used 
for further experiments. 
 
2.1.2.1.2 Mitotic inactivation of fibroblasts with -irradiation 
 
MEFs and human forskin fibroblasts (hFFBs) were mitotically inactivated for use as a 
feeder layer for undifferentiated mouse (Conner, 2001) and human embryonic stem 
cells (Soong et al., 2012), respectively. Inactivated MEF and hFFB feeder layers 
provide a supporting growth environment for both mouse and human embryonic stem 
cells without dividing and diluting the cultivation of undifferentiated stem cells 
(Fuegemann et al., 2010; Wombus et al., 1991; Soong et al., 2012). To produce large 
stocks of inactivated MEFs, cells were expanded and grown until confluent (90-100 
%) onto twenty five to fifty 15 cm culture plates. hFFBs were cultured on T175 
culture flasks and were similarly expanded and grown until confluent. MEFs or 
hFFBs were detached from plates/flasks (Section 2.1.2.1.5 and 2.1.2.2.3), resuspended 
in fresh growth medium (containing serum) and counted (Section 2.1.2.3.5). Cells 
were transferred into fresh 15 ml polypropylene tubes (2 x 10
6 
/ml) prior to 
irradiation. MEFs were then exposed to two individual cycles of 30 Gy from a 
irradiation source (Steuerungstechnik und Strahlenschutz GmbH) for 15 mins. 
hFFBs were exposed to only one cycle of 30 Gy irradiation. After irradiation, cell 
suspensions were counted again and frozen down into cryovial stocks (8 x 10
6
 cells/ 
vial) accordingly (Section 2.1.2.3.4) until further use. 
 
2.1.2.1.3 Preparation of inactive MEF feeder layer plates 
 
For feeder layer preparation, culture plates were coated with gelatin to facilitate cell 
attachment. Firstly, 4 ml of 0.1% Gelatin (Sigma, G2500; diluted in sterile water) was 
added sequentially to six 10 cm culture plates (Nunc). Plates were incubated for 20 
mins at 37 °C, 5% CO2. After, gelatin was aspirated and plates were allowed to air dry 
for 20 mins under a sterile laminar flow hood. A cryovial of inactivated MEFs 
(containing approximately 8 x 10
6
 cells/ vial) was then thawed (Section 2.1.2.3.4). 
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MEFs were resuspended in the appropriate amount of MEF medium and then 
transferred into the six 10 cm gelatin-coated plates. The feeder layer MEF plates 
could be used after 24 hrs of cell plating. MEF plates were kept in culture for a 
maximum of 9 days. 
 
2.1.2.1.4 Neonatal mouse cardiac fibroblast isolation  
 
Neonatal mouse cardiac fibroblasts (cFBs) were isolated from neonatal mice 0-3 days 
postnatally (dpn), according to a modified cell isolation protocol (Simpson and 
Savion, 1982). Briefly, mice were decapitated the thoracic cavity was opened and the 
hearts were taken out. The atria were removed and the ventricles were cut into 1-2 
mm pieces and washed twice in ice cold CBFHH buffer (see appendix A2). Tissues 
underwent alternating 3-4 min digestion cycles with Trypsin-working solution (see 
appendix A2) and DNase-working solution (see appendix A2) in CBFHH buffer 
(respectively) for over 4 hrs at RT, with continuous agitation and gentle triturating to 
aid in cell dissociation. From the first digestion supernatant was discarded. Thereafter, 
with the subsequent remaining trypsin and DNase treatment steps, the cloudy 
supernatant was collected into collection tubes. These tryspin/DNase digestion cycles 
were repeated and supernatant was collected, until no more cells were released from 
tissues. Dissociated cells were then gently centrifuged at 60 x g for 15 mins and 4 °C, 
pelleted and resuspended in 30 ml ice cold MEF medium with the addition of 250 µl 
DNase I (1 mg/ml). Cells were centrifuged again at 60 x g for 15 mins at 4 °C, 
pelleted and resuspended in fresh MEF medium, passed through a pre-wetted stainless 
steel sieve (250 µm pore size) and then transferred into a fresh polypropylene tube. 
Cells were counted by mixing a small volume of cell suspension with 0.4 % trypan 
blue solution (1:1 mixture) and then transferred into a Neubauer cell counting 
chamber to determine the number and viability of cells. To separate cardiomyocytes 
(CMs) from the non-myocyte cell fractions, the dissociated cells underwent a further 
pre-plating step. Cells were seeded (1 x 10
7
 cells/15 cm plate) and incubated in MEF 
medium for 60 mins at 37 °C, 5% CO2. The growth medium contained the majority of 
CMs and this was then collected and replaced with pre-warmed MEF medium. The 
plates containing the majority of adherent cFBs/non-myocytes were replaced with 
fresh MEF medium every second day to wash off cellular debris. The cFBs were 
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maintained in culture until the specific confluency had been reached. cFB from 
passages 1-3 were used for further experiments. 
 
2.1.2.1.5 Passaging of primary mouse fibroblasts 
 
Primary FBs (MEFs and cFBs) were routinely passaged when reaching full 
confluency (80-90 %). For passaging, cells were rinsed with an appropriate amount of 
PBS (pre-warmed at 37°C) than treated with pre-warmed Trypsin (0.25 % Trypsin-
ETDA; Invitrogen, 25200) for 2-5 mins at 37 °C, to facilitate cell detachment. Cell 
detachment from culture plates was controlled with a light microscope. The trypsin 
was subsequently deactivated by adding x2 volumes of MEF medium and triturated to 
produce a single cell suspension. Cells were thereafter pelleted at 300 x g for 5 mins 
and resuspended in fresh MEF medium. Cells were then counted (Section 2.1.2.3.5) 
and seeded at the required density on fresh culture plates or frozen down (Section 
2.1.2.3.4). 
 
2.1.2.2 Human primary cells 
 
2.1.2.2.1 Human foreskin fibroblasts 
 
Human foreskin fibroblasts (hFFBs) cells were purchased from the American Type 
Culture Collection (SCRC-1041; ATCC). hFFBs were cultivated in HEF medium (see 
appendix A2) and passages between P18-28 were used for all subsequent 
experiments.  
 
2.1.2.2.2 Human cardiac fibroblasts 
 
Human adult cardiac fibroblast cells (hcFB) were purchased from Lonza (V26C25). 
These cells were obtained from a middle aged male. hcFBs were cultivated in HEF 
medium (see appendix A2) and passages between P3-6 were used for all subsequent 
experiments. 
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2.1.2.2.3 Passaging and culture of primary human fibroblasts 
 
hFFBs and hcFBs were routinely passaged as described in section 1.2.3.5, with minor 
changes. Pre-warmed TrypLE (Invitrogen, 12604) was used for human FB cell 
detachment instead of 0.25% Trypsin-ETDA. After cell detachment, TrypLE was 
deactivated by adding x2 volumes of HEF medium and triturated to produce a single 
cell suspension. Cells were then counted and seeded at the required density on fresh 
non-coated culture plates or frozen down (Section 2.1.2.3.4). 
 
2.1.2.3.4 Freezing and thawing of primary mouse and human fibroblasts. 
 
Cultivated mouse FBs (MEFs; neonatal cFBs) and/or human FBs (hFFBs and hcFBs) 
were frozen down for practical storage purposes. Briefly, mouse and human cells 
were rinsed with pre-warmed PBS and then detached from culture plates into single 
cell suspensions (Sections 2.1.2.1.5 and 2.1.2.2.3), respectively. Cells were counted 
using a CASY counter (2.1.2.3.5), followed by centrifugation at 300 x g for 5 mins at 




 cells/ml) in freezing 
medium (see appendix A2) and gently mixed by trituration. Cells were finally 
transferred into cryovials (1 ml/vial), which were then immediately placed into an 
isopropanol insulated container at -80 °C, in order to freeze cells down slowly enough 
to maintain viability. Cells were able to be stored for years at -80 °C or -152 °C. For 
cell thawing, cells were thawed rapidly by placing cryovials into a 37 °C water bath. 
Thawed cells were immediately transferred into polypropylene tubes with 9 ml 
growth medium. Cells where then centrifuged at 300 x g for 5 mins at RT and 
resuspended in either; MEF (for mouse FBs) or HEF (for human FBs) medium, in 
order to remove the contaminating DMSO. Cell suspensions were then able to be used 
for subsequent experiments. 
 
2.1.2.3.5 Cell count and size measurements 
 
Cell number, size and viability measurements from single cell suspensions were 
assessed using a CASY Model TT cell counter (Roche), according to the 
manufacturer‟s instructions. A Neubauer cell counting chamber however was used to 
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determine the number of total viable single cells after the neonatal mouse heart 
isolation (Section 2.1.2.1.4). 
  
2.1.3 Embryonic stem cell generation and culture  
 
2.1.3.1 Mouse embryonic stem cells 
 
The mouse CM-selectable embryonic stem cell (mESC) line (αMHC-neoR “A6-line”; 
R1 background) was generated by electroporation of a plasmid encoding for a 
neomycin resistance gene (neoR), under the control of the cardiomyocyte restricted α-
myosin heavy chain (αMHC) promoter (Rogge, Dissertation 2007), as described 
previously (Klug et al., 1996). 
 
2.1.3.1.1 Culture of mouse embryonic stem cells  
 
Mouse ESCs were cultured on mitotically inactive MEFs (25,500 cells/cm
2
; Section 
2.1.2.1.3) in ESC culture medium (see appendix A2). Medium was exchanged every 
day. Once mESC-colonies reached 80-90 % confluency, cells were detached (Section 
2.1.2.1.5) with 0.25 % trypsin-EDTA and split at a 1:5 ratio. mESC-colonies were 
seeded onto new MEF feeder layer plates in ESC medium. Undifferentiated mESCs 
were cultured for at least 3 passages, prior to the initiation of cardiac differentiation. 
 
2.1.3.1.2 Scale up differentiation of mouse αMHC-NeoR ESCs 
 
The differentiation of mESCs was scaled up into spinner flasks, as described 
previously (Christalla, Dissertation 2010; Niebruegge et al., 2008). Undifferentiated 
mESCs were dissociated into single cells with trypsin (Section 2.1.2.1.5). Cells were 
resuspended in differentiation medium (see appendix A2) and pre-plated for 40 mins 
to minimize the MEF content. Cell suspensions were subsequently counted with a 
Neubauer cell counting chamber. Spinner flask culture vessels (125 ml) equipped with 
a bulb-shaped glass stirrer (Techne, F7988) were inoculated with 50 ml of medium 
containing 10x10
6
 cells and stirred at 60 rpm in a humidifying chamber at 37 °C in a 
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5% CO2 incubator. Flasks were filled up to 100 ml differentiation medium after 24 
hrs, followed by half medium exchange every 48 hrs. CM selection at day 11 was 
initiated by the addition of 400 µg/ml Geneticin (G418, PAA) for a further 6 days, in 
order to eliminate non-myocytes. 
 
2.1.3.1.3 Digestion of embryoid bodies into single cardiomyocytes 
 
At culture day 17, beating embryoid bodies (EBs) were harvested and dissociated into 
single CMs. EBs were transferred into two clean 50 ml polypropylene tubes. The 
tubes were left to rest for approximately 5-10 mins to allow the EBs to settle to the 
bottom of the tubes. The supernatant was very carefully removed and EBs were 
washed with pre-warmed 1X PBS and pelleted at 300 x g for 5 mins at RT. The 
supernatant again was carefully removed and EBs were resuspended in 6 ml 
Collagenase type I (Sigma-Aldrich, C0130; see appendix A2), containing DNase I (20 
µg/ml; Calbiochem). The EBs were triturated and then incubated at 37 °C for 60–90 
mins with agitation on a mechanical rocking platform (Biometra) to dissociate the 
EBs and yield single cells. Once all the EBs were dissociated, each tube was filled 
with pre-warmed 1X PBS and pelleted at 500 x g for 5 mins at RT. Cells were then 
resuspended in pre-warmed 6 ml 0.25% Trypsin-ETDA and were gently triturated for 
5-10 mins until all cell clumps were dissociated. The enzymatic digestion was 
inactivated with 24 ml differentiation medium + DNase I (20 µl/ml). The cell 
suspensions were then passed through a pre-wetted 70 µm cell strainer (BD falcon) 
into a fresh 50 ml polypropylene tube. The cells were pelleted at 200 x g for 5 mins at 
4 °C, resuspended in 10 ml differentiation medium and the tubes were pooled 
together. Cells were counted with (1:1) 0.4% trypan blue solution using a Neubauer 
cell counting chamber to determine the number and viability of cells. Cells were 
subsequently used for experiments, with a small cell fraction (~1 x 10
6
 cells) fixed in 
70% ethanol (EtOH) to assess the purity of CM via flow cytometry (FC) analysis 
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2.1.3.2 Human embryonic stem cells 
 
Experimentation with human embryonic stem cells were approved by the Robert-
Koch-Institute (www.rki.de; approval #12 from 13.09.2005 to W.H. Zimmermann 
according to §11 Stammzellgesetz) and the Human Embryonic stem cell (hES2) line 
was obtained from the lab of Prof. Gordon Keller, Toronto, Canada. hES2 line 
contained a targeted red fluorescence protein (tdRFP) reporter gene to the human 
ROSA26 locus (Irion et al., 2007). hES2 cells were initially adapted to culture with 
hESC medium (see appendix A2) on γ-irradiated hFFBs, prior to cardiac 
differentiation (Soong et al., 2012; Zimmermann et al., 2015). hESC-medium was 
exchanged daily until colonies covered 80% of the culture flasks.  
 
2.1.3.2.1 hES2 2D cardiac differentiation 
 
Cardiac differentiation in 2D culture was performed on hES2 cells using an optimized 
protocol (Hudson et al., 2012). All 2D differentiation experiments were performed in 
24 well plates filled with 0.5 ml culture medium and cultivated at 37°C in a 5% CO2 




 on Matrigel (growth 
factor reduced)-coated plates (1:60 diluted in 1X PBS; BD Biosciences, 354320) and 
cultured in 1:1 with hES-medium and irradiated hFFB-conditioned medium 
(conditioned for 2 days) with 10 ng/ml FGF2 (seeding phase). After 24 hrs seeding, 
hES2 cells were rinsed with RPMI medium (see appendix A2) and subsequently 
cultured in Mesoderm Induction medium (see appendix A2) for 3 days, followed by 
Cardiac Specification medium (see appendix A2) for 8 days, and thereafter 
Maturation medium for 1 day (see appendix A2). Differentiated cells were then 
cultivated for 5 days in Selection medium (0.28 ml/cm
2
; see appendix A2) to enrich 
the CM populations and eliminate non-myocytes via metabolic selection (Tohyama et 
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2.1.3.2.2 Single cell dissociation of hES2-cardiomyocyte monolayers 
 
Enriched CM populations derived from hES2 cardiac differentiation in monolayer 
culture (Section 2.1.3.2.1) were dissociated into single cells. Cells were washed twice 
in 1X PBS. Next, cells were incubated with Accutase solution (See appendix A2; 0.1 
ml/cm
2
) for 4 mins at RT. Cells were then incubated for a further 10-15 mins at 37 °C, 
until cells were detached from culture flasks and dissociated into single cells. The 
digestion procedure was deactivated with the addition of a threefold amount of serum-
free CM medium containing 5 µmol/l Rock inhibitor (see appendix A2). Cells were 
triturated to aid in single cell dissociation, transferred into fresh polypropylene tubes 
and counted using the CASY counter (Section 2.1.2.3.5) to determine cell number and 
viability. Cells were subsequently used for experiments, with a small cell fraction (~1 
x 10
6
 cells) fixed in 70% ethanol (EtOH) to assess the purity of CMs via Flow 
cytometry analysis (Section 2.1.4). 
 
2.1.4 Flow cytometry  
 
Flow cytometry (FC) was used to assess the purity of CMs derived from mESCs or 
hES2 cells. Fixed cell suspensions (in 70% EtOH) were initially passed through a 70 
µm cell strainer (to remove cell clumps), pelleted and then permeabilized in blocking 
buffer solution (see appendix A2) for 10 mins at RT. Cells were then incubated with 
primary antibody against CM-specific α-sarcomeric actinin (Sigma-Aldrich, A7811, 
1:4000) for 45 mins at 4 °C. Cell populations in parallel were also incubated with a 
primary antibody against Immunoglobulin G (IgG) isotype control (R&D systems), 
which served in samples as the respective negative control. Fixed cell suspensions 
were then washed (x2) in blocking buffer solution for 3 mins, followed by incubation 
with the Goat anti-Mouse Alexa 488 secondary antibody (Invitrogen, A-11001; 1: 
1000) and the nuclei labelling dye Hoechst (Invitrogen, H2570; 1: 1000) for 1 hr at 4 
°C in the dark. Cells were then again washed (x2) in blocking buffer for 3 mins. Cells 
were finally resuspended in PBS and cell populations were assessed on a LSRII 
cytometer (BD) and analyzed on FACSDiva Software 6.0 (BD).  
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2.2 Generation of Engineered Heart Muscle (EHM) 
 
Engineered Heart Muscle (EHM) are collagen-hydrogel based constructs comprising 
of the most abundant cellular and ECM components of native heart muscle, which 
resemble structural and functional properties of the native myocardium (Tiburcy et al., 
2011; Zimmermann et al., 2002).  
 
2.2.1 Construction and culture of EHMs 
 
Mouse and human EHMs were generated as described previously with minor 
modifications (Didié et al., 2013; Tiburcy et al., 2014). Custom-made culture dishes 





Figure 9. Design of casting molds for mouse and human EHM culture. EHM glass culture dishes 
consisted of 4 transparent silicon ring-shaped molds. The cylindrical silicon tubing in the middle was 
used as an inner central spacer during the first 3 days of the EHM casting/formation process. The inner 
diameter of molds was 4 mm, and outer diameter 10 mm (Images taken from Tiburcy et al., 2014). 
 
 
All pipetting steps were performed on ice to prevent premature polymerization of the 
EHM reconstitution mixture. Firstly, single cell suspensions (from mouse or human) 
containing 75% of CM and 25% FB cell fractions, were resuspended in the suitable 
volume of differentiation medium (cell suspension) to generate the respective number 
of EHMs (Table 1). Next, equal amounts of 2X concentrated medium (2X DMEM) 
(containing; FCS [40 %]; 10X DMEM [20 %]; P/S [2 %] in deionised water; sterile 
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filtered through a 0.22 µm syringe filter) were separately added to rat or bovine 
collagen type I. The yellow/orange colour change was an indicator for the acidity in 
the mixture. The pH was then adjusted (approx. 7.4) with the drop wise addition of 
0.1 N NaOH, as indicated by the pink colour change. The cell suspension was then 
added to the mixture and triturated several times to aid in homogeneity of the EHM 
reconstitution mixture. Finally, 450 µl of EHM mixture was distributed into 
individual casting mold recesses and incubated at 37 °C in a humidified incubator 
with 5 % CO2 for 1 hr.  
 
 
Mouse EHM master mix components Number of mEHMs 
 x1 x4 x8 
Rat tail collagen (4.2 mg/ml) 100 µl 400 µl 800 µl 
2x DMEM 100 µl 400 µl 800 µl 
0.1 N NaOH 20 µl 80 µl 150 µl 
Cell suspension* 306 µl 1224 µl 2448 µl 
Total volume of master mix 525 µl 2100 µl 4200 µl 
 
Human EHM master mix components Number of hEHMs 
 x1 x4 x8 
Bovine collagen (7.25 mg/ml) 65 µl 258 µl 515 µl 
2x DMEM 65 µl 258 µl 515 µl 
0.1 N NaOH 13 µl 50 µl 100 µl 
Cell suspension* 384 µl 1535 µl 3070 µl 
Total volume of master mix 527 µl 2110 µl 4200 µl 
 
Table 1. Composition of EHM mastermix. The respective total cell numbers in „cell suspension (*)‟ 
for different amounts of EHM mastermix: x1 (1.5 x10
6 
cells); x4 (6 x 10
6 
cells); x8 (12 x10
6
 cells), in 
mouse (mEHM) and human (hEHM). The final collagen concentration was 0.4 mg/EHM. 
 
 
After 1 hr EHM condensation, 6 ml of pre-warmed differentiation medium (see 
appendix A2) was added to each EHM casting dish 24 hrs. Images of EHM 
condensation on casting molds over the first 3 days of culture were taken using the 
Lumar V12 microscope (Zeiss) connected to the AxioCam (MRC) camera. On day 3, 
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the EHMs were progressively condensed and were transferred onto custom 
mechanical (static) stretchers (Figure 10) on 6 well plates. EHMs were maintained in 




Figure 10. Schematic overview outlining the formation and assessment of EHMs. EHM 
generation, tissue formation, mechanical (static) loading and functional (contractile force) 
measurements. 
 
2.2.2 Isometric force measurement 
 
Isometric force measurements of EHMs were performed as previously described 
(Zimmermann et al., 2000). Briefly, EHMs after a total of 10 days culture were 
carefully transferred into hooks of a force transducer in organ baths filled with 
Tyrodes solution (see appendix A2), maintained at 37 °C and perfused with carbogen 
(pH 7.4, 95% O2, 5% CO2). EHMs were electrically stimulated via two platinum 
electrodes at 4 Hz (5 ms monophasic pulses, 200 mA). EHMs were pre-stretched 
under 1.8 mmol/L [Ca
2+
] until the force of contraction reached a stable level (Lmax). 
After adjustment of extracellular Ca
2+ 
to 0.2 mmol/L, the contractile forces of EHMs 
were measured in response to a stepwise increase of extracellular [Ca
2+
] (0.2-2.4 
mmol/L). The maximum and minimum forces were evaluated using BMON software 
(G. Jaeckel, Hanau) and analysed by AMON software (G. Jaeckel, Hanau). Force of 
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2.2.3 Whole mount Immunoflourescence imaging 
 
Whole mount immunoflourescence imaging was performed to visualize cardiac 
muscle formation within EHMs. After cultivation, EHMs were washed once on 1X 
PBS and fixed in Roti® Histofix 4 % overnight at 4°C. Thereafter, EHMs were 
washed once in 1X PBS and incubated in permeabilizing blocking buffer solution (see 
appendix A2) for 24 hrs at 4 °C. EHMs were subsequently incubated with a mouse 
monoclonal primary antibody targeting alpha sarcomeric α-actinin (1:1000; Table 2) 
for 48 hrs on a rotary microfuge holder at 4 °C. EHMs were then washed (x3) in 
blocking buffer for 15 min incubation steps, followed by the incubation with the Goat 
anti-Mouse Alexa 488 secondary antibody (1: 400; Table 2) secondary antibody, F-
actin labelling dye, phalloidin (conjugated with Alexa Fluor® 633, 1:60; Table 2) and 
the nuclei labelling dye, Hoechst (1:1000; Table 2) for a further 24 hrs on the rotary 
microfuge holder at 4 °C in the dark. EHMs were again thoroughly washed (x3) in 
blocking buffer for 15 min incubation steps and were thereafter stored in x1 PBS. 
Finally, EHMs were mounted onto microscope slides using Fluoromount-G mounting 
medium (Southernbiotech). Microscope slides were imaged using the Zeiss LSM710 
confocal microscope. 
 
2.3 Integrin expression in fibroblast and cardiomyocyte populations 
2.3.1 Protein biochemical analysis 
 
Cultivated FBs and CMs were rinsed thoroughly in 1X PBS to remove any remaining 
medium/serum and cell debris. The following protein extraction (Section 2.3.1.2) or 
RNA extraction (Section 2.3.2.1) steps on cell lysates were then performed as 
described below. 
 
2.3.1.1 Protein extraction 
 
To obtain cell lysates from cultured cells, CytoBuster
TM
 Protein extraction reagent 
(Millipore; 71009; containing both Protease [Roche] and Phosphotase (PhosSTOP) 
inhibitor [Roche] cocktails), was layered over the cells (300 μl/well in 6 well plates) 
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and allowed to extract for 5 mins at 4 °C (according to manufacturer‟s instructions). 
Thereafter, a cell scraper (Sarstedt) was used to collect the lysated cells to be 
transferred into 1.5 ml microfuge tubes. Cell lysates were centrifuged at 14,000 x g 
for 5 mins at 4°C to pellet the cell debris. The supernatant containing cell lysates were 
separated from the bottom cell debris pellet, collected into sterile microfuge tubes and 
stored at -20°C until further use. 
 
2.3.1.2 Protein quantification (Bradford assay) 
 
The concentration of total protein in cell lysate samples was determined using a 
standard colorimetric Bradford protein assay (Bradford, 1976). Briefly, samples 
(thawed and stored on ice) and a standard curve with increasing protein BSA amounts 
(0, 1, 2, 4, 8, 16 µg) were prepared in 50 µL distilled H2O. Samples and standards 
were prepared in triplicates and transferred into a 96-well microplate. Into each 
sample and standard triplicate, 200 µL of 1x Bradford reagent (Roti Quant; K015.3) 
in H2O was added and incubated for 5 min at RT. The absorbance at 595 nm was 
detected with the Flexstation
®
 3 Multi-mode microplate reader (Molecular Devices) 
and the total protein concentrations of the samples were calculated from standard 
curves. 
 
2.3.1.3 Immunoblotting analysis 
 
For analysis of protein expression in total cell lysates, sodium dodecyl sulfate –
polyacrylamide gel electrophoresis (SDS-PAGE) was performed. To prepare SDS-
PAGE samples, 6X Laemmli Loading buffer (see appendix A2) was added to cell 
lysates (15 µg/sample) and incubated at 95 °C for 5 min for protein denaturation.  
 
Proteins were loaded on 10-15 % SDS-polyacrylamide gels (see appendix A2) and 





ladder (BioRad) was used for the estimation of molecular weights in all protein 
samples. Protein samples were ran in 1x electrophoresis running buffer (appendix A2) 
at 70 V for initial sample condensation and later at 120 V for protein separation. 
Thereafter, resolved SDS-PAGE gels were electrophoretically transferred onto 
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0.45, 10600023) and incubated in 1x transfer buffer (appendix A2) at 4 °C for 1 hr at 
100 V. All membrane blots were blocked with 10% Roti
®
-block blocking solution 
(diluted in ddH2O; Roth, A151.4) on a mechanical rocking platform (Biometra) for 1 
hr at RT, followed by incubation with the respective primary antibodies (Table 2) 
prepared in TBST buffer (see appendix A2) overnight at 4 °C. Thereafter, the 
membranes were thoroughly washed (x3) in TBST buffer for 10 mins and incubated 
with the following secondary antibodies (Table 2) on the rocking platform for 1 hr 
and RT. To visualize membrane bands, protein-antibody complexes were detected 
using the chemiluminescent reagent SuperSignal
®
 West Femto Maximum Sensitive 
Substrate (Thermo Scientific, # 34095). The signals were detected with a ChemDoc
TM
 
MP Imaging System (BioRad) and semi-quantitatively analyzed with Image Lab
TM
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Primary Antibody Dilution/Amount 
Name Species Manufacturer/Catalogue no. IHC WB FACS 
anti-Calsequestrin Rabbit ThermoFisher Scientific (PA1-913) - 1:1000 - 
anti-Cardiac Troponin I Rabbit Abcam (ab47003) 1:200 1:200 - 
anti-Collagen (pro-) type I 
(aminopropeptide) 
Mouse DSHB (SP1.D8) - 0.5 µg/ml - 
anti-Collagen type I Rabbit Abcam (ab34710) 1:200 - - 
anti-FSP-1 Rabbit Millipore (ABF32) - 1.0 µg/ml - 
anti-GAPDH Mouse Millipore (MAB374) - 1:1000 - 
anti-HSP47 Mouse Enzo Life Science (SPA470) 1:100 1:1000 - 
anti-Mouse IgG1 isotype 
control 
Mouse R&D Systems (MAB002) 1:100 - 1:1000 
anti-Integrin alpha 1 Rabbit Abcam (ab106267) - 2.0 µg/ml - 
anti-Integrin alpha 2 Rabbit Abcam (ab133557) - 1:10,000 - 
anti-Integrin beta 1 Rabbit Abcam (ab179471) - 1:2000 - 
anti-PDI Rabbit Cell Signalling (#2446) 1:50 1:1000 - 
anti-Pro-COL1A1 Rabbit Santa Cruz (sc-30136) 1:100 - - 
anti-Sarcomeric α-actinin Mouse Sigma-Aldrich (A7811) 1:1000 - 1:4000 
      
Secondary Antibody Dilution/Amount 
Name Species Manufacturer/Catalogue no. IHC WB FACS 
anti-Mouse IgG/HRP 
conjugate 
Goat Dako (P0260) - 1:10,000 - 
anti-Rabbit IgG/HRP 
conjugate 
Goat Dako (P0448) - 1:5000 - 
anti-Mouse-Alexa 488 Goat Invitrogen (A11001) 1:400 - 1:1000 
anti-Rabbit-Alexa 488 Goat Invitrogen (A11008) 1:400 - - 
anti-Mouse-Alexa 546 Goat Invitrogen (A11003) 1:400 - - 
anti-Rabbit-Alexa 546 Goat Invitrogen (A11010) 1:400 - - 
      
Fluorescent Conjugate Dilution/Amount 
Name Species Manufacturer/Catalogue no. IHC WB FACS 
Alexa Flour Phalloidin 633 - ThermoFisher Scientific (A22284) 1:60 - - 
Hoechst - Invitrogen (H3570) 1:1000 - 1:1000 
      
Blocking Antibody Dilution/Amount 
Name Species Manufacturer/Catalogue no. EHM blocking 
anti-Rat/Mouse CD49a 
(Integrin alpha 1 chain) 
Hamster BD PharmingenTM (555001) 50 µg/ml 
anti-Rat CD49b (Integrin alpha 
2 chain) 
Hamster BD PharmingenTM (554998) 50 µg/ml 
anti-Rat CD29 (Integrin beta 1 
chain) 
Hamster BD PharmingenTM (555002) 40 µg/ml 
 
 Table 2. List of primary and secondary antibodies/fluorescent conjugates used for protein biochemical 
analysis. Antibodies/fluorescent conjugates were diluted to final working concentrations (as shown) in blocking 
buffer solution (see appendix) for; immunohistochemistry (IHC) or Fluorescent-Activated Cell Sorting (FACS). 
Antibodies for Western blot (WB) were diluted in TBS-T (see appendix). Blocking antibodies were diluted in 
differentiation medium (see appendix). 
2. Materials and Methods 
42 
2.3.2 Transcript analysis 
2.3.2.1 RNA extraction 
 
Total RNA was extracted from cells using the standard Trizol protocol (According to 
manufacturer‟s instructions). Using sterile filter pipette tips, pre-rinsed samples were 
carefully layered over with 1ml TRIzol
®
 reagent per 10 cm
2
 culture dish (Ambion 
Life Technologies; 15596026). A cell scraper was used to collect the cell lysates. The 
resulting suspension was transferred into sterile 2 ml microtubes and 200 µl 
Chloroform (Applichem, A3691) was added to the tubes, mixed (vortex) and rested 
for 3 mins at RT. Samples were centrifuged at 12,000g at 4 °C for 15 mins. The clear 
aqueous phase supernatant was carefully removed and transferred into RNase free 1.5 
ml microfuge tubes. 500 µl isopropanol (Roth, 6752.2) was added to the tubes, 
vortexed and rested for 10 mins to allow RNA precipitation. Next, samples were 
centrifuged at 12,000 g at 4 °C for 10 mins to pellet the RNA and then rinsed with 
70% EtOH. Following another centrifuge step at 12,000 g at 4°C for 5 mins, the RNA 
tubes were allowed to airdry for 10 mins. RNA samples were thereafter suspended in 
DEPC water (Sigma, 95284). The amount (ng/ml) and quality (260/280 nm OD. Ratio 
≥ 1.8) of RNA was finally assessed with a spectrophotometer (Nanodrop, ND-1000, 
ThermoScientific) at a wavelength of 260 nm. Samples were subsequently stored at -
80 °C until further use. 
 
2.3.2.2 RNA reverse transcription (RT) 
 
RNA extracted from samples was initially treated with DNase I (Roche, 
04716728001) to remove contaminating genomic DNA. A reaction mixture 
containing 1 µg RNA was treated with 0.2 µl DNase I enzyme (10 U/µl), with the 
addition of 1 µl DNase I buffer and incubated for 20 mins at 37 °C. This was then 
followed by the addition of 1 µl EDTA solution (40 µmol/L stock) and incubated for 
10 mins at 75 °C to inactive DNase I activity. cDNA synthesis was subsequently 
performed on DNase treated samples using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems), following the manufacturer‟s instructions. A 
2X mastermix was added (containing; 2 µl 10X RT buffer, 0.8 µl 25X dNTPs [100 
mmol/L], 2 µl 10X RT Random Primers, 1 µl RNase inhibitor and 2.2 µl DEPC water 
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and 1 µl Multiscribe Reverse Transcriptase) to each RNA sample. To control for 
genomic DNA contamination, a substitute reaction mixture containing 1 µl DEPC 
water (replacing 1 µl Multiscribe Reverse Transcriptase) was additionally included for 
each sample [no reverse transcriptase (RT) control]. RNA samples were then place 
into the T gradient PCR thermocycler (Biometra) for PCR amplification (25 °C for 10 
mins, 37°C for 120 mins, 85 °C for 5 mins, and then 4 °C) for 40 cycles. The 
amplified cDNA products were subsequently diluted 1:5 in RNase-free water and 
stored at -20 °C until further use. 
 
2.3.2.3 Polymerase chain reaction (PCR) 
 
PCR reactions were performed using the T gradient PCR thermocycler (Biometra) and 
Extaq DNA polymerase (TaKaRa Bio. Inc) according to manufacturer‟s instructions. 
A PCR (4X reaction) mixture contained: 37.7 µl distilled water, 5 µl 10X Ex Taq 
Buffer, 4 µl dNTP mixture (2.5 mM), 1 µl of each forward (F) and reverse (R) 
primers (10 mM), 0.25 µl TaKaRa Ex Taq (5 U/µl) and 1 µl cDNA (Section 2.3.2.2). 
The primer sequences used for PCR are listed in Table 4. The PCR conditions are 
described below in Table 3. After PCR amplification, the PCR products were pre-
mixed with suitable volumes of 6X DNA loading buffer (see appendix A2), loaded 
into 1.5% DNA agarose gels (see appendix A2) and separated by electrophoresis in 
1X TAE gel running buffer (see appendix A2) at 90 V for approximately 30 mins. 
The band(s) of the respective DNA product sizes (Amplicons) were imaged by the 
Gel Doc XR (BioRad) system.  
 
Proceedure Temperature (°C) Time Cycles 
Initial denaturation 98 30 sec 1 
Denaturation 98 10 sec 
35 Annealing 60 30 sec 
Elongation 72 30 sec 
Final elongation 72 5 mins 1 
Stop 4 ∞ 1 
 
Table 3. Thermocycler conditions used for PCR. 
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 2.3.2.4 Quantitative polymerase chain reaction (qPCR) 
 
All qPCR runs were performed on the ABI PRISM 7900HT Fast Real-Time PCR 
system (Applied Biosystems) on 384-well plate format. A mastermix (9 µl) was 
prepared for each different primer (targeting a specific gene of interest) containing: 
3.75 µl Nuclease-free water, 5 µl Fast track SYBR
® 
Green Master Mix (Applied 
Biosystems; 4385612) and 0.25 µl Primers (containing both forward (F) and reverse 
(R) primers; from 2 µM stocks). All sample reactions were performed in triplicates. 
Mastermixes for each gene (9 µl/well) were firstly pipetted into a MicroAmp® 
Optical 384-Well Reaction Plate (Applied Biosystems, 4309849) on ice, followed by 
the addition of 1 µl cDNA to each different mastermix respectively. Separate wells 
both containing 1 µl „no RT‟ and 1 µl „water‟ (no template DNA) were included as 
controls to ensure no genomic DNA presence or any primer contamination. Next, the 
384-well plate was covered with a clear adhesive film (Applied Biosystems, 4306311) 
and centrifuged at 1,000 g for 2 mins. qPCR amplification was then performed with 
the following PCR conditions: 50 °C  for 2 mins, denaturation at 95 °C  for 10 mins 
and a cycle amplification at 95 °C for 15 s and 60 °C  for 1 min (for a total of 40 
cycles). A melting point dissociation curve step was added to determine primer 
specificity. The results obtained from the run were assessed on the Sequence 
Detection System ABI 7900HT v2.4 software (Applied Biosystems). The relative 
gene transcript expression, relative to the housekeeping gene expression in samples 
was analysed using the ΔCt or ΔΔCt method (Livak and Schmittgen, 2001). Cycle 
threshold (Ct) values for all genes of interest were normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene. All primer sequences (F 
and R) are listed below (Table 4). GAPDH expression levels did not differ 
significantly between the investigated samples groups in all experiments, and was 















ACC GAT GGA TTC 
CCG TTC G 




GCT GGG AAA CAT 
GGA AAC CG 
GGA TGC CTT GAG 
GAC CAC TA 
ENSMUSG00000029661 100 
Itgα1 
CAA TGC CAG AAC 
TTC GGC TG 
AAA GGG TCC TCA 
AGG CTT CG 
ENSMUSG00000042284 130 
Itgα2 
GGG ACC TCA CAA 
ACA CCT TCA G 
TCG CCA TCG GTC 
ACA ACT AC 
ENSMUSG00000015533 115 
Itgβ1 
GCC AAA TCT TGC 
GGA GAA TGT 
ACA TCG TGC AGA 
AGT AGG CA 
ENSMUSG00000025809 99 
Hsp47 
CTG CAG TCC ATC 
AAC GAG TGG GC 
ATG GCG ACA GCC 
TTC TTC TGC 
ENSMUSG00000070436 403 
Gapdh 
ATG TTC CAG TAT 
GAC TCC ACT CAC G 
GAA GAC ACC AGT 
AGA CTC CAC GAC A 
ENSMUSG00000057666 171 
β-Actin 
CTA AGG CCA ACC 
GTG AAA AGA 
AGA GGC ATA CAG 




CAG CGC CTT CTG CCT 
CCT GGA G 
CGC CTT GCC GCC 




CCG TGG GTG TCA 
TGA TGA TG 
CTT CCC CAT CCA GAT 




GAA AAG CTG CTA 
ACC AAA G 
GAA GAT GAA GGG 
GTG GTC G 
ENSG00000149257 327 
GAPDH 
CCT CAA GAT CAT 
CAG CAA TGC C 
ATG TTC TGG AGA 
GCC CCG C 
ENSG00000111640 189 
 
Table 4. Primers used in RT-PCR and qPCR analysis 
 
 
2.3.2.5 RNA sequencing (RNA-seq) and bioinformatics 
 
RNA-seq analysis was performed at the Transcriptome and Genome Analysis 
Laboratory at the University Medical Center Göttingen. Total RNA was isolated from 
samples (hES2-CMs, hcFBs and hFFBs; n=3/group) using the Trizol extraction 
method, as described in Section 2.3.2.1. RNA quality was assessed with the 
Bioanalyzer 2100 Fragment Analyzer and all samples subjected to RNA sequencing 
exhibited an RNA integrity number of > 7. Total RNA was thereafter subjected to 
library preparation (TruSeq Stranded Total RNA Sample Prep Kit from Illumina) and 
RNA-sequencing was performed on an Illumina HighSeq-2000 platform (50 bp single 
end run; >25 million reads /sample).  
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Sequence images were transformed with Illumina software BaseCaller to bcl files, 
which were demultiplexed to fastq files with CASAVA (v1.8.2). Reads were aligned 
by STAR (2.3.9e) to the Ensembl human genome (37.74) (Dobin et al., 2013). 
Counting the reads to each gene to the Ensembl gene annotation file gtf (37.74) was 
done via HTSeq python scripts. Data was pre-processed and analysed in the R 
environment (3.0.2/2.14) loading DESeq, gplots, and biomaRt packages (Durinck et 
al., 2009). After filtering the genes exceeding more than 20 counts for at least one 
sample; normalisation, estimation of dispersions and testing for differentially 
expressed genes based on a test assuming negative binomial data distribution was 
computed via DESeq (Anders and Huber, 2010). Candidate genes were filtered to a 
minimum of 2x fold change and False Discovery Rate (FDR) corrected to P < 0.05. 
Functional association for the candidates genes were analysed using gene ontology 
and Kyoto Encyclopedia of Genes and Genomes pathway enrichment via goseq. 
 
The script language R was utilized for data analysis and for heat map generation, 
together with the gplot-package for visualizing the expression values for pre-selected 
genes from the normalized RNA-seq data (Development Core Team R, 2009; Warnes 
et al., 2009). 
 
2.4 Assessment of integrin-ECM signalling in EHM formation  
2.4.1 Integrin blocking in EHM formation 
 
To investigate the role of collagen binding integrin Itgα1, Itgα2 and Itgβ1) signalling 
in EHM formation, human and mouse purified CM and FB populations were mixed 
(75 % purified CMs + 25 % FBs) and incubated with the respective integrin blocking 
antibodies targeting integrin α1 chains (CD49a; 50 µg/ml), integrin α2 chains 
(CD49b; 50 µg/ml) and Integrin β1 chains (CD29; 40 µg/ml) (Table 2) at 37 °C for 30 
minutes. As EHMs failed to form condensed tissue in the absence of FBs, EHMs 
generated with purified CMs (only) was used a negative control for tissue contraction. 
EHMs were generated (as described in Section 2.2.1) and 40 µl of EHM 
reconstitution mixture were distributed into wells (1.25 x 10
5
 cells/well; scaled down 
to 1:12 of the original master mix for x1 EHM) of an ultra-low attachment surface flat 
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bottomed 96-microwell plate (Corning, 13414054) and incubated at 37 °C in a 
humidified incubator with 5 % CO2. Surface treated ultra-low attachment plates 
prevented the EHM reconstitution mixtures from sticking to the sides/bottom of wells.  
 
After 1 hr of initial casting, 100 µl of fresh differentiation medium supplemented with 
the respective; α1 chain (50 µg/ml), α2 chain (50 µg/ml) and β1 chain (40 µg/ml) 
blocking antibodies (as described above) were added to wells and placed back into 
culture. After 21 hrs of casting („blocking‟), images of EHMs in wells were captured 
using a high throughput automated Cellavista machine (SynenTec Bio Services 
GmbH). The medium in each well was then carefully removed using a microwell 
aspirator, without making contact with the tissues and replaced with 100 µl of fresh 
differentiation medium to wash out the blocking antibody from tissues. After 72 hrs of 
casting („recovery‟), images of EHMs in wells were again obtained. The surface area 
of retracted EHM tissues during blocking (21 hrs) and recovery (72 hrs) was assessed 
using Image J software (National Institutes of Health). The percentage (%) of EHM 
contraction/retraction per well was calculated as summarized below: 
 




2.5 Assessment of collagen processing heat shock protein 47 knockout (HSP47 
KO) MEFs  
2.5.1 HSP47 KO MEFs 
 
HSP47 KO MEFs were kindly provided from the lab of Prof. Nagata (Kyoto Sangyo 
University, Kyoto, Japan). The HSP47 KO MEF cell line was established from 8.5 
dpc embryos of HSP47 KO mice (C57BL/6J), in which the Hsp47 gene was disrupted 
using homologous recombination with targeting vectors deleting exon 4 and a part of 
exon 5 (Nagai et al., 2001). These collagen processing-defective HSP47 KO MEFs 
were compared to wild-type (WT) C57BL/6J MEFs for all purposes of this study. 
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2.5.2 Characterization of HSP47 KO MEFs 
 
The absence of HSP47 expression in HSP47 KO MEFs in culture, was characterized 
at both RNA level via RT-PCR (Section 2.3.2.2 and 2.3.2.3), and at protein level by 
immunoblotting analysis (Section 2.3.1.4) and immunoflourescence staining (Section 
2.7.4), respectively.  
  
2.6 Investigating collagen secretion in HSP47 KO MEFs 
2.6.1 Assessment of soluble collagen secretion 
 
To quantitatively compare the amount of soluble collagen secreted from WT and 
HSP47 KO FBs, the amount of soluble collagen in the culture medium was assessed 
using the soluble Sircol
TM
 assay kit. A schematic outline of the experiment is 





Figure 11. The measurement of soluble collagen secretion in MEFs. WT and HSP47 KO MEFs 
were resuspended in low serum medium (containing; DMEM, 0.5% FCS; 1% P/S; 148 µg/ml L-
Ascorbic Acid 2-phosphate magnesium salt [AA]) and seeded on 6 well plates (3 x 10
5
 cells/well; 2 
ml/well). Cells were cultured for 72 hrs in at 37 °C, 5% CO2. Conditioned medium and cells were 
thereafter subjected to 1) conditioned medium analysis using the Sircol
TM
 assay kit, and 2) cells were 
counted using the Cellavista image platform (SynenTec Bio Services GmbH), respectively. 
 
 
The cell conditioned medium from each well was transferred into fresh 2 ml 
microtubes and pelleted at 300 x g for 5 mins at RT, to remove cellular debris. 
Conditioned medium (1 ml) was then transferred into clean 1.5 ml microtubes and 
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total soluble collagen in the conditioned medium was measured using the Sircol™ 
assay kit (Biocolor), according to manufacturer‟s instructions. Low serum medium (1 
ml) cultivated on plates in the absence of cells were used as normalization controls. 
Conditioned medium samples were initially treated with 200 µl ice-cold Isolation and 
Concentration reagent (provided by the manufacturer‟s), mixed and incubated 
overnight at 4°C to concentrate the collagen within samples, prior to measurements.  
 
Next, samples were centrifuged at 15,300 x g and supernatants were then carefully 
removed leaving a remaining 100 µl and the invisible pellet of hydrated transparent 
collagen at the bottom of the microtube. Rat tail collagen reference standards (0, 1.25, 
2.5, 5, 10 µg; provided by the manufacturer) were then prepared in 100 µl sterile 
water. Sircol dye reagent (1 ml) containing Sirius red in picric acid was added to each 
standard, control and sample tubes. Microtubes were then mixed by inversion and 
placed on a mechanical rocking platform (BioMetra) for 30 mins at RT in order to 
form collagen-dye complexes which precipitate out collagen from the soluble 
unbound dye. Tubes were then centrifuged again at 15,300 x g for 10 mins at 4 °C, 
and carefully inverted to remove the excess unbound dye reagent. Provided ice-cold 
Acid-Salt wash (750 µl) was gently added to tubes and gently mixed in order to 
remove any unbound dye on the surface of pellets and on the inside surfaces of tubes. 
Microtubes were again centrifuged at 15,300 x g for 10 mins at 4 °C and acid-wash 
reagent was gently drained out from the tubes as much as possible without disturbing 
the red/pink precipitated collagen-dye pellet. To release and remove collagen from the 
bound dye, 250 µl of provided ice-cold Alkali reagent was added to all tubes. 
Microtubes were mixed until the bound dye dissolved (~5 mins), and were 
subsequently transferred into individual wells (200 µl) of a 96-microwell plate.  
 
The absorbance of standards, controls and samples at 555 nm was detected with the 
Flexstation
®
 3 Multi-mode microplate reader, against water (blank) and the collagen 
amount of all conditioned medium samples (in 2 ml) were calculated from standard 
curves. The measured value of collagen in control tubes (containing low serum 
medium only) was subtracted from the sample values. 
 
Plates used in the experiment outlined above were then washed once in 1X PBS and 
subsequently fixed in Roti
®
 Histofix 4% for 15 mins at RT. Cells were then washed 
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(x2) in 1X PBS, permeabilized in blocking buffer solution (see appendix A2), and 
labelled with Hoechst. Thereafter, the total number of fluorescence-labelled cell 
nuclei in each well was assessed using a high-throughput automated imaging platform 
(Cellavista; SynenTec Bio Services GmbH). The total amount of soluble collagen 
normalized to cell number (xg/cell) was thus determined from these two experiments, 




* Determined via Soluble Collagen Sircol™ assay kit.per cell (xg/cellaaaaaaaaaaaaaaaaaa) was thus ca 
#
  Determined via Cell nuclei counting/Cellavista. 
 
 
2.6.2 Deoxychelate (DOC)-separation ECM components 
 
WT and HSP47KO MEFs were assessed for differences in ECM secretion. The 
protocol for extraction of the deoxycholate (DOC)-insoluble ECM in MEFs was 
modified from (Van Duyn Graham et al., 2010; Midwood et al., 2002). WT and 
HSP47 KO MEFs were cultured at high seeding density (1 x 10
5
 cells/well, on 24-
well plates) for 7 days in MEF medium containing: 148 µg/ml L-Ascorbic Acid 2-
phosphate magnesium salt. Culture medium was removed and cells were washed once 
in 1X PBS. Cells and ECM suspensions were harvested in 300 µl cold DOC buffer (4 
% DOC in 20 mM Tris-HCl, pH 8.8 and Protease inhibitors [Roche]), scraped off and 
transferred into 1.5 ml microtubes. The extracts were homogenized (x5) with a 27
1
/2 
gauge needle and then pelleted at 18,000 x g for 20 mins at 4 °C. The supernatants 
(DOC-soluble fraction) were carefully collected and transferred into fresh 1.5 ml 
microtubes. The pellets were washed again with 200 µl DOC buffer and centrifuged at 
18,000 x g for 20 mins at 4 °C. The supernatant was transferred into the DOC-soluble 
fraction, containing cellular material and components not incorporated into the ECM. 
The DOC-insoluble pellet fraction containing ECM components (Van Duyn Graham 
et al., 2010; Midwood et al., 2002) was solubilised in 200 µl DOC insoluble buffer 
(1% SDS, 25 mmol/l Tris-HCl, pH 8.0, and protease inhibitors). DOC-insoluble ECM 
fractions were incubated at 95 °C for 5 mins. 
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Prior to SDS-PAGE analysis, protein content was quantified with a standard 
Pierce™ bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific), to 
standardize loading protein concentrations (Smith et al., 1985). Proteins 
were resolved on 10% SDS-polyacrylamide gels (as described in Section 2.3.1.4). A 
rat tail collagen sample was used as a comparative molecular weight reference for 
collagen type I. To visualize all proteins resolved on gels from DOC insoluble ECM 
fractioned samples, coomassie blue staining was used to stain SDS-PAGE gels: 
Resolved SDS-PAGE gels were carefully removed from casting chambers and were 
gently washed (x3) in deionized water for 5 mins at RT. Gels were then incubated for 
1 hr at RT in Coomassie Brilliant Blue solution (G-250). Next, staining solution was 
carefully removed and SDS-PAGE gels were washed once in distilled water for 5 
mins to remove any unbound dye, and then rinsed overnight at RT. Images of 
coomassie stained gels were taken on the ChemDoc
TM
 MP Imaging System (BioRad). 
 
2.6.3 Mass spectrometric analysis of DOC-insoluble ECM components  
 
Mass spectrometric (MS) analyses were performed by the Proteomics Core Facility at 
the University Medical Center Göttingen (Dr. C. Lenz; Prof. H. Urlaub).  
 
2.6.3.1 Sample preparation  
 
DOC-insoluble ECM fractions from WT- and HSP47 KO MEFs (n=1 sample/group) 
were reconstituted in 1× NuPAGE
 
LDS Sample Buffer (Invitrogen) and separated on 
4-12 % NuPAGE Novex Bis-Tris Minigels (Invitrogen). Gels were stained with 
Coomassie Blue for visualization purposes, and each lane was sliced into 23 
equidistant segments, regardless of staining. After washing, gel slices were reduced 
with dithiothreitol (DTT), alkylated with 2-iodoacetamide and digested with trypsin 
overnight. The resulting peptide mixtures were then extracted, dried in a SpeedVac, 
reconstituted in 2 % acetonitrile/0.1 % formic acid/ (v:v) and prepared for Nanoscale 
liquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS) as 
described previously (Atanassov and Urlaub, 2013). 
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2.6.3.2 NanoLC-MS/MS analysis  
 
For MS analysis, samples were enriched on a self-packed reversed phase-C18 
precolumn (0.15 mm ID x 20 mm, Reprosil-Pur120 C18-AQ 5 µm, Dr. Maisch, 
Ammerbuch-Entringen, Germany) and separated on an analytical reversed phase-C18 
column (0.075 mm ID x 200 mm, Reprosil-Pur 120 C18-AQ, 3 µm, Dr. Maisch) 
using a 30 min linear gradient of 5-35% acetonitrile/ 0.1% formic acid (v:v) at 300 nl 
min
-1
). The eluent was analyzed on a Q Exactive hybrid quadrupole/orbitrap mass 
spectrometer (ThermoFisher Scientific, Dreieich, Germany) equipped with a FlexIon 
nanoSpray source and operated under Excalibur 2.4 software using a data-dependent 
acquisition method. Each experimental cycle was of the following form: one full MS 
scan across the 350-1600 mass-to-charge ratio (m/z) range was acquired at a 
resolution setting of 70,000 Full Width at Half Maximum (FWHM), and Automatic 
Gain Control (AGC) target of 1 x 10
6
 and a maximum fill time of 60 ms. Up to the 12 
most abundant peptide precursors of charge states 2 to 5 above a 2 x 10
4
 intensity 
threshold were then sequentially isolated at 2.0 FWHM isolation width, fragmented 
with nitrogen at a normalized collision energy setting of 25 %, and the resulting 
product ion spectra recorded at a resolution setting of 17,500 FWHM, and AGC target 
of 2 x 10
5
 and a maximum fill time of 60 ms. Selected precursor m/z values were then 
excluded for the following 15 s. Two technical replicates per sample were acquired. 
 
2.6.3.3 Data processing  
 
Peaklists were extracted from the raw data using Raw2MSMS software v1.17 (Max 
Planck Institute for Biochemistry, Martinsried, Germany). Protein identification was 
achieved using MASCOT 2.4 software (Matrixscience, London, United Kingdom). 
Proteins were identified against the UniProtKB mouse reference proteome v2014.12, 
along with a set of 51 contaminants commonly identified in our laboratory. The 
search was performed with trypsin as enzyme and iodoacetamide as cysteine blocking 
agent. Up to two missed tryptic cleavages and methionine oxidation as a variable 
modification were allowed for. Search tolerances were set to 10 ppm for the precursor 
mass and 0.05 Da for fragment masses, and ESI-QUAD-TOF specified as the 
instrument type. 
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Scaffold software version 4.4.1.1 (Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications 
were accepted if they could be established at greater than 95.0 % probability by the 
Percolator algorithm. Protein probabilities were assigned by the Protein Prophet 
algorithm (Nesvizhskii et al., 2003). Protein identifications were accepted if they 
could be established at greater than 99% by the Percolator algorithm and contained at 
least 2 identified peptides. Protein hits that contained similar peptides and could not 
be differentiated based on MS/MS analysis alone were grouped to satisfy the 
principles of parsimony. Proteins sharing significant peptide evidence were grouped 
into clusters. Proteins were annotated with GO terms from NCBI downloaded Feb 23, 
2015 (Ashburner et al, 2000). Relative quantification of proteins in the samples was 
achieved by Analysis of Variance (ANOVA) of normalized Spectral Counts using a 
Benjamini-Hochberg-corrected p value of 0.05 to judge significance. To allow for the 
calculation of low abundance protein ratios, a minimum value of 3 spectral counts 
was introduced where necessary.  
 
2.7 Fibroblast-derived ECM characterization 
2.7.1 Generation of fibroblast-derived ECM  
 
FB-derived ECM was generated as previously described with minor modifications 
(Beacham et al., 2007). WT or HSP47 KO MEFs were plated at high seeding density 
on 24-well tissue culture plates and cultured for 11 days to deposit matrices on pre-
coated glass coverslips. Firstly, sterile 15 mm glass coverslips (prior to cell seeding) 
were incubated in 0.2 % prepared gelatine solution (Sigma, G2500) for 1 hr at 37 °C. 
Coverslips were then washed once in 1X PBS and thereafter treated with 1% 
Gluteraldehyde (Sigma-Aldrich, G5882; prediluted in 1X PBS and sterile filtered 
through a 0.22 µm syringe filter) for 30 mins at RT to crosslink Gelatine and stabilize 
the attachment of ECM to culture dish surfaces. Coverslips were subsequently 
thoroughly washed (x3) in 1X PBS and treated with 1 mol/L ethanolamine (Sigma-
Aldrich, E9508; prediluted in deionized water and sterile filtered through a 0.22 µm 
syringe filter) for 30 mins and RT. Coverslips were again thoroughly washed (x3) 
with 1X PBS and ready for use.  
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MEFs (WT and HSP47 KO) were subsequently plated at high seeding density (1x10
5
 
cells/well) onto coated coverslips. After 24 hrs of cell seeding, medium was replaced 
with fresh MEF medium containing; 148 µg/ml L-Ascorbic Acid 2-phosphate 
magnesium salt (Sigma-Aldrich), to facilitate in the deposition of a dense ECM 
network (Beacham et al., 2007). Medium was changed every second day. 
Decellurization was performed by utilizing prewarmed extraction buffer containing: 
0.5 % Triton X-100 (Sigma, T8787); 20 mmol/l mmonium hydroxide (NH4OH; 
Sigma-Aldrich, 338818) in 1X PBS. Plates were incubated for approximately 2-5 
mins at 37 °C and 5% CO2, until no intact cells are visible under the inverted 
microscope. 1X PBS was gently added and plates were stored overnight at 4 °C. 
Afterwards, cellular debris was carefully aspirated to prevent detachment of the 
freshly denuded ECM layer. Plates were gently washed once in 1X PBS and 
incubated with DNase I (10 U/ml) for 30 mins at 37 °C. Matrices were thereafter very 
carefully washed (x2) in 1X PBS and stored at 4 °C until further use. Complete 
decellurization was assessed by Hoechst and F-Actin staining (Section 2.7.4). The 
quality of the FB-derived ECMs was assessed with Ponceau S staining (Section 
2.7.2), under an inverted phase-contrast microscope. Prior to the seeding of enriched 
mESC-CMs, the FB-derived ECMs were incubated with 5% FBS (prediluted in 1X 
PBS) for 1 hr at 37 °C. 
 
2.7.2 Ponceau S staining 
 
PBS was gently aspirated from decellularized ECM. Plates were then incubated with 
0.5 ml Ponceau S solution (Sigma Aldrich; P7170) for 15 mins at RT. After staining, 
Ponceau S solution was carefully aspirated and plates were was washed once with 1 
ml deionized water. The decellurized ECMs became visible and look as a fibrous 
mesh-like network of amorphous material. Brightfield imaging was performed with a 
Zeiss AxioObserver.A1 inverted microscope equipped with an AxioCam MRc5 
camera (Zeiss).  
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2.7.3 Seeding of purified mESC-cardiomyocytes on fibroblast-derived ECMs  
 
To investigate the cardio-instructive properties of FB-derived ECM, purified mESC-
CMs were seeded on 24-well plates (3 x 10
4 
cells/well) and cultured on either pre-
treated (0.2% gelatine) coverslips (as described in section 2.7.1) or FB-derived ECMs 
for a total of 6 days. Medium was replaced with fresh Differentiation medium every 
48 hrs.  
 
2.7.4 Immunoflourescence imaging  
 
Samples were initially fixed in Roti® Histofix 4% for 15 mins at RT, followed by one 
wash in 1X PBS. Next, samples were blocked and permeabilized with blocking buffer 
solution (see appendix A2) for 30 mins, and were subsequently incubated with the 
respective primary antibodies (Table 2) for 60 mins at RT. Samples were then washed 
(x2) in blocking buffer for 3 min intervals, followed by secondary antibody incubation 
with respective antibodies/dyes (Table 2) for 60 mins in the dark at RT. Samples were 
subsequently washed in blocking buffer (x2) after each incubation step and thereafter 
stored in PBS. Coverslip-containing samples were removed from plates and mounted 
into microscope slides. Microscope slides were imaged using either the Olympus 
inverted fluorescence microscope camera (XM-10) or the Zeiss LSM710 confocal 
microscope. 
 
2.7.5 Image analysis 
 
Image J software (National Institutes of Health) was used to determine from images 
the; aspect ratio (AR), roundness, mean area (µm
2
) and mean length (µm) of CMs on 
cardio-instructive FB-derived ECM (Section 2.7.3). Cell area and AR was determined 
by measuring the α-actinin fluorescence staining of the cells. Cell clumps with >2 
DAPI stained nuclei were excluded from the analysis.  
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2.8 Assessment of HSP47 KO MEFs on EHM formation and functionality. 
 
The influence of HSP47 KO MEFs on EHM formation and functionality were 
performed, with methods described in Sections 2.2 (EHM construction [2.2.1], force 
of contraction [2.2.2] and whole mount EHM immunostaining [2.2.3]). 
 
2.9 Generation of human HSP47 mutant cell lines 
 
To investigate the influence of collagen processing HSP47 in the human system, the 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/ CRISPR 
associated protein 9 (Cas9) nickase system was used for genome editing by 
introducing site-specific mutations in the SERPINH1 gene in hES2-RFP cells. Two 
SERPINH1 mutant hES2 lines were generated by Dr. Claudia Noack (Institute of 
Pharmacology, University Medical Center Göttingen). The first mutant line (Mut.1) 
was generated based on a recent mutation identified in a human patient (Christiansen 
et al., 2010) by CRISPR/Cas9 mediated deletion in exon 3 of the SERPINH1 locus. 
The second mutant line (Mut.2) was generated simulating the KO in the HSP47 
mouse model (Nagai et al., 2000) by mediated deletion in exons 4-5.  
 
In brief, guide RNA (gRNA) sequences were designed to target site specific 20 
nucleotide sequences upstream of a NGG protospacer adjacent motif (PAM). This 
guides the Cas9 enzyme to its specific complementary target DNA sequence, 
facilitating a site-specific cleavage of the DNA. To minimize off-target cleavage, a 
double-nicking strategy was used via the Cas9 nickase mutant Cas9 (D10A) by 
cloning the gRNA sequences into the pX335A-hCas9 (D10A) vector (Kindly 
provided by Dr. Greber, MPI Münster). These CRISPR gRNA-Cas9n plasmids were 
thereafter transfected into pluripotent hES2-RFP cells. This strategy led only to single 
strand breaks of genomic DNA. After nicking of both DNA strands, the genomic 
region were repaired by the non-homologous end joining (NHEJ) process, leading to 
insertion/deletion mutations. NHEJ can mediate gene knock-outs for example via 
frameshift mutations with introduction of premature stop codons; in frame mutations 
will result in a modified protein product with changed/impaired function. After 
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transfection, clones were selected and genotyping was performed to screen for 
positive SERPINH1 mutant clones (Section 2.9.1). The positive clones for Mut.1 and 





Positive clones were validated by genotyping. Experiments were performed by Dr. 
Claudia Noack (Institute of Pharmacology, University Medical Center Göttingen). 
Genomic DNA was extracted from colonies (half) using the NucleoSpin
®
 Tissue Kit 
(740952.250, Macherey-Nagel), according to manufacturer‟s instructions. The 
extracted DNA was used as a template for PCR. The primers for detecting the site 
specific SERPINH1 mutations are listed in Table 5.   
 
 







CTT TGA GTA GGG AGG 
TAA CAG AGG C 
CGC ACG AAG TCA TCA 
GCG A 
663 bp Mut 1: 502 bp 
SERPINH1 
(Exon 4-5) 
TTA AGG GTG GTC ATG 
GGG CA 
CAG ACC TGC TGA ATT 
GGT GAG 
943 bp Mut 2: 762 bp 
 
Table 5. Primers for the genotyping of the SERPINH1 mutation hES2 cells. 
 
 
For each PCR reaction: 1 µl DNA, 4 µl 5x GC-Buffer (1x), 0.4 µl dNTPs (10 
mmol/L), 0.2 µl of each primer (100 µmol/L), 1 µl DMSO (100%), 0.2 µl Phusion 
Polymerase and 13 µl ddH20 were mixed in a total volume of 20 µl. PCR was 
performed using the T gradient PCR thermocycler (Biometra). H20 was used as a 
negative control for genomic DNA. The PCR conditions used for each of the primers 
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98 30 sec 1  
Initial 
denaturation 
98 30 sec 1 
Denaturation 98 30 sec 
28 
 Denaturation 98 30 sec 
30 Annealing 66 30 sec  Annealing 66 30 sec 
Elongation 72 30 sec  Elongation 72 30 sec 
Final 
elongation 
72 7 mins 1  
Final 
elongation 
72 7 mins 1 
Stop 4 ∞ 1  Stop 4 ∞ 1 
 
Table 6. Thermocycler conditions used for genotype PCR. 
 
 
The PCR products were checked with agarose electrophoresis to screen for positive 
hES2 mutant colonies, under UV visualization with the Gel Doc XR (BioRad) system. 
The DNA product sizes of Mut. 1 (Exon 3 mutation) and Mut.2 (Exon 4-5 mutation) 
clones were smaller in size (for the respective primer) compared to WT, indicating 
that the CRISPR/Cas9 system genome editing was successful in mutating these site 
specific regions. The correct DNA fragments from these positive clones were 
subsequently excised from gels and DNA-gel extraction clean-up was performed 
using the NucleoSpin
®
 Gel and PCR Clean-up Kit (740609.250, Macherey-Nagel), 
according to manufacturer‟s instructions. DNA sequencing was performed on the 
excised PCR products with the primers used for PCR (Table 5), to verify the 
mutations.  
 
2.9.2 Characterization of SERPINH1 mutant hES2 lines 
 
The expression of HSP47 at both mRNA and protein level was characterized on the 
positive SERPINH1 mutant hES2 lines (Mut.1 and Mut. 2) via RT-PCR (Section 
2.3.2), immunoblotting (Section 2.3.1) and immunohistochemisty (Section 2.7.4).    
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2.10 Statistical analysis 
 
Data are presented as mean ± SEM. Statistical analysis was performed using 1-way 
ANOVA followed by the Bonferroni‟s multiple comparison test, when comparing 
more than 2 groups. Alternatively, pair wise group comparisons were performed using 
two-tailed Student‟s unpaired t-test (Gaussian distribution was assumed). A value of 
*P<0.05 was considered statistically significant. Data analysis was performed with 





















3.1 EHM as a defined model of heart muscle development 
3.1.1 Cardiomyocyte differentiation and purification 
 
The heart is a complex multicellular organ comprised of CMs and non-myocytes. 
Several lines of evidence have suggested that the non-myocytes, particularly cFBs are 
important in mediating CM growth and cardiac tissue formation. Initial studies in our 
lab utilized the EHM rodent model of heart muscle development to investigate 
whether cFBs are able to promote cardiac tissue formation and maturation (Naito et 
al., 2006; Christalla, Dissertation 2011). Specifically in both mice and human, we 
could now address the role of FBs by making use of pluripotent genetically 
engineered ESC lines.  
 
In mice, we made use of a genetically engineered mESC line, containing the 
expression of the neomycin resistance cassette under the control of the CM-restricted 
α-myosin heavy chain promoter (αMHC-NeoR; Klug et al., 1996). mESCs were 
initially differentiated in spinner flasks for 11 days, and CMs were selected under 
Geneticin (G418) treatment (400 µg/ml) in order to obtain CM-enriched cell 
populations (mCMs; Figure 12). After 17 days of culture in spinner flasks, we were 
able to obtain highly purified mCMs (93 ± 1.7% α-actinin [ACTN2] positive; n=6) as 










(10 x 106 cells/flask)
d11 d17d0 G418 (400 µg/ml)
CM Selection



































Figure 12. CM differentiation and purification of αMHC-NeoR mESCs. (A) Undifferentiated 
mESCs (αMHC-NeoR) were seeded into spinner flasks (10 x 10
6 
cells/flask) and differentiated for 11 
days in culture with constant stirring to generate embryoid bodies (EBs). CM selection at d11 was 
initiated with the addition of G418 (400 µg/ml) to eliminate non-myocytes. At d17, EBs were harvested 
and dissociated into single CMs. (B) Morphology of undifferentiated mESC colonies cultivated on 
irradiated MEF feeder layers, prior to differentiation. (C) Morphology of EBs on d17 of cardiac 
differentiation and selection, prior to harvesting. (D) Representative FC scatter plot for IgG (control) 
and ACTN2 populations from a CM differentiation run. (E) FC analysis demonstrated effective 
enrichment of CMs to 93 ± 1.7 % α-actinin positive (n=6). 
 
 
Specifically in human, we differentiated genetically engineered hES2-RFP cells (Irion 
et al., 2007) into purified CMs (hES2-CM) using recently established and robust 2D 
cardiac differentiation (Hudson et al., 2012) and purification (Tohyama et al., 2013) 
protocols (Figure 13). After 23 days of culture, we were able to obtain highly purified 
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Figure 13. CM differentiation and purification of hES2-CMs. (A) Undifferentiated single cell 
adapted hES2 colonies were subjected to a cardiac differentiation and purification protocol to generate 
enriched hES-CMs. Briefly, undifferentiated hES2 cells were exposed to: Mesoderm induction (3 
days), cardiac specification (8 days), metabolic purification (5 days, to eliminate non-myocytes) and 
cardiac maturation (6 days). Enriched hES2-CMs were subsequently harvested and dissociated into 
single cells. (B) Representative FC scatter plot for IgG (control) and ACTN2 populations from a CM 
differentiation run. (C) FC analysis demonstrated enrichment of hES2-CMs to 80 ± 1.4 % ACTN2 
positive (n=4). 
 
3.1.2 Cardiac fibroblasts are essential for EHM formation and maturation 
 
Purified mCMs were mixed with acetic acid solubilized rat tail collagen type I after 
pH neutralization with NaOH (mCM only) to investigate whether this environment 
alone was sufficient to drive maturation in mCMs. The predominant constituent of the 
myocardial ECM is collagen, and collagen type I accounts for approximately 80% of 
total myocardial collagen (Weber, 1989). The generation of EHMs (as outlined in 
Figure 10; Materials and Methods) supplemented with highly pure populations of 
mCMs were not able to compact into functional tissue and formed a „spongy-like‟ 
phenotype (Figure 14A). Immunoflourescence imaging demonstrated the mCMs 
(green) within these EHMs stayed isolated with no tendency to form a functional 
syncytium, as indicated by the majority of immature round shaped CMs. EHMs were 
next generated with mixed populations of cFBs isolated from neonatal mouse hearts 
and purified mCMs (75 % mCMs; 25 % cFBs) to investigate whether cFBs are 
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important for tissue formation and maturation in EHM. EHMs supplemented with the 
addition of cFBs resulted in advanced condensation of EHMs (Figure 14B). mCMs 
within these EHMs formed tightly packed anisotropically organized muscle bundles 
and matured from an embryonic round shape into a typical postnatal rod-shaped 
phenotype with characteristic sarcomeric cross-striations. In addition, cFB-
supplemented EHMs developed contractile forces analysed by concentration response 
measurements under increasing extracellular Ca
2+
 (Figure 14C). EHMs comprised of 
pure mCMs (only) failed to develop any contractile forces. These results support 
previous studies from our group (Figure S1, Appendix A1).  
 



















Figure 14. Advanced mCM maturation in cFB-supplemented EHMs. (A) EHMs generated with 
enriched mCMs (only) after 10 days culture formed a non-condensed spongy-like tissue with rounded 
immature mCMs (green: α-actinin). (B) Supplementation of cFBs (25 % of total EHM composition) 
facilitated the formation of the typical compact EHM ring structure. mCMs developed into tightly 
packed and longitudinally orientated muscle bundles. Inset scale bars: 2 mm. (C) Twitch tension from 
cFB-supplemented EHMs (n=4 EHMs), analysed by concentration response measurements under 
increasing concentrations of extracellular Ca
2+
 (mmol/L). No contractile force was developed in EHMs 
generated from enriched mCMs only. 
 
This data collectively suggests that cFBs are essential for tissue formation and CM 
maturation in our EHM model of heart muscle development. Similar results were 
observed when highly purified hES2-CMs were supplemented with human cardiac 




3.2 ECM-integrin crosstalk in fibroblasts is responsible in mediating tissue 
formation in EHMs 
 
Interactions between cells and the ECM are mainly regulated via heterodimeric 
integrin receptors composed of α- and β-subunits. Integrins physically link the ECM 
to the cytoskeleton and are thereby able to translate extracellular signals into 
biochemical responses (Ross and Borg, 2001). In consequence, mechanisms of 
mechanotransduction are important not only for tissue homeostasis, but also to 
orchestrate the development of multicellular organs and tissues. Given the facts that 
purely-enriched mCMs alone failed to form compact, functional cardiac tissue in our 
EHM model, we wanted to know whether FB-specific mechanisms of 
mechanotransduction are responsible for the initial formation and maturation of 
EHMs in both mouse and human model systems.  
 
3.2.1 Collagen binding integrins are highly expressed in fibroblasts 
 
As collagen type I is the major component of the myocardial ECM and employed for 
the initial entrapment of cells in the EHM model, the expression of collagen binding 
integrin chains α1, α2 and β1 (ITGA1, ITGA2 and ITGB1) was analysed in both 
mouse and human purified CM and FB fractions (Figure 15). As it is not clearly 
understood whether different types of FBs can improve tissue quality; FBs from both 
embryonic and cardiac origin were used in this study. Both α subunits are associated 
with ITGB1 to form functional receptor complexes (α1β1 and α2β1) known to 
specifically bind to native collagen I (Langholz et al., 1995; Terracio et al., 1991; 
Kirchhofer et al., 1990). 
 
Immunoblotting analysis revealed that collagen binding integrins; ITGA1, ITGA2 and 
ITGB1 were more abundantly expressed in both mouse neonatal cFBs and MEFs 
compared to purely-enriched mCMs (Figure 15B and C). Cross-contaminations of the 
analysed FBs and CM populations appeared negligible; based on the identification of 
FSP-1 exclusively in FBs populations, and calsequestrin (CASQ) and cardiac troponin 




Likewise, immunoblotting analysis revealed the expression of collagen binding 
integrins; ITGA2 and ITGB1 were more abundantly expressed in human FB 
populations (hcFBs and hFFBs; Figure 15D and E). Procollagen 1 (ProCol1) was 
found to be exclusively expressed in human fibroblast populations and both CTNI and 
CASQ in hES2-CM populations. We did not however identify a specific antibody for 
the detection of ITGA1 in human samples (Figure S2, Appendix A1). 
 














































































































































































Figure 15. Collagen type I binding integrins ITGA1, ITGA2 and ITGB1 are highly expressed in 
mouse and human FBs. (A) Simplified schematic diagram illustrating the interaction of FBs and CMs 
with ECM Collagen type I in our 3D EHM model of heart muscle development. The interaction 
between heart cells (FBs and CMs) and collagen type I (red) are regulated via transmembrane 
heterodimeric integrin receptors composed of α and β subunits (blue). (B) Western blot analysis of 
collagen type I binding integrins; ITGA1, ITGA2 and ITGB1 in mouse cell FB populations (mcFB and 
MEFs) and purely enriched mCM populations (n=3/group). Purity of investigated cell populations was 
demonstrated by cell type specific expression of CTNI, CASQ and FSP-1. „L‟: Protein molecular 
weight ladder. (C) Densitometry analysis of ITGA1, ITGA2 and ITGB1 expression levels in mouse cell 
populations, normalized to GAPDH (n=3 samples/group; *P<0.05; 1-way ANOVA with Bonferroni 
post-hoc test). (D) Collagen binding integrin expression in human FB populations (hcFB and hFFB) 
and purely enriched hES2-CMs (n=3/group). Purity of investigated cell populations was demonstrated 
by cell type specific expression of ProCol1, CTNI and CASQ. (E) Densitometry analysis of ITGA2 and 
ITGB1 expression levels in human cell populations, normalized to GAPDH (n=3 samples/group; 







Furthermore, the abundance of Itga1, Itga2 and Itgb1 transcripts in mouse cells (cFB, 
MEF and mCM populations) were analysed via qPCR. qPCR analysis comfirmed 
Itga1 and Itga2 transcripts to be of low abundance in mCMs (*P<0.05; n= ≥3 
samples/group) (Figure 16A and 16B) compared to MEFs, however this was not 
significantly different compared to cFBs. Itgβ1 transcripts were significantly more 
abundant (*P<0.05; n= ≥3 samples/group) in embryonic and cardiac FB populations 
















































































































Figure 16. Higher abundance of collagen-binding Itga1, Itga2 and Itgb1 subunit transcripts in FB 
populations. qPCR analysis of (A) Itga1, (B) Itga2 and (C) Itgb1 transcripts in FB populations (cFBs 
and MEFs) and mESC-enriched CMs, relative to GAPDH (samples/group as indicated in the bars; 
*P<0.05; 1-way ANOVA with Bonferroni post-hoc test). 
 
 
RNA-seq transcriptome analysis was performed on individual human FB populations 
(hFFB and hcFB) and hES2-enriched CM populations (n=3/group) to assess the 
abundance of individual integrin subunits associated with collagen, laminin, and 
RGD-receptors. This data confirmed that all transcripts encoding for collagen-binding 
integrins, including; ITGA1, ITGA2 and ITGB1, were highly abundant in FB 
populations over CM populations (Figure 17A). In addition, cell type specific 
transcript assessments demonstrate that both FB-associated markers (Vimentin [VIM], 
FSP-1 [S100A4], DDR2, CD90 [THY1], Periostin [POSTN] and Transcription factor 
21 [TCF21]) and CM-specific markers (TNNT2, ACTN2, MYH6 and MYH7) were 
exclusively expressed in human FB populations and enriched-CM populations, 
respectively (Figure 17B). The purity of human CMs was confirmed by FC for 





















































RNA-seq analysis furthermore revealed that human FB populations do not express 
laminin-specific Itgα7 in contrast to human CMs. This could be explained due to the 
fact that FBs have no laminin-containing basement membrane (Ross and Borg, 2001). 
RNA-seq analysis furthermore revealed that all transcripts encoding for RGD 
receptors were of low abundance in CM populations compared to FB populations, 
with exception to ITGB6. 
Figure 17. Integrin subunit transcript abundance in hES2-enriched CMs and FB populations. 
(A) Heat map illustrating log2 fold change expression values of integrin subunit transcripts identified 
by RNA-seq analysis. Collagen receptor integrin subunits were of higher abundance in human 
fibroblast populations (hFFB and hcFB) compared to purely enriched hES2-CMs (n=3/group). Darker 
blue shadings on the heat map represent higher transcript abundance. (B) FB- and CM- associated 
transcript markers were highly abundant in FB populations (VIM, S100A4, DDR2, THY1, POSTN and 
TCF21) and CM populations (TTNT2, ACTN2, MYH6 and MYH7), respectively. (C) FC analysis 








Next, we investigated the role of ITGA1, ITGA2 and ITGB1 mediated signalling in 
the initial phases of EHM formation in mouse and human cells. Mixed populations of 
single cells derived from purely enriched CMs and FBs (75: 25 ratio respectively) 
were treated for 30 mins with blocking antibodies targeting individual ITGA1 
(CD49a), ITGA2 (CD49b) and ITGB1 (CD29) chains respectively, prior to the 
generation of EHMs. For controls, cells were treated with IgG antibody. For negative 
controls, EHMs were generated containing only purely enriched mCMs, which fail to 
form compact tissue. To enable parallel screening for assessing the effects of each 
integrin blocking antibody on EHM formation, both EHM cell 
suspension/reconstitution mixture volumes were scaled down and cast onto individual 
wells of 96-well low attachment plates (1.25 x 10
5
 cells/well) for initial tissue 
formation (Figure 18A). Low attachment plates were used to prevent cell 
suspensions/tissues from adhering and interfering with the bottom and sides of the 
plates. After 1 hr of initial EHM condensation, medium (containing the respective 
blocking antibody) was added to each casting EHM well and tissues were cultured for 
a further 20 hrs. The level of tissue retraction after 21 hrs („blocking‟) from initial 
EHM casting was then evaluated in each well. The antibody was subsequently washed 
out from EHMs and tissue contraction was assessed after a further 72 hrs („recovery‟). 
The surface area for each EHM relative to the total surface area in each well (%) was 
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Figure 18. Integrin-mediated signalling in FBs facilitated EHM formation. (A) Schematic representation of 
the experimental design. Cell suspensions (FBs and CMs) and EHMs were incubated with individual blocking 
antibodies against collagen binding integrins; ITGA1 (CD49a; 50 µg/ml), ITGA2 (CD49b; 50 µg/ml) and ITGB1 
(CD29; 40 µg/ml). The effects of „blocking‟ and „recovery‟ on EHM formation were assessed via optical feature 
tracking (Cellavista). (B) The blocking of ITGA1, ITGA2 and ITGB1 inhibited mouse EHM formation after 21 
hrs (red), as indicated by the % of EHM area relative to the surface area of each well. These effects were strongly 
pronounced with Itgβ1 blocking (*P<0.05; 1-way ANOVA with Bonferroni post-hoc test). EHMs comprised of 
mCMs (only) failed to form compact tissue. Similar effects were observed with EHMs comprised of MEFs and 
mCMs. The images below each graph display a representative EHM per well for each different condition, after 21 
hrs blocking. Representative FC scatter plot for IgG (control) and ACTN2 populations from a mESC enriched-
CMs used for experiments. FC analysis demonstrated that populations of purely enriched CMs were on average 
93 ± 1.7 % ACTN2 positive (n=6). (C) Using a similar experimental design as in (B), we confirmed the mouse 
data in a human model. Note that the CM enrichment was less optimal with 80 ± 1.4 % ACTN2 positive CMs in 
this experimental series (n=4), explaining the condensation in the hES2-CM (only) group. 
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For mouse cells, in neonatal cFB-supplemented EHMs, blocking of the ITGB1-
collagen type I interaction significantly abolished the initial EHM formation (4 
EHMs/group; *P<0.05), indicating that ITGB1 is involved in collagen type I matrix 
condensation and necessary for EHM formation. In addition, blocking of the ITGA2-
collagen type I interaction also significantly abolished initial EHM formation (4 
EHMs/group; *P<0.05), but to a lesser extent than with ITGB1 blockade. Lastly, 
blocking of ITGA1-collagen type I interactions partially inhibited EHM formation 
however this was shown to be not significant compared to IgG-treated controls. The 
effects of the blocking antibodies on EHM condensation were reversible with 
antibody washout after 72 hrs (recovery), indicating that inhibition of tissue retraction 
was not due to cell death. EHMs comprised of purely enriched CM only (as 
determined via FC; Figure 18B) failed to contract and form compact tissue throughout 
the entire duration of tissue culture. Since the ITGB1 chain subunit is present in all 
collagen binding (as well as Laminin and RGD binding) integrin heterodimeric 
receptor complexes, these dramatic effects we observed with ITGB1 blockade on 
tissue formation most likely influencing other important integrin heterodimeric 
receptors. Likewise, similar observations were made with MEF-supplemented EHM, 
supporting the notion that FB-specific mechanisms of mechanotransduction from 
different FB cell sources are responsible in mediating the initial tissue formation 
process in EHMs.  
 
Next, integrin blocking experiments were subsequently performed using hcFB- and 
hFFB- supplemented EHMs (Figure 18C). Similarly, blocking of the ITGB1-collagen 
type I interaction significantly inhibited initial tissue formation (4 EHMs/group; 
*P<0.05) in both cFB and hFFB-supplemented EHMs. Blocking of ITGA2-collagen 
type I interactions partially inhibited EHM formation, however this was shown to not 
be significant compared to IgG-treated controls. Finally, blocking of the ITGA1-
collagen type I interaction did not show any inhibitory effects on EHM contraction 
after 21 hrs blocking treatment, compared to IgG-treated controls. Interestingly, 
EHMs comprised of enriched hES-CMs were able to partially contract after 21 hrs 
blocking, and further after 72hrs. This was most likely due to fact that these CM 
populations were not entirely enriched in ACTN2 immunopositive CMs (80 ± 1.4 %; 
n=4). Taken together, these data collectively indicate that ECM-integrin 
mechanotransduction mediated via collagen, laminin and RGD-binding integrin 
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receptors in FBs are essential for matrix condensation and tissue maturation in our 
EHM model of heart muscle development. 
 
3.3 Cardiac fibroblasts construct an ECM environment in EHMs 
 
Multicellular tissues including the heart are composed of a complex ECM architecture 
which is built by FBs. Since we have shown that FBs are essential for heart muscle 
formation and maturation in our EHM model, the following studies were performed to 
further investigate the influence of the FB-producing ECM environment in promoting 
the maturation of CMs in the EHM. The ECM composition was investigated in EHMs 
by transcriptomics and proteomics. 
 
Explorative transcriptome profiling was performed at different points of EHM 
maturation and a massive up regulation of ECM-related transcripts was observed 
(Figure 19A) (Christalla et al., unpublished data). The collagen type I chains Col1a1 
and Col1a2 were the most abundant transcripts. Besides collagen type I, other 
transcripts which are mainly involved in collagen I fibrillogenesis and maturation 
were also highly abundant, such as decorin (Dcn) and biglycan (Bgn) (Campbell et al., 








































































Figure 19. cFBs construct a heterogeneous ECM architecture in mouse EHMs. (A) Microarray 
analysis of the most abundant ECM-related transcripts during EHM maturation (n=1/group). (B) Heat 
map showing differentially expressed ECM-related proteins identified by proteomics in d6 EHMs 
composed of mCMs alone vs. FB-supplemented EHMs (n=3/group). Heat map outlining differentially 
expressed proteins clustered into Collagen type I modifying proteins, ECM components, Cell-ECM 
interacting and ECM associated proteins. Red represents high protein abundance, blue represents low 
protein abundance. (Data from Christalla et al., unpublished data). 
 
 
Next, the cFB-derived ECM components in EHMs were then analysed by proteomic 
profiling (Figure 19B). De novo synthesized ECM components and cellular proteins 
were fractioned and enriched from the original input collagen (used to initially 
generate EHMs) by salt (NaCl), followed by subsequent SDS treatment (Didangelos 
et al., 2009). In total, 663 proteins were identified by liquid chromatography tandem 
mass spectrometry (LC-MS/MS). Interestingly, 33 differentially expressed ECM-
related proteins were only expressed in the FB-supplemented EHMs but not 
detectable in EHMs composed of purified mCMs only (n=3; p<0.05). The detected 
COL1A1 expression by proteomics in EHMs containing only mCMs reflects the lack 
of ECM (collagen) remodelling in this condition.  
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Furthermore, proteins which are involved in collagen type I modification and 
organisation, such as procollagen C-endopeptidase enhancer 1 (PCOC1), procollagen-
lysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2) and PLOD3, Prolyl 4-Hydroxylase 
alpha polypeptide 1 (P4HA1) and P4HA2 were mainly expressed in FB-supplemented 
EHMs, which suggest these FB populations within the tissue reorganise the collagen 
matrix and are able to build a structural ECM environment. Taken together, these data 
indicate that cFBs are able to synthesize collagen modifying proteins, and are 
furthermore able to construct a heterogeneous ECM environment in our EHM mouse 
model of heart development. 
 
Since mouse cFB-supplemented EHMs show an increase abundance of many ECM-
related proteins compared to EHMs comprised of only mCMs, we also wanted to 
observe for any differences in the human system, when comparing individual human 
CM and FB (hcFB and hFFB sources) populations. RNA-seq transcriptome analysis 
performed on purely enriched hES2-derived CMs, hcFBs and hFFB populations 
(n=3/group) demonstrate that (1) collagen modifying, (2) ECM component, (3) Cell-
ECM interacting, and (4) ECM associating transcripts were predominantly of higher 
abundance in human FBs popultations than in hES2-CMs (Figure 20), further 
supporting the notion that FBs from both mouse and human are able to construct an 
ECM cardiac microenvironment. Interestingly however, we identified that several 
laminin subtype transcripts: LAMA1, LAMA2 and LAMC3 were exclusively highly 
abundant in human CMs. LAMA4 appeared to not be expressed in both human CM 
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Figure 20. Collagen modifying and ECM-related transcripts are highly expressed in human FBs. 
Heat map illustrating log2 fold change expression values of ECM-related transcripts identified by 
RNA-seq analysis. Differentially expressed transcripts are clustered into; Collagen type 1 modifying 
proteins , ECM components, Cell-ECM interacting and ECM associated proteins. ECM-related 
transcripts were generally of higher transcript abundance in FB cell populations (hcFB and hFFBs; as 
outlined) compared to purely enriched hES2-CMs (n=3/group). Darker blue shadings on the heat map 
represent higher transcript abundance.  
 
 
3.4 Influence of collagen processing HSP47 on cardiomyocyte maturation and 
homeostasis. 
 
It has previously been shown that HSP47 is a collagen specific ER molecular 
chaperone essential for the maturation of collagen type I and IV (Ishida et al., 2006). 
HSP47 KO mice die early during development showing abnormal orientated epithelial 
tissues and ruptured blood vessels (Nagai et al., 2001). Although the embryos from 
HSP47 KO mice show developmental retardation and exhibit cardiac hypertrophy, it 
is not clearly understood how HSP47 can influence the myocardium. Due to the fact 
that collagen type I is the major component of the myocardial ECM and that its 
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organization seems to be a crucial factor for EHM maturation in our model of heart 
muscle development, we next scrutinized our transcription and protein data for the 
presence of HSP47 cell type specific expression, in CMs and FBs.  
 
3.4.1 Collagen processing HSP47 is highly expressed in fibroblast populations 
 
Since collagen processing HSP47 has been shown to be expressed in the ER of 
collagen-secreting cells (Nagata and Hosokawa, 1996; Taguchi and Razzaque, 2007) 
we wanted to evaluate its expression in both FB and purified CM populations in 
mouse and human cells. Immunoblotting analysis revealed that HSP47 (47 kDa) 
expression was higher in mouse FB populations (cFBs and MEFs) than in CM (Figure 
21A), however this was not statistically significant. Furthermore, 
immunohistochemistry analysis of differentiated CM populations containing very 
small contaminating populations of non-myocytes (which do not express CM-specific 
cardiac troponin I type 3 [TNNI3] - green) demonstrate that non-myocytes exhibit a 
strong pattern expression of HSP47 (red), localized in the cellular cytoplasm 
surrounding the nucleus (Figure 21B). TNNI3-expressing CMs show at a weaker 




































Figure 21. Collagen processing HSP47 is highly expressed in mouse FBs compared to mCMs. (A) 
Western blot analyses reveals greater expression of HSP47 in mouse FB populations (mcFBs and 
MEFs) compared to purely enriched mCMs (n=3/group). „L‟: Protein molecular weight ladder. (B) 
Immunostaining analysis of mCMs expressing CM-specific TNNI3 (green) revealed strong HSP47 
expression patterns (red) localized in the cytoplasm of small contaminating non-myocyte fractions (not 
expressing TNNI3) from enriched mCM populations. Weak HSP47 expression was observed in 
TNNI3-expressing mCM, in line with the western blot data. 
 
 
Next, we wanted to evaluate the expression of HSP47 in the human system. 
Immunoblotting analyses in human FB populations (hcFBs and hFFBs) also show 
greater expression of HSP47 than in hES2-CMs (Figure 22A). Likewise, 
immunohistochemistry analysis of differentiated hES2-CM populations (Figure 22B) 
also containing small contaminating populations of non-myocytes (which do not 
express TNNI3) demonstrated again that these cells exhibit a strong pattern 
expression of HSP47 localized in the cellular cytoplasm surrounding the nucleus. 
TNNI3-expressing hES2-CMs showed lower expression levels of HSP47. Since these 
differentiated hES2 populations were not as much enriched (80.4 ± 1.4% ACTN2 
positive; n=4), we suspected that the contaminating presence of non-myocyte 
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populations resulted in a stronger than anticipated HSP47 signal in the CM group. The 
RNA-seq analysis from even purer CMs populations (93 ± 3.8 % ACTN2 positive; 
n=3; Figure 17C) demonstrate significantly low SERPINH1 (HSP47) expression as 
compared to cFBs (*P<0.05; n=3) (Figure 22C). On the contrary, hFFBs at protein 
level exhibited higher HSP47 expression compared to hcFBs. Interestingly, although 
purified CMs show negligible abundance of collagen type I transcripts (COL1A1 and 
COL1A2) (Figure 22C), these cells however express HSP47, but at low protein and 
transcript level. 
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Figure 22. Collagen processing HSP47 is highly expressed in human FBs compared to CMs. (A) Western 
blot analyses reveals greater expression of HSP47 in human fibroblast populations (hcFBs and hFFBs) 
compared to purely enriched hES2-CMs (n=3/group; *P<0.05; 1-way ANOVA with Bonferroni post-hoc test). 
„L‟: Protein molecular weight ladder. (B) Immunostaining analysis revealed strong HSP47 expression patterns 
(red) localized in the cytoplasm of small contaminating non-myocyte fractions from enriched CM populations. 
(C) RNA-seq analysis from purer CM populations revealed high SERPINH1 transcript levels in hcFBs 
compared to hES2-CMs. Collagen-related transcripts COL1A1 and COL1A2 showed negligable expression in 
hES-CMs (n=3/group; *P<0.05; 1-way ANOVA with Bonferroni post-hoc test).    
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Taken together, this data indicate that collagen-synthesizing cFBs express higher 
levels of HSP47 than CMs in both mouse and human cells.  
 
3.4.2 Characterization of HSP47 KO MEFs 
 
To investigate the influence of collagen type I organisation on CM maturation, we 
utilized collagen defective HSP47 KO MEFs which were obtained from the lab of 
Prof. Kazuhiro Nagata in Japan (Nagai et al., 2001; Ishida et al., 2006), to study how 
the absence of HSP47 can influence the collagen secretion/deposition, and how this 
can directly influence CM maturation in both 2D culture and in our 3D EHM model 
of heart muscle development.  
 
HSP47 KO MEFs were originally obtained from HSP47 KO mice. The HSP47 gene 
was disrupted in mice using homologous recombination, with a targeting vector 
deleting exon IV and part of exon V of the gene, and simultaneously inserting a 
neomycin resistance gene (as described in Nagai et al., 2001) (Figure 23A). Both RT-
PCR and immunoblotting analysis was initially performed to confirm the absence of 
HSP47 at both RNA and protein level in these MEFs. Firstly, primers targeting part of 
exon III to exon V of the Hsp47 gene were used for the RT-PCR assay (Figure 23A). 
The absence of an amplified PCR product band in HSP47 KO MEFs (+) confirmed 
the disruption of the Hsp47 gene compared to „WT‟ MEFs at mRNA level (Figure 
23B). The No RT controls (-) demonstrates that no contaminating genomic DNA was 
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Figure 23. Confirmation of Hsp47 gene targeted disruption in HSP47 KO MEFs. (A) Homologous 
recombination with targeting vectors deleting exon IV and part of exon V, and simultaneously inserting 
a Neo gene. Arrows indicate the orientation of the Neo gene and DT-A cassettes. Arrowheads targeting 
part of exon III and exon V indicate the location of primers used for RT-PCR analysis (Image taken 
from Nagai et al., 2000). (B) RT-PCR analysis confirmed the absence of Hsp47 expression at mRNA 
level in HSP47 KO MEFs compared to WT MEFs, using the primers denoted above. Housekeeping 
genes; Gapdh and β-actin were present in both WT- and HSP47 KO- MEFs. „+‟ indicates cDNA 
synthesis in the presence of reverse transcriptase, and „-„in the absence of reverse transcriptase.  
 
 
Next we wanted to confirm the absence of HSP47 at protein level via immunoblotting 
analysis. Indeed, HSP47 expression was completely absent in the HSP47 KO MEFs, 
compared to WT (Figure 24A). In addition, fluorescent staining clearly showed the 
absence of HSP47 expression in HSP47 KO MEFs compared to WT, where there is a 
strong expression pattern of HSP47 (red) localized in the cellular cytoplasm 
surrounding the nucleus (Figure 24B). In addition, Procollagen 1 (ProCol1α1) (green) 
expression within WT cells colocalizes in particular regions where HSP47 is 
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expressed. Interestingly, the intracellular ProCol1α1 expression in HSP47KO MEFs 
revealed to be very strongly expressed at particular intracellular regions near the ER, 
in contrast to WT MEFs in which ProCol1α1 displayed a fairly more homogeneously 
distributed expression pattern throughout the cells. These observations suggest that 
ProCol1α1 in HSP47 KO MEFs is being aggregated and retained within the ER of 










HSP47, ProCol1α1, F-actin, Hoechst










Figure 24. Absence of ER localized HSP47 at the protein level in HSP47 KO MEFs. (A) 
Immunoblotting analysis confirmed the absence of HSP47 protein in HSP47 KO MEFs, in contrast to 
WT MEFs (n=3/group). „L‟: Protein molecular weight ladder. (B) ProCol1α1 (green) appeared as dense 
aggregates in HSP47 KO MEFs, in contrast to it‟s more uniformly distribution in WT MEFs. (C) 
HSP47 expression in WT MEFs (red) colocalizes with PDI (green) in the ER. (D) CASY analysis from 
cell suspensions revealed that HSP47 KO MEFs were significantly smaller in cell diameter (µm) and 
volume (µm
3
) compared to WT MEFs (*P<0.05; n=3 measurements/group; Student‟s unpaired t-test).  
 
 
Immunoflourescence staining furthermore revealed that HSP47  colocalizes with the 
protein disulphide-isomerase (PDI) (Figure 24C), which is another ER resident 
chaperone protein (Wang et al., 1998; Gilbert, 1997) involved in procollagen 
synthesis (Gelse et al., 2003; Canty et al., 2005). Interestingly, HSP47 appeared to 
localize exclusively at the periphery of PDI. These data collectively suggest that 
HSP47 expression is localized predominantly in the ER. HSP47KO MEFs 
furthermore exhibit both significantly smaller cell diameter and cell volume compared 
to WT MEFs (*P<0.05; n=3/group) (Figure 24D). 
 
As we observed dense intracellular ProCol1α1 aggregates in HSP47KO MEFs, we 
next wanted to examine whether the expression of other ER localized chaperones 
were influenced as a consequence for HSP47 deletion in HSP47 KO MEFs. We 
identified that PDI revealed a trend towards increased protein expression via 
immunoblotting analysis (n=3/group), however this increase was not significant 









































Figure 25. Expression of ER-resident chaperone PDI in HSP47 KO MEFs. Immunoblotting 
analysis demonstrates that PDI expression showed a trend towards increased expression in HSP47 KO 
MEFs (n=3/group; *P<0.05; Student‟s unpaired t-test). „L‟: Protein molecular weight ladder. 
 
 
3.4.2.1 Defective Collagen type I secretion in HSP47 KO MEFs 
 
 
HSP47 KO MEFs have previously been shown to display slower secretion rates of 
collagen type I and IV (Ishida et al., 2006; Marutani et al., 2004) leading to the 
intracellular accumulation of procollagen. In addition, these collagens secreted from 
HSP47 KO MEFs were sensitive to trypsin/chymotrypsin digestion (Ishida et al., 
2006; Marutani et al., 2004), which collectively suggests that procollagens were not 
correctly folded into triple helix structures within the ER.  
 
From our studies, we firstly wanted to also observe whether HSP47 KO MEFs display 
a defective secretion rate of collagen compared to WT MEFs. Both, WT and HSP47 
KO MEFs were cultured in low serum containing medium on 6 well plates, at an 
equal seeding density per well (Figure 26A). The conditioned medium was collected 
after 72 hrs. Thereafter, the amount of soluble collagen secreted into the conditioned 
medium was analysed using the SircolTM assay. In addition, plates were fixed and 
stained for nuclei (Hoechst). The total cell number/well could then be evaluated using 
a high throughput automated imaging system (Cellavista). HSP47 KO cells showed 
significantly reduced secreted collagen (ng) per cell (*P<0.05; n=5 
experiments/group) after 72 hrs in contrast to WT cells (Figure 26B), supporting 
previous finding that these cells exhibit retarded collagen secretion rates. 
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1) Conditioned medium analysis (SircolTM)
2) Cell number (Cellavista)
Seed WT or HSP47 KO FBs
(3x105 cells/well)
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Figure 26. Absence of HSP47 expression in MEFs reduces secretion of soluble collagen. (A) WT 
and HSP47 KO MEFs were plated at fixed seeding densities (3 x 10
5
 cells/well) on 6 well plates and 
cultivated for 72 hrs in low serum-containing medium (AA: 148 µg/ml L-Ascorbic Acid 2-phosphate 
magnesium salt). Condition medium was subsequently collected from each well and secreted soluble 
collagen levels were assessed by the Sircol
TM
 assay. Cells were then fixed and stained with Hoechst. 
Total cell numbers in each well were analyzed using the Cellavista platform. (B) Soluble collagen 
levels were normalized to cell number. HSP47 KO MEFs display markedly lower levels of soluble 
secreted collagen in the conditioned medium, in contrast to WT MEFs (*P<0.05; n=5; Student‟s 
unpaired t-test).  
 
 
3.4.2.2 Deoxychelate (DOC)-separation of ECM fractions 
 
In order to assess ECM components secreted from WT and HSP47KO MEFs, DOC 
extraction was used to separate cellular material and components not incorporated into 
the ECM (DOC soluble fraction) from insoluble material containing ECM (DOC-
insoluble fraction; Van Duyn Graham et al., 2010; Midwood et al., 2002). DOC-
insoluble ECM fractions were obtained from WT and HSP47KO MEFs seeded at 
equal high density and cultured for 7 days (Figure 27A). These isolated fractions were 
subsequently solubilised and analysed by SDS-PAGE and coomassie blue staining 

















DOC soluble fraction (CELL)
DOC insoluble fraction (ECM)
MEFs
Culture conditions 
(DMEM; 10% FCS; 1% NEAA; 1% P/S; 150ug/ml L-Ascorbic 
Acid 2-phosphate magnesium salt)
Col1 α- chain transcripts:
(n=5/group)
























































































Figure 27. Reduced collagen type I protein incorporation into the ECM in HSP47 KO MEFs. (A) 
WT and HSP47 KO MEFs were plated at equal high seeding densities and cultured for 7 days. DOC 
was used to separate the cellular fractions (DOC-soluble) from the ECM fraction (DOC-insoluble). 
DOC-insoluble fractions were solubilised and were separated by SDS-PAGE. (B) Proteins incorporated 
into the ECM of WT and HSP47 KO MEFs showed distinctive profiles on Coomassie blue stained gels 
(n=3/group). ECM samples were compared to monomeric rat tail Collagen type I. Collagen type I 
chains; COL1A1 (138 kDa) and COL1A2 (130 kDa) were visibly expressed in WT-derived ECMs, in 
contrast to HSP47 KO-derived ECMs. „L‟: Protein molecular weight ladder. (C) qPCR analysis 
suggested enhanced Col1a1 and Col1a2 transcript abundance in HSP47 KO MEFs (n=5/group; P<0.05; 
student‟s unpaired t-test). 
 
 
Interestingly, proteins incorporated into the ECM in both WT- and HSP47 KO MEFs 
showed distinctive protein profiles.  HSP47 KO MEFs revealed that collagen type I 
chains COL1A1 (138 KDa) and COL1A2 (130 KDa) showed negligible expression 
compared to WT MEFs, indicating that Procollagen type I failed to be incorporated 
into the ECM from HSP47KO FBs. qPCR analysis comparing Col1a1 and Col1a2 
transcript levels between WT and HSP47KO MEFs revealed that Collagen type I 
transcripts showed a trend towards higher levels in HSP47 KO than WT MEFs 
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(Col1a1, P=0.06; Col1a2, P=0.06) suggesting a compensatory mechanism (Figure 
27C). Taken together, these data suggests that Procollagen type I synthesized in 
HSP47 KO MEFs exhibit reduced secretion and incorporation into the ECM. 
 
3.4.2.3 Mass spectrometric analyses of ECM fractions 
 
Mass spectrometric analyses were performed to identify other proteins in ECM 
(DOC-insoluble) fractions derived from WT and HSP47 KO MEFs (n=1; with 2 
technical replicates). In total, 304 proteins were identified by nanoLC-MS/MS (Figure 
28). Furthermore, 2 differentially expressed proteins; Periostin (POSTN) and 
Collagen 6 alpha-chain 2 (COL6A2) were exclusively expressed in WT ECM 
fractions, in contrast to 19 proteins (predominantly extracellular vesicular exosome-
related) expressed only in HSP47 KO ECM fractions. Its has recently been suggested 
that exosomes may have a functional role in selectively secreting harmful/damaged 
proteins, in order to alleviate intracellular stress conditions and preserve intracellular 
protein homeostasis (Baixauli et al., 2014). POSTN has been shown to promote 
proliferation and myofibroblast differentiation of FBs (Crawford et al., 2015). 
Furthermore, POSTN has been implicated in the regulation of collagen type I 
fibrillogenesis and organization (Norris et al., 2007). We also identified ECM laminin 
subunit proteins: Laminin subunit alpha 5 (LAMA5) and laminin subunit gamma 1 
(F8VQJ3 or LAMC1) to be exclusively expressed in HSP47 KO ECM fractions.  
 
In agreement with the data presented before (Figure 27B) collagen type I protein 
chains; COL1A1 (138 kDa) and COL1A2 (130 kDa) were significantly lower in 
protein abundance (P<0.01) in HSP47 KO- versus WT-ECM fractions that there is 
markedly reduced collagen type I incorporation into the ECM in HSP47KO MEFs. 
Moreover, collagen type V proteins (COL5A1, COL5A2), collagen type VI proteins 
(COL6A2) and Keratin, type II cytoskeletal 1 (K2C1) were of higher abundance in 
WT ECM fractions. On the other hand; 2 vesicular exosome proteins Heat Shock 
Protein 90-beta (HSP90B) Endoplasmin (ENPL) were identified to be higher 












































Figure 28. Venn diagram illustrating the number of proteins identified in ECM fractions from 
WT- and HSP47 KO MEFs. Proteins identified by mass spectrometry analysis were found to be 
exclusively expressed in the respective WT or HSP47KO ECM (DOC-insoluble) fractions, or 
significantly upregulated/downregulated in HSP47 KO ECM (purple box) (*P<0.01; n=1/group; 2 
technical replicates). 19 proteins were identified to be exclusively expressed in the HSP47KO ECM 
fraction, in contrast to 2 proteins expressed exclusively in WT ECM fractions. Collagen type I chains 
(COL1A1 and COL1A2) expression was significantly less abundant (P<0.01) in the HSP47 KO ECM 
fraction, compared to WT. 
 
Taking together, this data suggests that HSP47 KO MEFs exhibit ECM dysregulation, 
as shown by the reduced expressions levels of collagens and incorporation of collagen 
type I into the ECM, compared to WT MEFs. 
 
3.4.3 Investigation of cardio-instructive properties of fibroblast-derived ECM 
 
It has previously been shown that embryonic cFBs develop coinciding with expansion 
of the ventricular compact layer and regulate proliferation of immature CMs via 
secretion of growth factors the ECM components (Ieda et al., 2009). We specifically 
asked whether the FB-derived ECM environment has an impact not only on 
proliferation but also in maturation of CMs. Furthermore, since our study suggested 
collagen defective HSP47 KO MEFs display reduced collagen secretion (Figure 26) 
and reduced collagen type I incorporation into the ECM (Figure 27 and 28), we 
wanted to determine whether the ECM produced from collagen defective HSP47 KO 
MEFs can impact the cardio-instructive properties of CMs.  
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3.4.3.1 Generation of fibroblast-derived ECM 
 
We established a FB-derived ECM model by growing MEFs at high density on 
culture plates for 11 days in serum containing medium containing; 148 µg/ml L-
Ascorbic Acid 2-phosphate magnesium salt, to facilitate the deposition of a dense 
ECM network. Thereafter, the ECMs were denuded of FBs and cellular remnants 
were removed via DNase I treatment (Figure 29A). This extraction procedure resulted 
in an intact FB-derived ECM that was free of cellular debris. Immunostaining analysis 
of the decellularized FB-derived ECM revealed a dense fibrous mesh-like ECM 
network deposited on the bottom of plates, which comprised of dense collagen type I 
fibrillar ECM (red) (Figure 29B). In addition, ECMs were free of nuclei (blue) and 
cellular cytoskeletal actin (green) indicating complete cellular lysis, compared to 










Figure 29. Generation of denuded FB-derived ECM before and after decellularization. (A) MEFs 
were plated at high seeding densities and cultured for 11 days in medium containing 148 µg/ml L-
Ascorbic Acid 2-phosphate magnesium salt. FB-derived ECMs were subsequent obtained after cell lysis 
(decellularization) and DNase I treatment. (B) Denuded FB-derived ECMs were free of cellular nuclei 
(blue) and cellular cytoskeletal actin (green) [AFTER], compared to before decellularization [BEFORE]. 
In addition, a dense collagen type I fibrillar ECM network (red) was deposited from the FBs. 
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3.4.3.2 Reduced ECM deposition and abnormal Collagen type I fibril formation 
in HSP47 KO MEFs 
 
Next, we wanted to investigate the deposition and structural organization of secreted 













Figure 30. Reduced Collagen type I fibril formation and deposition in HSP47 KO MEF-derived 
ECMs. (A) Schematic overview of the fabrication of FB-derived ECM from WT or HSP47 KO MEFs. 
(B) Staining of the total ECM proteins by Ponceau S and (C) immunoflourescence staining of Collagen 
type 1 (red) show dense microfibrillar network structures from WT MEF-derived ECM, in contrast to 
HSP47 KO MEF-derived ECM which displayed markedly reduced Collagen type 1 deposition, and 




Ponceau S staining (Figure 30B) and immunostaining analysis of extracellular 
collagen type I (Figure 30C) in FB-derived ECM deposited from HSP47 KO MEFs 
were sparse and weakly stained compared to the dense ECM networks observed in 
WT MEFs. Furthermore, longitudinally aligned collagen type I fibres were present in 
WT MEFs, in contrast to abnormal Collagen type I fibril formation observed from 




























3.4.3.3 Impaired cardiomyocyte phenotype on defective collagen processing 
HSP47 KO FB-derived ECMs 
 
To directly investigate whether the absence of HSP47 can influence the cardio-
instructive properties of the ECM niche secreted from FBs, we cultured immature 
mESC-enriched CMs (mCMs) on purely FB-derived ECM from WT and HSP47 KO 
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Figure 31. Impaired CM morphology on collagen defective HSP47 KO MEF-derived ECMs. (A) To assess 
the cardio-instructive properties of FB-derived ECMs, genetically enriched immature mCMs were cultivated for 
6 days on WT- or collagen defective HSP47 KO MEF-depleted ECMs. (B) mCMs (α-actinin-green; Hoechst-
blue) showed advanced morphological features with regular cross-striations and elongated rod-shaped cell 
bodies on WT MEF-depleted ECMs (Collagen 1-red), in contrast to HSP47  KO-MEF-depleted ECMs and 
classic monolayer culture (gelatin), which displayed mainly immature morphology and disorganized sarcomeric 
structures. (C) Analysis of single cell morphological parameters; Aspect ratio (AR), roundness, cell area and cell 
perimeter. (n= ≥30 cells/group; *P<0.05; 1-way ANOVA with Bonferroni post-hoc test).  
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Interestingly, mCMs cultured on well organized- WT MEF-derived ECM conditions 
displayed advanced sarcomeric organization and morphological features with regular 
cross striations (green) and primarily rod-shaped bodies and containing centrally 
localized nuclei (blue; Figure 31B). In addition, morphological analysis demonstrated 
that these mCMs exibit a significantly higher „Aspect Ratio (AR)‟ and low 
„roundness‟ value (*P<0.05), compared to when cultured on gelatin-coated classical 
monolayers (Figure 31C). Moreover, CMs within the ECM were orientated along the 
collagen type I microfibrillar structure (red). In contrast, mCMs cultured on collagen 
defective HSP47KO MEF-derived ECM conditions showed mainly immature 
morphology and disorganized sarcomeric structures. This morphology was similar to 
mCM cultured on gelatine-coated classical monolayer cultures. Morphological 
analysis demonstrates that mCMs did not show differences in „AR‟ and „roundness 
values‟ compared to mCMs cultured on gelatin-coated substrates (Figure 31C). In 
addition, these mCMs were more flat and spread out (as indicated by their large 
surface area) on HSP47KO MEF- ECMs. This data firstly suggests FBs provide a 
cardio-instructive ECM environment which is guiding advance maturation of mCMs. 
Secondly; improper processed Collagen type I deposited from HSP47 KO MEFs 
impairs the cardio-instructive properties of the ECM.  
 
 
3.4.3 Collagen defective HSP47 KO MEFs impair EHM formation and 
functionality 
 
As we have demonstrated that HSP47 KO MEFs exhibit both retarded collagen type I 
secretion and defective ECM cardio-instructive properties, we next wanted to 
investigated the role of collagen type I organisation in cardiac tissue formation and 
maturation, utilizing our 3D EHM model of heart muscle development.  
 
Purified mCMs were supplemented with either WT MEFs, HSP47 KO MEFs or 
without FBs [mCM (only)] to generate EHMs (Figure 32A). As previously shown, 
EHMs comprised of mCMs only failed to initially retract and form condensed tissue 
after 3 days on circular casting molds (8 EHMs/group; *P<0.0001; Figure 32B). 
Interestingly, HSP47 KO FB-supplemented EHMs failed to form well condensed 
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tissue after 3 days, in contrast to more compact WT FB-EHMs (8 EHMs/group; 
*P<0.0001). Subsequently, after 7 days of static mechanical strain, flourescent 
stainings revealed that HSP47 KO-EHMs showed less elongated and anisotropically 
organised CMs and non-myocytes (α-actinin-green; F-actin-red; Hoechst-blue), in 
contrast to beating WT-EHMs in which the mCMs formed tightly packed muscle 
bundles (Figure 32C). This observation was comparable to EHMs generated with 
mCMs (only), which failed to form a functional syncytium and were structurally 
immature, as indicated by the majority of round shaped mCMs. The functionality of 
these EHMs was assessed by a measurement of contractile forces under isometric 
conditions (Figure 32D). HSP47 KO MEF-supplemented EHMs failed to develop 
contractile forces under these conditions, in contrast to WT MEF-supplemented 
EHMs (n=4; WT-supplemented EHMs: 0.143 ± 0.008 mN at 2.4 mmol/L Ca
2+
). 
Taken together, this data collectively suggests that collagen defective HSP47 KO-
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Figure 32. Immature EHMs after supplementation with HSP47 KO MEFs. (A) Schematic 
overview outlining the experimental details. (B) EHM 3 days after casting with: mCM (only), WT-
MEF and HSP47 KO-MEFs (from left to right) and red arrows indicating EHM thickness 
(condensation). Bar graph summarizes the data from n=8 EHMs/group (*P<0.05; 1-way ANOVA with 
Bonferroni post-hoc test). Scale bar: 2 mm. (C) Immunoflourescence staining of EHM with mCM 
(only) and EHM supplemented with WT-MEF or HSP47 KO MEF with 10 days of culture. Inset scale 
bars: 2 mm. (D) Twitch tension analysed by concentration response measurements under increasing 
concentrations of extracellular Ca
2+
 (mmol/L). No contractile force was developed in HSP47 KO MEF-
supplemented EHMs (n=4/group). 
 
 
3.4.3.1 Reduced Itgβ1 integrin expression in HSP47 KO MEFs 
 
Since our studies have collectively demonstrated that ECM-integrin crosstalk from 
FBs is necessary for EHM formation and maturation (Figures 15, 16, 17 and 18) and 
we observed that HSP47 KO MEF-supplemented EHMs failed to form compact 
functional tissue, we thus wanted to compare the expression of the predominant 
collagen binding integrin receptor subunit Itgβ1, in HSP47KO- and WT-MEFs. qPCR 
analysis revealed that Itgb1 transcript levels were significantly reduced in HSP47KO 
MEFs compared to WT MEFs (*P<0.05; n=4-5/group; Figure 33A), however no 
difference was observed on protein level (n=3; Figure 33B).  
 
In order to address whether HSP47 KO MEFs show reduced ECM interaction, we 
performed 2D cell attachment assays. Single cell suspensions of WT- or HSP47 KO-
MEFs were initially incubated with ITGB1 blocking antibody (CD29; 40 µg/ml) for 
30 mins (Figure 33C). Treated cells were then incubated for 6 hrs on collagen type I 
coated plates, and subsequently counted. ITGB1 blocking of cell-collagen interactions 
significantly inhibited cell attachment in both WT- and HSP47 KO MEFs compared 
to without blocking treatment (control; Figure 33D). Blocking of cell-collagen 
attachment in HSP47 KO MEFs however was significantly less pronounced compared 
to WT MEFs which is likely due to reduced Itgβ1 expression in HSP47 KO MEFs. 
Unexpectedly, the levels of cell attachment between untreated WT and HSP47KO 




Overall, these data confirm the importance of Itgβ1 for cell attachment and suggesting 
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Figure 33. Reduced Itgβ1 integrin expression in HSP47 KO MEFs. (A) qPCR analysis showed a 
significant reduction of Itgb1 transcripts in HSP47 MEFs (n= ≥4/group; *P<0.05; Student‟s unpaired t-
test). (B) Immunoblotting analysis revealed a not significantly reduced expression of ITGB1 in 
HSP47KO MEFs, compared to WT (n=3/group). (C) Schematic diagram outlining „integrin block cell 
attachment‟ experiments. WT and HSP47 KO MEFs were individually incubated in the absence 
(control) or presence of ITGB1 (CD29; 40 µg/ml) blocking antibody for 30 mins, prior to being plated 
onto collagen-coated 96 well plates. Cells were allowed to attach for 6 hrs, and were thereafter fixed 
and stained for cell count analysis (32 mm
2
/well analyzed with >7 technical replicates/group in 3 
independent experiments [Cellavista]). (D) WT cells treated with the ITGB1 blocking antibody (red) 
showed markedly reduced cell attachment (n=3 experiments/group; *P<0.05) compared to untreated 
cells (black). HSP47 KO MEFs also displayed reduced cell attachment with blocking treatment; 




3.4.4 Generation and validation of HSP47 KO hES2 cell line 
 
As HSP47KO MEFs exhibit reduced collagen type I secretion, defective ECM cardio-
instructive properties and impair mouse EHM tissue formation and maturation, we 
next wanted to assess whether these findings were similar in a human system. In order 
to investigate this, we employed the CRISPR/Cas9 system to mutate site specific 
regions of the SERPINH1 gene in pluropotent hES2-RFP cells (Irion et al., 2007).  
 
Two different human mutant HSP47 KO cell lines were produced; Mut.1 and Mut.2. 
The Mut.1 cell line has a 117 bp deletion of exon 3, including the genomic region of a 
published SERPINH1 human mutation (Christiansen et al., 2010). The Mut.2 cell line 
has a 200 bp deletion in exon 4-5 (start of exon 4 and start of exon 5 [90 bp of the 
coding DNA sequence], and the intron in between [110 bp]), similar to mouse HSP47 
KO mouse model (Nagai et al., 2001). Both mutations lead to an in-frame truncation 
of HSP47. PCR genotyping demonstrates that both mutations were homozygous and 
present in the genomic DNA (Figure 34). Further experiments were additionally 
performed to determine whether HSP47 expression was successfully disrupted in 















Figure 34. PCR genotyping of SERPINH1 homozygous mutant cell lines. (A) PCR genotyping for 
exon 3 confirmed that the Mut.1 (exon 3) cell line (denoted in red) had a ~117 bp deletion, compared to 
WT (663 bp) and Mut.2. (B) PCR for exon 4-5 confirmed that Mut.2 (exon 4-5) cell line (denoted red, 
in the blue box) had a ~200 bp deletion, compared to WT (943 bp) and Mut.1. Both mutant lines were 
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Figure 35. Confirmation of the HSP47 mutations in hES2 cells. (A) Schematic overview of human SERPINH1 
mRNA (WT) and where the mutations (red) were introduced in Mut.1 (exon 3 mutation), Mut.2 (exon 4-5 mutation), 
and where primers were specifically targeted (blue) to validate respective target-specific deleted/mutated regions. 
Primers targeted; Exon 5-6 (localized out of the site-specific mutated regions), exon 3 and exon 4-5 (targeting the 
specific sites of mutation). (B) RT-PCR confirmed the site-specific mutations in Mut.1 (exon 3) and Mut.2 (exon 4-5) 
at RNA level. The „no RT‟ (reverse transcriptase) controls indicated cDNA synthesis was performed in the absence of 
reverse transcriptase. Base pairs (bp). (C) Immunoblotting analysis demonstrates HSP47 protein expression was 
markedly reduced in both Mut.1 and Mut.2. Both mutations show band shifts that are the result of the mutated protein 
(3 biological replicates/group). (D) Immunofluorescence analysis confirmed the dramatic reduction of HSP47 (green) 
in Mut.1 and Mut.2 pluripotent (red) hES2 cells compared to WT cells.  
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Interestingly, Mut.1 shows a band shift that is a result of the mutated protein, which 
has 39 amino acids (aa) (aa 53-91 of the HSP47 protein sequence) less than WT. This 
consequently produced a smaller product size. This band shift was similarly observed 
in Mut.2, which has 30 amino acids (aa 229-258 of the HSP47 protein sequence) less 
than WT. This shift was however much less pronounced. Furthermore, 
immunohistochemical analysis additionally confirmed that HSP47 (green) showed 
negligible expression in pluripotent Mut.1 and Mut.2 cell lines, in contrast to WT 
cells (red, blue) (Figure 35D). A very small population of HSP47 positive cells were 
present in Mut.2, however since WT cDNA was not found to be present in both Mut.1 
and Mut.2 cells at PCR level (Figure 35B), we can thus exclude that there was 
contamination of WT cells present in both mutant cell lines. 
  
For ongoing future experiments, the functional consequences of the human HSP47 
KO mutations in cardiac tissue formation and maturation will be assessed by utilizing 










The heart is a complex multicellular organ which undergoes many critical changes 
during development and under pathological conditions. It is clear that both the CM 
and non-myocyte components in the heart play essential roles in the processes 
involved in the development of cardiac hypertrophy, remodelling and heart failure 
(Takeda and Manabe, 2011). cFBs represent the predominant non-myocyte population 
in the adult mammalian heart (Frangogiannis, 2013; Souders et al., 2009; Camelliti et 
al., 2004a) and while studies of CMs in the heart have been extensive, cFBs have 
received less attention. Emerging evidence suggests that cFBs are one of the key 
components actively participating not only in response to pathological injury and 
stress, but also in normal cardiac function (Kakker and Lee, 2009). It has also been 
suggested that cFBs are able to interact with CMs in a paracrine manner, via the 
influence of ECM secretion and remodelling, and via direct cell-cell interactions, 
which influence cardiac development, normal physiology and pathophysiology 
(Kakker and Le, 2009). The mechanisms of how cFBs contribute to the formation of a 
cardio-instructive environment remain largely undefined. 
 
We hypothesized that the mechanical and paracrine effects of cFBs and its secreted 
ECM influence cardiac tissue formation and CM maturation. We were able to 
demonstrate that: 
 
- FBs are essential for mouse and human engineered heart muscle formation. 
 
- Integrin mediated FB-ECM interactions are essential for engineered heart 
muscle formation.  
 
- FBs secrete a cardio-instructive ECM environment important in mediating 
heart muscle maturation. 
 
- Collagen processing HSP47 is an important regulator of heart muscle 




4.1 Fibroblasts are essential for engineered heart muscle formation 
 
Engineered myocardium provides a simplified 3D cellular environment model to 
study cell-cell interactions. We utilized the in vitro EHM model of heart muscle 
development to investigate the role of cFBs in cardiac tissue development and 
maturation in mouse and human systems. Firstly, by use of genetically engineered 
ESC lines, we were able to successfully generate by directed differentiation highly 
purified CMs for both mouse (Figure 12) and human (Figure 13), to exclusively 
define the cellular constituents (CMs to non-myocytes) in the EHM model. Most 
technologies to generate engineered myocardium up until now have been mainly 
based on mixed or relatively non-purified cell populations enriched for CMs, derived 
from mouse ESCs (Guo et al., 2006), human ESCs (Tulloch et al., 2011) and rodent  
primary heart cells (Naito et al., 2006). 
 
We were able to demonstrate that enriched mouse CMs alone mixed with collagen 
type I (the most abundant ECM protein in the myocardium) is insufficient to form 
compact functional cardiac tissue (Figure 14). Similar observations were found in the 
human collagen-based EHM (Tiburcy et al., unpublished data) and fibrin-based 
engineered myocardium (Zhang et al., 2013). Furthermore, studies from our lab have 
also revealed in mice that the addition of FB-conditioned medium, as well as the 
supplementation with additional growth factors and ECM proteins in matrigel to 
highly purified CMs and collagen type I is insufficient to rescue this failed tissue 
phenotype (Figure S1, Appendix A1, Christalla et al., unpublished data). These 
observations argue against the critical importance of paracrine mechanisms in 
exclusively mediating initial heart muscle formation.  
 
We next tested whether the addition of cFBs would support EHM formation and 
tissue maturation. We indeed found that the addition of 25% cFBs to EHMs resulted 
in the generation of mature compact tissue engineered myocardium with organotypic 
morphology and functionality in both mouse (Figure 14; Figure S1, Appendix A1, 
Christalla et al., unpublished data) and human (Tiburcy et al., unpublished data). 
These observations are in line with a previous study in our lab using a similar cell-
defined (25% cFBs mixed with 75% genetically purified mouse parthenogenetic stem 
cell-derived CMs) approach to generate EHMs, with the addition of matrigel (Didié et 
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al., 2013). Our observations furthermore support a previous study from our lab which 
have shown that EHMs derived from mixed populations of rodent neonatal heart cells 
(containing a higher fraction of cFBs) on collagen type I and Matrigel compared to 
constructs comprised of purer CM populations display improved contractile force 
generation and increased inotropic response (Naito et al., 2006).  
 
Several other cardiac tissue engineering-based approaches have furthermore 
suggested that cFBs greatly enhance the growth and formation of well structured, 
functional myocardial tissue (Caspi et al., 2007; Nichol et al., 2008; Radisic et al., 
2008) in addition to promoting CM survival and coupling (Kensah et al., 2012; Liau 
et al., 2011; Matsuura et al., 2011; Pfannkuche et al., 2010). Many of these studies 
above, including other reports in the field of cardiac tissue engineering have relied on 
the use of matrigel for the generation of cardiac tissue constructs. Given the fact that 
our study furthermore demonstrates the addition of ECM proteins and growth factor 
from matrigel are not critical for the generation of compact functional EHM in both 
mouse and human systems, this further supports the notion that cFBs are exclusively 
essential for the generation and support of myocardial tissue.  
 
Several other findings have highlighted the importance of cFBs in playing a role in 
myocardial compaction during cardiac development. The embryonic pool of cFBs 
during development has been suggested to partially originate from the epicardium by 
epithelial-mesenchymal transformation (EMT) (Lie-Venema et al., 2007; 
Gittenberger-de Groot et al., 1998; Dettman et al., 1998; Cai et al., 2008) and several 
studies have shown these epicardial-derived cells (EPDCs) migrate into the 
ventricular wall of the embryonic heart, leading to myocardial compaction and 
maturation (Sengbusch et al., 2002; Pérez-Pomares et al., 2002; Ieda et al., 2009). 
Preventing the migration and invasion of EPDCs into the ventricular wall of the 
embryonic heart has been shown to result in myocardial non-compaction, causing 
lethal cardiac failure (Sengbusch et al., 2002; Pérez-Pomares et al., 2002). Our data 
suggests that cFBs exhibit a similar function by compaction of EHM. To further 
define the cellular mechanism underlying this observation, we investigated whether 
direct cell-cell interactions, paracrine signalling or other factors from cFBs mediate 




4.2 Integrin mediated fibroblast-ECM interactions are essential for engineered 
heart muscle formation 
Integrin transmembrane receptors are fundamental components in the myocardium 
which function as mechanotransducers in mediating the interaction between the ECM 
and CMs or cFBs, in the process of normal cardiac development (Ross and Borg, 
2001) and in response to physiological and pathological signals (Simpson et al., 1999; 
Parker and Ingber, 2007). Given the fact that CMs alone failed to develop functional 
and mature compact cardiac tissue in both mouse and human EHM, we thus 
investigated whether FB-specific mechanisms of mechanotransduction are responsible 
for the initial formation of EHMs.   
 
We analysed the expression of collagen binding integrin chains; Itgα1, Itgα2 and 
Itgβ1 in purified CMs and FB single cell populations in monolayer culture, at both 
protein and RNA level (Figure 15, 16 and 17). As it has not been clearly demonstrated 
whether different types of FBs (besides cardiac origin) can improve tissue quality, the 
properties of FBs from both embryonic and cardiac origin were thus investigated in 
this study. Interestingly, we identified that FBs express higher levels of ITGA1, 
ITGA2 and ITGB1 in contrast to CMs in both mouse and human models at the protein 
and RNA level. In both mouse and human systems, we found Itgα2 transcribed in 
FBs, however negligible expression was detected in CMs. This is in agreement with 
previous findings which have demonstrated that Itgα2 is uniquely expressed in rodent 
cFBs but not by CMs (Terracio et al., 1991; Terracio et al., 1989). We confirmed a 
similar expression profile in human cells.  
 
Although our data reveals that Itgβ1 expression is lower at both protein and RNA 
level in CMs compared to FBs in both mouse and human systems, Itgβ1 has however 
been reported to be expressed in enriched mouse embryonic CMs (Ieda et al., 2009). 
The expression levels of these integrins may differ in a 3D environment or upon 
interaction with the ECM (Harston and Kuppuswamy, 2011), as it is becoming 
increasingly appreciated that cell receptor, protein and gene expression can differ 
between 2D and 3D culture environments (Edmondson et al., 2014; Pontes Soares et 
al., 2012). Further studies would be required to investigate whether integrin 
expression in FBs and CMs is altered upon interaction with the ECM.  
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We next tested whether inhibition of integrin-mediated signalling functionally impairs 
initial EHM formation and tissue compaction, using collagen binding integrin chain 
blocking antibodies. We indeed found that blocking of Itgβ1 (CD29) inhibits EHM 
formation in both mouse and human models (Figure 18). Since Itgβ1 associates with 
both Itgα1 and Itgα2 subunits, and interacts with collagens, fibronectin and laminins 
(Barczyk et al., 2010), it is no surprise that blocking of Itgβ1 exhibits the most 
pronounced inhibitory effects on EHM formation. Furthermore, blocking of Itgα2 
(CD49b) interactions has shown to inhibit initial EHM formation in the mouse (to a 
lesser extent than Itgβ1 blocking) and partially in the human model. Blocking of Itgα1 
(CD49a) interactions however did not demonstrate to inhibit initial EHM formation. 
This is in agreement with several other studies which have demonstrated the role of 
Itgβ1, in particular the α2β1 receptor (and to a lesser extent the α1β1 receptor) in 
mediating collagen gel contraction by FBs (Gullberg et al., 1990; Carver et al., 1995; 
Langholz et al., 1995; Schiro et al., 1991; Grinnell, 1994).  
 
Other studies have highlighted the importance of integrin mediated signalling in the 
myocardium. Cardiac cells from chimeric mice constructed with a Itgβ1 integrin-null 
allele exhibited delayed development and differentiation of cardiac lineage, as well as 
abnormal myofibrillogenesis (Fässler et al., 1996). A lack of Itgβ1 expression in 
homozygous mice leads to embryonic lethality (Fässler and Meyer, 1995). Moreover, 
using Itgβ1 deficient embryonic stem cells for the in vitro differentiation of CMs, 
severely disrupted cardiomyogenesis and defective myofibrillogenesis was observed 
(Fässler et al., 1996). Furthermore, when Itgβ1 is inactivated exclusively in 
ventricular CMs, this resulted in myocardial fibrosis and heart failure (Shai et al., 
2002). In addition, the disruption of Itgβ1 function in CMs by a high level of 
dominant-negative Itgβ1 mutant under the control of the CM-specific α-myosin heavy 
chain (αMHC) promoter, displayed a more severe pathological phenotype. These 
transgenic mice died perinatally and displayed fibrotic replacement of the 
myocardium (Keller et al., 2001). cFBs have also  been suggested to play critical roles 
in cardiac remodelling via ECM-integrin interactions (Manso et al., 2009). These 
studies thus indicate that cell–ECM interactions via integrin signalling are essential 




We collectively show that FB populations express higher levels Itgβ1 compared to 
CMs, and CMs alone failed to support the formation of a functional syncytium and 
organotypic maturation. We can thus conclude that ECM-Cell interactions mediated 
via integrin mechanotransduction signals in FBs are essential in mediating cardiac 
tissue formation.  
 
4.3 Fibroblasts secrete a cardio-instructive ECM environment important in 
mediating heart muscle maturation 
 
The ECM in the heart has been primarily recognized as a structural scaffold for 
embedding and supporting CMs and non-myocytes, in order to maintain functional 
integrity of the myocardium. It is becoming increasingly understood that the different 
ECM components within the heart provide a more complex insight into the biological 
and regulatory function of the cardiac ECM. We investigated the influence of the 
cFB-producing ECM environment in promoting cardiac organotypic maturation in our 
mouse EHM model (Figure 19; Christalla et al., unpublished data). Firstly, we 
identified that several ECM-related transcripts (Col1a1 and Col1a2), in addition to 
collagen-modifying transcripts, are massively upregulated during tissue cardiac 
maturation in cFB-supplemented EHMs (Figure 19A). Besides collagen type I, other 
gene transcripts which are mainly involved in collagen I fibrillogenesis and 
maturation were also highly expressed, such as Dcn and Bgn (Campbell et al., 2008), 
indicating that collagen type I modification is also important for EHM maturation. 
Furthermore, proteomic analysis revealed a number of ECM-related proteins, several 
collagen type I modifying proteins are exclusively expressed in mouse cFB-
supplemented EHMs, compared to EHMs comprised only of enriched CMs (Figure 
19B; Christalla et al., unpublished data). Proteins which are involved in collagen type 
I de novo synthesis, modification and organisation such as; PCOC1, PLOD2, PLOD3, 
P4HA1, P4HA2 and HSP47 (Goldsmith et al., 2013; Uzawa et al., 1999; Canty et al., 
2005) indicate that cFBs are able to reorganize the collagen matrix and build a 
structured ECM environment. Furthermore, the high abundance of COL1A1 protein 
in EHMs containing purely CMs further point to the lack of tissue organization in the 




In line with the observations from our EHM model, it has been previously 
demonstrated that during cardiac development, embryonic cFBs development 
coincides with ventricular compaction, ECM production (including collagens and 
fibronectin) and growth factor secretion, which stimulates the proliferation of 
immature CMs through Itgβ1 signalling (Ieda, et al., 2009; Hornberger et al., 2000). 
Furthermore, the influence of mechanical stimulation on cultured cFBs has been 
shown to impact ECM gene expression (MacKenna, 2000). In addition to our 
observations in the mouse system, we identified that human FB populations (from 
both dermal and cardiac origin) highly express these similar ECM-related gene 
transcripts, in contrast to enriched human CMs (Figure 20). Interestingly we also 
identified that several laminin subtype transcripts: LAMA1, LAMA2 and LAMC3 
were however exclusively highly abundant in human CMs, in contrast to FB 
populations. Whether or not these ECM-related genes are upregulated or down 
regulated in a 3D environment in human cardiac tissue formation and maturation 
however requires further investigation.  
 
The binding of ECM to specific integrins in CMs and FBs has the potential to activate 
signalling cascades with a potential role in cell fate regulation. Several studies have 
highlighted the importance of the ECM environment in supporting CM differentiation 
of ESCs, derived from mouse (Haguchi et al., 2013; Baharvand et al., 2005) and 
human (Oberwallner et al., 2015). Additionally, an earlier study suggested that 
collagen I and laminins provide adequate cues for promoting the upregulation of CM 
maturation marker genes in rodents (LaNasa, 2009). Furthermore, the FB-derived 
microenvironment changes during development to promote stage-specific processes 
of CM differentiation, integration and maturation (Ieda et al., 2009). In rodents, 
collagen synthesis (Mays et al., 1991) and fibronectin expression (Farhadian et al., 
1995) changes with development and integrin isoforms change simultaneously with 
the transition from CM proliferation to terminal differentiation (Maitra et al., 2000). 
Several studies have suggested the ECM from young developmental age promotes the 
expansion of CMs in vitro compared to older aged ECM (Ieda et al., 2009; Williams 
et al., 2014). Further studies to investigate the ECM environment constructed from 
FBs from different stages of development (and disease) in a defined 3D EHM model 
may provide further information of key proteins which can promote or impair 
formation of a functional myocardial syncytium.  
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The complexity of the heterogeneous ECM environment produced from FBs provides 
spatial information for the cellular components and transmits mechanical forces that 
allow tissues to both develop and function efficiently in vivo (Goldsmith et al., 2013; 
Nelson and Tien, 2006). In conclusion, our findings collectively demonstrate that FBs 
mechanically support tissue formation and construct a heterogeneous ECM 
environment composed of primarily of collagens and collagen modifying proteins, to 
biologically construct a functional myocardial syncytium.  
 
4.4 Collagen processing HSP47 is an important regulator of heart muscle 
formation and maturation  
4.4.1 HSP47 is highly expressed in fibroblasts  
 
Myocardial collagens provide both mechanical strength and structural support to the 
heart. In the healthy myocardium, fibrillar collagens play a critical role in guiding CM 
orientation, size and function (Porter and Turner, 2009) in order to facilitate efficient 
contraction, force transduction and electrical transmission of cells in the myocardium. 
It has not been demonstrated how alterations in ECM collagen modification and 
processing in cFBs can influence CM structure and function in the myocardium. 
Mutations of various types of collagen genes have also been identified to cause 
various collagen-related diseases including; Osteogenesis Imperfecta (OI), Ehlers-
Danlos syndrome and Alport syndrome (Nagai et al., 2001). The collagen-specific 
molecular chaperone HSP47 is essential for the molecular maturation, processing and 
secretion of Collagens type I and IV and it has been shown that the disruption of the 
Hsp47 gene in mice is embryonically lethal (Nagai et al., 2001). No differences in the 
molecular forms of other predominant ECM proteins, including: collagen III, Laminin 
and Fibronectin were however detected in HSP47 KO mice (Nagai et al., 2001).   
 
We firstly compared the expression of collagen processing HSP47 in FBs and CMs to 
demonstrate that HSP47 expression is highly abundant in both mouse and human FBs 
(Figure 21 and 22). Comparing the FB populations in human cells, we identified 
hFFBs express higher HSP47 protein levels compared to cFBs. On the contrary, cFBs 
possess higher SERPINH1 transcript levels compared to hFFBs. Further studies will 
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be required to compare regulatory mechanisms between both populations. Human 
ESC derived-CMs express both low levels of SERPINH1 and collagen type I 
transcripts (COL1A1 and COL1A2), accordingly only minimal procollagen I protein 
was detected in CMs compared to FBs (Figure 15D). We have also identified that 
HSP47 expression is highly abundant exclusively in mouse cFB-supplemented EHMs 
(Figure 19B). In agreement with previous observations, the expression of HSP47 
under normal conditions is closely linked with the expression of collagens in various 
cell types and tissues (Nakai et al., 1990; Hirayoshi et al., 1991; Sauk et al., 1994; 
Kambe et al., 1994) and HSP47 expression is not detected in cells which do not 
synthesize collagen (Nagata and Hosokawa, 1996). 
 
4.4.2 Absence of HSP47 in mouse fibroblasts impairs ECM Collagen type I 
secretion and fibrillar organisation  
  
Based on the observation that HSP47 is predominantly expressed in collagen-
producing FBs, we next set out to investigate its influence on mouse CM maturation 
by utilizing HSP47 KO MEFs derived from HSP47KO mice (Nagai et al., 2001). We 
confirmed the absence of HSP47 in MEFs at both mRNA and protein levels (Figure 
3.12), as previously shown (Nagai et al., 2001; Ishida et al., 2006). Our study revealed 
that HSP47 partially colocalizes in the same compartment with PDI and procollagen 1 
in WT MEFs, however the expression pattern of procollagen 1 in HSP47 KO cells 
reflects that it is accumulated in the intracellular ER compartment (Figure 24). 
Additionally, we found that PDI protein levels were partially elevated in HSP47 KO 
MEFs (Figure 25). PDI is another ER resident chaperone protein (Wang et al., 1998; 
Gilbert, 1997) that also has functions during procollagen synthesis specifically in the 
formation of procollagen inter-chain disulphide bonds within the ER (Koivu et al., 
1987; Gelse et al., 2003; Canty et al., 2005). Our observations are in close agreement 
with other studies, which have demonstrated that HSP47 transiently associates with 
procollagen in the ER and dissociates before reaching the cis-Golgi (Satoh et al., 
1996). Further immunoflourescence experiments to assess whether HSP47 partially 
colocalizes with GM130 (a marker of the cis-Golgi compartment) would be needed to 
specify the localization within the ER and Golgi compartments.  
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It has also been reported that misfolded procollagen 1 accumulates within the ER in 
HSP47 KO MEFs, resulting in ER dilation (Ishida et al., 2006). This partial increase 
in PDI levels we observed may thus be a compensatory effect to protect these cells 
from the accumulation of procollagen we observed in the ER in HSP47 KO MEFs. In 
contrast, a previous study however has shown that procollagen misfolded aggregates 
are eliminated from the ER via the autophagic lysosome pathway, as a protection 
strategy in HSP47KO MEFs (Ishida et al., 2009). Further experiments to examine the 
expression of ER markers: IRE1α, PERK, ATF6 and CHOP1, via immunoblotting 
and qPCR (Oslowski and Urano, 2011) would be needed to provide further 
information to whether the accumulation of misfolded procollagen in HSP47 KO 
MEFs result in ER stress.  
 
We were able to demonstrate that HSP47 KO MEFs display markedly reduced 
secretion of soluble collagens after 72 hrs (Figure 26). Additional time points could be 
assessed in the future to determine differences in the rate of collagen secretion. 
Previous findings however have reported that the secretion of collagen type I and IV 
is distinctly delayed in HSP47 KO MEFs (Ishida et al., 2006; Marsuoka et al., 2004), 
probably due to improper formation of the procollagen molecule structure. 
Importantly, Ishida et al., reported that P4H is also clearly detected in HSP47 KO 
MEFs, indicating that improper collagen triple helix formation in these cells is not due 
to insufficient prolyl-hydroxylation (Ishida et al., 2006). 
 
As we found that collagen defective HSP47 KO MEFs exhibit reduced collagen 
secretion after 72 hrs, we also demonstrated that the incorporation of collagen type I 
chains; COL1A1 and COL1A2 into the ECM is dramatically reduced in HSP47 KO 
MEFs (Figure 27B). We were able to confirm these findings via proteomic analysis 
(Figure 28). Interestingly, and despite an evident reduction in collagen secretion and 
collagen type I ECM incorporation in HSP47 KO MEFs, we observed that there is a 
trend towards a higher abundance of Col1a1 and Col1a2 chain transcripts at mRNA 
level in these cells compared to WT (Figure 27C). Nagai et al., reported that there 
were no significant differences in Col1a1 and Col1a2 mRNA levels between WT and 
HSP47 KO embryos (Nagai et al., 2001), however a more recent study from this 
group conditionally inactivated the Hsp47 gene in chondrocytes using a Cre-LoxP 
system in mice and revealed that Col1a1 mRNA is upregulated in mouse embryos 
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(Masago et al., 2012). In relation to our observations, HSP47 ablation in MEFs might 
thus cause the compensatory production of procollagen, although collagen secretion is 
impaired. This may also account for why we observed higher PDI protein expression 
in HSP47 KO MEFs.  
 
Taken together, our data suggests that there is defective collagen type I processing 
and secretion in the absence of HSP47. Interestingly, proteomic analysis also revealed 
that Periostin (POSTN) expression is absent in HSP47 KO secreted ECMs. POSTN 
has been demonstrated to promote the proliferation and myofibroblast differentiation 
of FBs (Crawford et al., 2015). Further experiments would need to be performed to 
determine whether HSP47 KO MEFs are able differentiate into a myofibroblast 
phenotye in culture. POSTN has furthermore been implicated in the regulation of 
collagen type I fibrillogenesis and organization (Norris et al., 2007). Collagen fibrils 
from POSTN-deficient mice have shown to be reduced in size, disorganized and less 
efficiently cross-linked (Snider et al., 2009; Norris et al., 2007; Shimazaki et al., 
2008). Furthermore, POSTN is expressed during fetal cardiac development (Bowers 
et al., 2010) and is found to promote CM proliferation in vitro and improved heart 
function after myocardial infarction in adult rodents (Kühn et al., 2007). Interestingly, 
we also identified that several extracellular vesicular exosome proteins were 
exclusively incorporated into the HSP47 KO ECM (Figure 28). It has been recently 
demonstrated that paracrine intercellular communication in between FBs and CMs 
occurs via exosomes and microvesicles (Bang et al., 2015). Furthermore, it has been 
suggested that exosomes may also have a functional role in selectively secreting 
harmful/damaged proteins, in order to alleviate intracellular stress conditions and 
preserve intracellular protein homeostasis (Baixauli et al., 2014). This may suggest 
that protein trafficking and secretion may be impaired in HSP47 KO cells. Since the 
mass spectrometry experiments were performed on 1 sample/group with 2 technical 
replicates, additional repeats of this experiment would be required to confirm these 
findings and further investigate whether a feedback loop regulation exists between 
these proteins and the mechanisms behind it.  
 
We next examined that structure of the ECM deposited from collagen defective 
HSP47 KO MEFs and revealed that this ECM showed dramatically reduced fibrillar 
structures, which appeared thinner with more frequent branchlike structures (Figure 
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30). Collagen type I deposition is markedly reduced and displayed thinner, reduced 
fibrous ECM networks. The deficient POSTN expression we observe in HSP47 KO 
ECM may further account for why we observed disrupted collagen type I fibrils, 
however further studies at both protein and RNA level in HSP47 KO MEFs would be 
required to verify this observation.  
 
These findings are in line with previous studies by Nagata and colleagues, which have 
extensively shown that: (1) HSP47 KO MEFs produce abnormally thin and frequently 
branched collagen type I fibrils evidenced by electron microscopy (Ishida et al., 
2006), a phenotype that could be restored by transient expression of HSP47 in HSP47 
KO cells (Ishida et al., 2006); (2) Collagens secreted from HSP47 KO MEFs were 
more susceptible to protease digestion, suggesting that there is defective triple helix 
formation of collagens I and IV in the ER of these cells (Nagai et al., 2001; Matsuoka 
et al., 2004); (3) Immature collagen type I with unprocessed N-terminal propeptides 
are secreted from HSP47 KO MEFs and accumulated in the ECM (Ishida et al., 2006). 
Taken together, our observations corroborated by these studies demonstrate that 
HSP47 is required for correct folding of procollagen in the ER, which is necessary for 
efficient secretion, processing and fibril formation of collagen type I.  
 
4.4.3 Defective ECM Collagen type I secretion and organisation impairs 
cardiomyocyte homeostasis and maturation 
 
As fibrillar collagen plays a critical role in maintaining cardiac shape, size and 
function (Porter and Turner, 2009), we next investigated how defective collagen 
processing HSP47 influences the cardio-instructive properties of the ECM. We firstly 
demonstrated that purified mESC-CMs cultured on WT MEF-derived ECM displayed 
a mature CM phenotype with advanced sarcomeric organization and morphological 
features with regular cross striations and primarily rod shaped bodies, which are 
orientated along the collagen type I microfibrillar structure (Figure 31). Interestingly, 
CMs exhibited an impaired phenotype when cultured on collagen defective HSP47 
KO MEF-derived ECMs, displayed by a rounded, flat, immature morphology with 
disorganized sarcomeric structures. 
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The structure and orientation of ECM fibrillar collagen has shown to be important in 
determining CM structure. Mechanically aligned collagen fibrils have the capacity to 
elongate muscle cells along its parrellel axis (Vandenburgh and Karlisch, 1989). 
Furthermore, in vitro studies have demonstrated that microcontact printing parallel 
lines of ECM proteins on 2D substrates induce CM alignment (Pong et al., 2011; 
Feinberg et al., 2012; Grosberg et al., 2011). Alignment of CMs is important for both 
electromechanical coupling and contractile force generation (Black et al., 2009; 
Chung et al., 2007) and it can also promote differentiation and maturation of cardiac 
progenitor cells (Domian et al., 2009). Further immunohistochemical stainings for 
cardiac gap junction protein Cx43 and Cx45 would provide further information into 
possible differences in electrical coupling of CMs on collagen-defective ECMs.  
 
Due to FBs depositing dense ECM networks of insoluble proteins (after 11 days) in 
culture, we tested several different published protocols in attempt to solubilise and 
quantity of ECM protein deposited on plates (Beacham et al., 2007; DeQuach et al., 
2010; Harvey et al., 2013 Turoverova et al., 2009). None were able to aid in 
successful homogeneous solubilisation of FB-derived ECMs. We are thus unable to 
clearly distinguish whether this impaired CM phenotype is a consequence of the  
immature unprocessed collagen depostion, or due to the insufficient amount of total 
collagen deposited from HSP47 KO MEFs. Future experiments using higher 
concentrations of SDS (≥3 %) may aid in successful solubilization of ECM. In 
addition, the stiffness of the myocardial ECM enviroment may also be important for 
CM maturation and function (Majkut et al., 2013; Young and Engler, 2011). 
Additional studies to assess the biophyisal properties (stiffness) of these ECMs 
produced from these MEFs would provide us further information of how defective 
collagen processing in FBs can influence the mechanical enviroment of the ECM, and 
CM structure and function.  From these obervations, we can however conclude that 
defective collagen processing and secretion from HSP47 KO MEFs impairs the ECM 
cardio-instructive properties in guiding immature CMs towards a mature phenotype.  
 
We next investigated the influence of defective ECM collagen type I in cardiac tissue 
formation and maturation utilizing our 3D EHM model of heart muscle development. 
We found that HSP47 KO MEF-supplemented EHMs demonstrate a lower degree of 
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maturation (Figure 32), which is characterized by the failure to form compact mature 
functional tissue. These tissues exhibited an impaired CM phenotype, with 
disorganized sarcomeric structures, immature rounded morphology and failed to form 
tightly pack, dense, aligned CM muscle bundles. Furthermore, these EHMs failed to 
develop contractile force which is representative of a impaired functional syncytium. 
This obervation may likely be due to reduced Itgb1 expression and impairment of 
mechanical signalling in HSP47 KO MEFs (Figure 33), which may explain for why 
these tissues failed to condense. We did not observe a significant difference in ITGB1 
at protein level (n=3 group), however further experiments with more replicates/group 
may elimate variability and demonstrate signficant differences. The defective ECM 
collagen type I derived from HSP47KO MEFs (observed in 2D culture) may 
furthermore impair CM structure and organisation within the tissue. It would also be 
critical to assess whether ER stress is induced within these tissues, by assessing 
markers of ER stress at both protein and mRNA levels. We could speculate that this 
reduction in Itgb1 transcripts could be due to defective protein trafficking and ER 
stress induction in HSP47 KO MEFs. This however requires further investigation. In 
addition, further experiments to determine whether this impaired EHM phenotype 
could be rescued by transiently expressing HSP47 into HSP47 KO cells via 
transfection with a mouse HSP47 expression vector (Ishida et al., 2006; Nagai et al., 
2000), would provide additional evidence that HSP47 in FBs is critical for EHM 
formation and maturation.   
 
Although the role of HSP47 in the myocardium has currently not been extensively 
studied, the influence of HSP47 inhibition in cardiac remodelling after myocardial 
infarction has been previously investigated (Hagiwara et al., 2011). This study 
demonstrated that HSP47 antisense-oligonucleotides could reduce ligated left anterior 
descending (LAD) coronary artery-induced myocardial infarction in rats. Rats with 
ligated LAD coronary artery exhibited an upregulation of HSP47 expression, 
remodelling of the left ventricle, and cardiac dysfunction. In contrast, rats with ligated 
LAD coronary artery treated with antisense oligonucleotides had significantly reduced 
HSP47 expression, cardiac remodelling, and improved cardiac function (Hagiwara et 
al., 2011). HSP47 has been closely related to the development of many different types 
of fibrosis (Kakugawa et al., 2010; Masuda et al., 1994; Hagiwara et al., 2007; 
Kakugawa et al., 2004). Several studies have also suggested that the pro-fibrotic 
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cytokine TGF-β can induce HSP47 expression (Sasaki et al., 2002). In addition, the 
microRNA-29 (miR-29) family act as regulators in cardiac fibrosis (van Rooij et al., 
2008) and have been recently suggested to target and down regulate HSP47 
expression (Zhang et al., 2014; Zhu et al., 2015; Zhao et al., 2014; Yamamoto et al., 
2013).  
 
Another more recent study has demonstrated that administration of the statin 
Atorvastatin, ameliorated cardiac fibrosis and improved left ventricular diastolic 
function in a rat model of hypertensive diastolic heart failure while reducing the 
expression of HSP47 in fibrotic hearts and cFBs (Akahori et al., 2014). In addition to 
mouse models, previous studies have revealed that the SERPINH1 is one of the genes 
responsible for recessive OI in both human (Christiansen et al., 2010) and dog 
(Lindert et al., 2015; Drogemuller et al., 2009). It has been recently reported that 
patients with IO have increased risk of heart disease and in particular valve diseases, 
which include dilation of the aorta, compared to healthy control patients (Ashournia et 
al., 2015; Karamifar et al., 2013; Rudunovic et al., 2011). Taken together, these data 
along with our findings demonstrate the importance of collagen processing HSP47 as 
a key regulator of ECM homeostasis, which can thus impact cardiac remodelling and 
function. 
 
4.4.4 Generation and validation of human HSP47 mutant cell lines 
 
From our observations in the mouse model, we wanted to further investigate whether 
(1) functional mutations in the human HSP47 protein impairs collagen type I 
processing and secretion in human FBs, and whether, (2) alterations in ECM collagen 
influence CM structure and tissue functionality, by modelling this in vitro in human 
3D EHMs. Taking exclusive observations of genetic mutations in the 
Hsp47/SERPINH1 gene in mice (Nagai et al., 2001) and in human (Christiansen et al., 
2010), we utilized the CRISPR/Cas9 system to mutate site specific regions of the 
SERPINH1 gene in pluropotent hES2 cells. We were able to successfully generate 2 
in-frame mutation cell lines: Mut.1 and Mut.2. The Mut.1 cell line has a 117 bp 
deletion exclusively in exon 3 of SERPINH1, confirms the missense mutation 
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(c.233T>C, p.Leu78Pro) in human OI patients with an autosomal-recessive disease. 
(Christiansen et al., 2010). The Mut.2 cell line has a 200 bp deletion in exon 4-5 (end 
of exon 4 and start of exon 5 [90 bp of the coding DNA sequence], and the intron in 
between [110 bp]), covering a similar deleted region in HSP47 KO mouse model 
(Nagai et al., 2001).  
 
We confirmed the presense of the mutations in Mut.1 (Exon 3) and Mut.2 (Exon 4-5) 
in the SERPINH1 gene (Figure 35B). HSP47 protein levels were dramatically reduced 
in both mutant lines compared to WT. The smaller protein size observed in Mut.1 
samples (Figure 35C) is the consequence of a mutated protein sequence deletion (39 
aa). The reported human OI-study revealed that exon 3 mutations in SERPINH1 
generated an unstable protein which is degraded, but could still be detected in dermal 
FBs (Christiansen, et al., 2010). This study also concluded that the overall rate of 
procollagen type I production is effectively normal, but triple helical conformation of 
secreted collagen type I (failure to mature) is altered (Christiansen, et al., 2010). They 
were however not able to conclude whether the small remaining detected protein is 
still functional. They speculated that if this protein remained functional, this may 
account for the less severe phenotype and differences in effects observed compared to 
the more severe phenotype in the HSP47 KO mouse model (Nagai et al., 2001; Ishida 
et al., 2006). These observations may explain for why there were small detected 
amounts of protein expressed in Mut.1. 
 
Immunostaining analysis of Mut.2 cells revealed a negligible number of single cells 
showed positive staining (Figure 35D). Since RT-PCR confirmed the presence of the 
mutation in both cell lines, we can confirm from these findings that no contaminating 
WT cDNA is present in both homozygous mutations (Figure 35B). As WT cells 
appear to grow faster than mutant cells and that these positively expressed cells fail to 
outgrow the mutated cells in culture, we can furthermore exclude that no WT 
contaminants were present in the both mutant cell lines. In comparision to HSP47 KO 
mice that were generated via homologous recombination (see Figure 23), no HSP47 
was detected at protein level in MEFs from HSP47 KO homozygous mice (Figure 24; 
Nagai et al., 2001; Ishida et al., 2006). Since our human site-specific mutation 
generated an inframe deletion, this may account for why we observe minor HSP47 
protein expression in the Mut.2. We have no information on which epitope region in 
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the HSP47 protein sequence the monoclonal HSP47 antibody used in all studies, 
recognises. Whether this detected protein is functional or not needs to be determined. 
In addition, a mutation in the C-terminal end of the HSP47 protein (c.977C>T, 
p.L326P) in OI-Dachshunds, has also been reported to impair collagen processing, 
secretion and collagen type I cross-linking (Lindert et al., 2015; Drogemuller et al., 
2009). Mutant HSP47 protein is expressed as a stable protein, however its level is 
reduced to half the control level.  This further demonstrates the critical importance of 
HSP47 as an ER chaperone involved in collagen type I processing, secretion and 
maturation. 
 
The next critical experiments will be to test whether these mutations have functional 
effects, by differentiating these mutant hES2 lines, isolating the non-myocyte cellular 
fractions and characterize HSP47 expression, in addition to mesenchymal/FB 
markers, including: VIM, FSP-1, Procollagen 1, Platelet-derived growth factor 
(PDGF), in addition to surface markers: CD90, CD105 and CD73. Karyotyping would 
be necessary to rule out for any chromosomal abnormalities from these genetic 
mutations. Subsequent experiments would be necessary to examine whether these 
human HSP47 mutant non-myocytes have functional consequences in regards to 
collagen type I processing, secretion and ER stress. Critical experiments would finally 
need to be performed to assess whether these mutant cells functionally impair cardiac 
tissue formation in our human EHM model of heart muscle development.  
 
This would thus provide us further evidence in human that: (1) the interaction 
between FB-secreted ECM collagen type I and CMs is important in controlling 
cardiac tissue homeostasis and maturation in the myocardium, and (2) HSP47 
represents a attractive therapeutic target to specifically control collagen type I 
processing and maturation and support CMs in collagen-related diseases in the heart, 
such as cardiac fibrosis.  
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5. Summary and Perspectives 
 
In conclusion to these studies, we have collectively shown that cFBs are necessary for 
both the generation and maturation of a functional organotypic engineered 
myocardium, utilizing both mouse and human EHM models of heart muscle 
development. Firstly, we established that FB-ECM interactions mediated via integrins 
is essential in mediating cardiac tissue formation. Furthermore, FBs secrete a cardio-
instructive ECM environment composed of primarily of collagens and collagen 
modifying proteins, important in mediating heart muscle maturation.  
 
Moreover, we identified the collagen-specific molecular chaperone HSP47 in FBs to 
be an important regulator of cardiac tissue formation and maturation. Utilizing HSP47 
KO MEFs, we demonstrated the absence of HSP47 impairs both the deposition of 
ECM-collagen and CM morphology and functionality in both recently established 2D 
and 3D EHM mouse culture systems. We identified these impairments in EHM 
formation and maturation may be due to: (1) reduced Itgb1 expression and 
impairment of mechanical signalling in HSP47 KO MEFs; (2) defective ECM 
collagen type I deposition and organisation, which may impair CM structure and 
organisation. Additional experiments to determine whether this impaired EHM 
phenotype could be rescued by transient HSP47 expression would provide supporting 
evidence that HSP47 is critical for heart muscle formation and maturation. 
 
Further critical experiments need to be performed to assess whether human HSP47 
mutant stromal cells (generated via the CRISPR/Cas9 system) can also functionally 
impair cardiac tissue formation in the human EHM model. This would provide us 
additional evidence in the human system that the interaction between FB-secreted 
collagen type I and CMs is important in controlling cardiac tissue homeostasis and 
maturation. HSP47 may thus represent an attractive therapeutic target in regulating 
cardiac tissue homeostasis and support CMs in collagen-related diseases in the heart 





Abercrombie, M., and G. A. Dunn. 1975. Adhesions of fibroblasts to substratum 
during contact inhibition observed by interference reflection microscopy, Exp Cell 
Res, 92: 57-62. 
Abraham, W. T., B. H. Greenberg, and C. W. Yancy. 2008. Pharmacologic therapies 
across the continuum of left ventricular dysfunction, Am J Cardiol, 102: 21G-28G. 
Akahori, H., T. Tsujino, Y. Naito, M. Matsumoto, N. Sasaki, T. Iwasaku, A. Eguchi, 
H. Sawada, S. Hirotani, and T. Masuyama. 2014. Atorvastatin ameliorates cardiac 
fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart 
failure model rats, J Hypertens, 32: 1534-41; discussion 41. 
Akins, R. E., R. A. Boyce, M. L. Madonna, N. A. Schroedl, S. R. Gonda, T. A. 
McLaughlin, and C. R. Hartzell. 1999. Cardiac organogenesis in vitro: 
reestablishment of three-dimensional tissue architecture by dissociated neonatal rat 
ventricular cells, Tissue Eng, 5: 103-18. 
Alam, N., H. L. Goel, M. J. Zarif, J. E. Butterfield, H. M. Perkins, B. G. Sansoucy, T. 
K. Sawyer, and L. R. Languino. 2007. The integrin-growth factor receptor duet, J Cell 
Physiol, 213: 649-53. 
Alford, P. W., A. P. Nesmith, J. N. Seywerd, A. Grosberg, and K. K. Parker. 2011. 
Vascular smooth muscle contractility depends on cell shape, Integr Biol (Camb), 3: 
1063-70. 
Anders, S., and W. Huber. 2010. Differential expression analysis for sequence count 
data, Genome Biol, 11: R106. 
Ashburner, M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. 
Davis, K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-
Tarver, A. Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. 
Rubin, and G. Sherlock. 2000. Gene ontology: tool for the unification of biology. The 
Gene Ontology Consortium, Nat Genet, 25: 25-9. 
Ashournia, H., F. T. Johansen, L. Folkestad, A. C. Diederichsen, and K. Brixen. 2015. 
Heart disease in patients with osteogenesis imperfecta - A systematic review, Int J 
Cardiol, 196: 149-57. 
Aszodi, A., K. R. Legate, I. Nakchbandi, and R. Fassler. 2006. What mouse mutants 
teach us about extracellular matrix function, Annu Rev Cell Dev Biol, 22: 591-621. 
Atanassov, I., and H. Urlaub. 2013. Increased proteome coverage by combining 
PAGE and peptide isoelectric focusing: comparative study of gel-based separation 
approaches, Proteomics, 13: 2947-55. 
Baharvand, H., M. Azarnia, K. Parivar, and S. K. Ashtiani. 2005. The effect of 
extracellular matrix on embryonic stem cell-derived cardiomyocytes, J Mol Cell 
Bibliography 
119 
Cardiol, 38: 495-503. 
Baixauli, F., López-Otín, C., & Mittelbrunn, M. 2014. Exosomes and Autophagy: 
Coordinated Mechanisms for the Maintenance of Cellular Fitness, Frontiers in 
Immunology, 5, 403.  
Banerjee, I., J. W. Fuseler, R. L. Price, T. K. Borg, and T. A. Baudino. 2007. 
Determination of cell types and numbers during cardiac development in the neonatal 
and adult rat and mouse, Am J Physiol Heart Circ Physiol, 293: H1883-91. 
Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., Just, 
A., Remke, J., Zimmer, K., Zeug, A., Ponimaskin, E., Schmiedl, A., Yin, X., Mayr, 
M., Halder, R., Fischer, A., Engelhardt, S., Wei, Y., Schober, A., Feidler, J., Thum, T. 
2014. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes 
mediate cardiomyocyte hypertrophy, The Journal of Clinical Investigation, 124(5), 
2136–2146.  
Barczyk, Malgorzata, Sergio Carracedo, and Donald Gullberg. 2010. Integrins, Cell 
and Tissue Research, 339: 269-80. 
Baudino, T. A., W. Carver, W. Giles, and T. K. Borg. 2006. Cardiac fibroblasts: 
friend or foe?, Am J Physiol Heart Circ Physiol, 291: H1015-26. 
Beacham, D. A., M. D. Amatangelo, and E. Cukierman. 2007. Preparation of 
extracellular matrices produced by cultured and primary fibroblasts, Curr Protoc Cell 
Biol, Chapter 10: Unit 10 9. 
Bell, E., B. Ivarsson, and C. Merrill. 1979. Production of a tissue-like structure by 
contraction of collagen lattices by human fibroblasts of different proliferative 
potential in vitro, Proc Natl Acad Sci U S A, 76: 1274-8. 
Bellis, S. L. 2011. Advantages of RGD peptides for directing cell association with 
biomaterials, Biomaterials, 32: 4205-10. 
Berk, B. C., K. Fujiwara, and S. Lehoux. 2007. ECM remodeling in hypertensive 
heart disease, J Clin Invest, 117: 568-75. 
Berrier, A. L., and K. M. Yamada. 2007. Cell-matrix adhesion, J Cell Physiol, 213: 
565-73. 
Black, L. D., 3rd, J. D. Meyers, J. S. Weinbaum, Y. A. Shvelidze, and R. T. 
Tranquillo. 2009. Cell-induced alignment augments twitch force in fibrin gel-based 
engineered myocardium via gap junction modification, Tissue Eng Part A, 15: 3099-
108. 
Boheler, K. R., L. Carrier, C. Chassagne, D. de la Bastie, J. J. Mercadier, and K. 
Schwartz. 1991. Regulation of myosin heavy chain and actin isogenes expression 
during cardiac growth, Mol Cell Biochem, 104: 101-7. 
Bonaldo, P., P. Braghetta, M. Zanetti, S. Piccolo, D. Volpin, and G. M. Bressan. 
1998. Collagen VI deficiency induces early onset myopathy in the mouse: an animal 
model for Bethlem myopathy, Hum Mol Genet, 7: 2135-40. 
Bibliography 
120 
Boudoulas, K. D., and A. K. Hatzopoulos. 2009. Cardiac repair and regeneration: the 
Rubiks cube of cell therapy for heart disease, Dis Model Mech, 2: 344-58. 
Bowers, S. L., I. Banerjee, and T. A. Baudino. 2010. The extracellular matrix: at the 
center of it all, J Mol Cell Cardiol, 48: 474-82. 
Bradford, Marion M. 1976. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding, 
Analytical Biochemistry, 72: 248-54. 
Bray, M. A., S. P. Sheehy, and K. K. Parker. 2008. Sarcomere alignment is regulated 
by myocyte shape, Cell Motil Cytoskeleton, 65: 641-51. 
Bristow, M. R. 2000. beta-adrenergic receptor blockade in chronic heart failure, 
Circulation, 101: 558-69. 
Brown, R. D., S. K. Ambler, M. D. Mitchell, and C. S. Long. 2005. The cardiac 
fibroblast: therapeutic target in myocardial remodeling and failure, Annu Rev 
Pharmacol Toxicol, 45: 657-87. 
Brutsaert, D. L. 2003. Cardiac endothelial-myocardial signaling: its role in cardiac 
growth, contractile performance, and rhythmicity, Physiol Rev, 83: 59-115. 
Burkin, D. J., and S. J. Kaufman. 1999. The alpha7beta1 integrin in muscle 
development and disease, Cell Tissue Res, 296: 183-90. 
Burridge, K., and M. Chrzanowska-Wodnicka. 1996. Focal adhesions, contractility, 
and signaling, Annu Rev Cell Dev Biol, 12: 463-518. 
Bursac, N., M. Papadaki, R. J. Cohen, F. J. Schoen, S. R. Eisenberg, R. Carrier, G. 
Vunjak-Novakovic, and L. E. Freed. 1999. Cardiac muscle tissue engineering: toward 
an in vitro model for electrophysiological studies, Am J Physiol, 277: H433-44. 
Butt, R. P., G. J. Laurent, and J. E. Bishop. 1995. Collagen production and replication 
by cardiac fibroblasts is enhanced in response to diverse classes of growth factors, 
Eur J Cell Biol, 68: 330-5. 
Cai, C. L., J. C. Martin, Y. Sun, L. Cui, L. Wang, K. Ouyang, L. Yang, L. Bu, X. 
Liang, X. Zhang, W. B. Stallcup, C. P. Denton, A. McCulloch, J. Chen, and S. M. 
Evans. 2008. A myocardial lineage derives from Tbx18 epicardial cells, Nature, 454: 
104-8. 
Calderone, A., S. Bel-Hadj, J. Drapeau, V. El-Helou, H. Gosselin, R. Clement, and L. 
Villeneuve. 2006. Scar myofibroblasts of the infarcted rat heart express natriuretic 
peptides, J Cell Physiol, 207: 165-73. 
Calderwood, D.A. 2004. Integrin activation, J Cell Sci, 117:657–666. 
Camelliti, P., G. P. Devlin, K. G. Matthews, P. Kohl, and C. R. Green. 2004a. 
Spatially and temporally distinct expression of fibroblast connexins after sheep 
ventricular infarction, Cardiovasc Res, 62: 415-25. 
Bibliography 
121 
Camelliti, P., C. R. Green, I. LeGrice, and P. Kohl. 2004b. Fibroblast network in 
rabbit sinoatrial node: structural and functional identification of homogeneous and 
heterogeneous cell coupling, Circ Res, 94: 828-35. 
Campbell, P. H., D. L. Hunt, Y. Jones, F. Harwood, D. Amiel, J. H. Omens, and A. D. 
McCulloch. 2008. Effects of biglycan deficiency on myocardial infarct structure and 
mechanics, Mol Cell Biomech, 5: 27-35. 
Canty, E. G., and K. E. Kadler. 2005. Procollagen trafficking, processing and 
fibrillogenesis, J Cell Sci, 118: 1341-53. 
Carrier, R. L., M. Papadaki, M. Rupnick, F. J. Schoen, N. Bursac, R. Langer, L. E. 
Freed, and G. Vunjak-Novakovic. 1999. Cardiac tissue engineering: cell seeding, 
cultivation parameters, and tissue construct characterization, Biotechnol Bioeng, 64: 
580-9. 
Carver, Wayne, Ivan Molano, Titus A. Reaves, Thomas K. Borg, and Louis Terracio. 
1995. Role of the α1β1 integrin complex in collagen gel contraction in vitro by 
fibroblasts, Journal of Cellular Physiology, 165: 425-37. 
Caspi, O., A. Lesman, Y. Basevitch, A. Gepstein, G. Arbel, I. H. Habib, L. Gepstein, 
and S. Levenberg. 2007. Tissue engineering of vascularized cardiac muscle from 
human embryonic stem cells, Circ Res, 100: 263-72. 
Chacko, K. J. 1976. Observations on the ultrastructure of developing myocardium of 
rat embryos, J Morphol, 150: 681-709. 
Chen, C. S., M. Mrksich, S. Huang, G. M. Whitesides, and D. E. Ingber. 1997. 
Geometric control of cell life and death, Science, 276: 1425-8. 
Chen, C. S., J. Tan, and J. Tien. 2004. Mechanotransduction at cell-matrix and cell-
cell contacts, Annu Rev Biomed Eng, 6: 275-302. 
Chen, W., and N. G. Frangogiannis. 2013. Fibroblasts in post-infarction inflammation 
and cardiac repair, Biochim Biophys Acta, 1833: 945-53. 
Chien, K. R., I. J. Domian, and K. K. Parker. 2008. Cardiogenesis and the complex 
biology of regenerative cardiovascular medicine, Science, 322: 1494-7. 
Chilton, L., W. R. Giles, and G. L. Smith. 2007. Evidence of intercellular coupling 
between co-cultured adult rabbit ventricular myocytes and myofibroblasts, J Physiol, 
583: 225-36. 
Christalla, P., J. E. Hudson, and W. H. Zimmermann. 2012. The cardiogenic niche as 
a fundamental building block of engineered myocardium, Cells Tissues Organs, 195: 
82-93. 
Christiansen, H. E., U. Schwarze, S. M. Pyott, A. AlSwaid, M. Al Balwi, S. 
Alrasheed, M. G. Pepin, M. A. Weis, D. R. Eyre, and P. H. Byers. 2010. 
Homozygosity for a missense mutation in SERPINH1, which encodes the collagen 
chaperone protein HSP47, results in severe recessive osteogenesis imperfecta, Am J 
Hum Genet, 86: 389-98. 
Bibliography 
122 
Chung, C. Y., H. Bien, and E. Entcheva. 2007. The role of cardiac tissue alignment in 
modulating electrical function, J Cardiovasc Electrophysiol, 18: 1323-9. 
Clarke, E. P., G. A. Cates, E. H. Ball, and B. D. Sanwal. 1991. A collagen-binding 
protein in the endoplasmic reticulum of myoblasts exhibits relationship with serine 
protease inhibitors, J Biol Chem, 266: 17230-5. 
Conner, D. A. 2001. Mouse embryo fibroblast (MEF) feeder cell preparation, Curr 
Protoc Mol Biol, Chapter 23: Unit 23 2. 
Crawford, Justin, Karen Nygard, Bing Siang Gan, and David Brian O'Gorman. 2015. 
Periostin induces fibroblast proliferation and myofibroblast persistence in 
hypertrophic scarring, Experimental Dermatology, 24: 120-26. 
Curtis, M. W., and B. Russell. 2011. Micromechanical regulation in cardiac myocytes 
and fibroblasts: implications for tissue remodeling, Pflugers Arch, 462: 105-17. 
de Jong, S., T. A. van Veen, J. M. de Bakker, and H. V. van Rijen. 2012. Monitoring 
cardiac fibrosis: a technical challenge, Neth Heart J, 20: 44-8. 
de Lange, F. J., A. F. Moorman, R. H. Anderson, J. Manner, A. T. Soufan, C. de Gier-
de Vries, M. D. Schneider, S. Webb, M. J. van den Hoff, and V. M. Christoffels. 
2004. Lineage and morphogenetic analysis of the cardiac valves, Circ Res, 95: 645-
54. 
de Melker, A. A., and A. Sonnenberg. 1999. Integrins: alternative splicing as a 
mechanism to regulate ligand binding and integrin signaling events, Bioessays, 21: 
499-509. 
de Souza, R. R. 2002. Aging of myocardial collagen, Biogerontology, 3: 325-35. 
DeQuach, J. A., V. Mezzano, A. Miglani, S. Lange, G. M. Keller, F. Sheikh, and K. 
L. Christman. 2010. Simple and high yielding method for preparing tissue specific 
extracellular matrix coatings for cell culture, PLoS One, 5: e13039. 
Dettman, R. W., W. Denetclaw, Jr., C. P. Ordahl, and J. Bristow. 1998. Common 
epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and 
intermyocardial fibroblasts in the avian heart, Dev Biol, 193: 169-81. 
Development Core Team, R. 2009. R: a language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna. 
Dhawan, L., B. Liu, B. C. Blaxall, and M. B. Taubman. 2007. A novel role for the 
glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 
mRNA stability, J Biol Chem, 282: 10146-52. 
Didangelos, A., X. Yin, K. Mandal, M. Baumert, M. Jahangiri, and M. Mayr. 2010. 
Proteomics characterization of extracellular space components in the human aorta, 
Mol Cell Proteomics, 9: 2048-62. 
Didié, Michael, Peter Christalla, Michael Rubart, Vijayakumar Muppala, Stephan 
Döker, Bernhard Unsöld, Ali El-Armouche, Thomas Rau, Thomas Eschenhagen, 
Bibliography 
123 
Alexander P. Schwoerer, Heimo Ehmke, Udo Schumacher, Sigrid Fuchs, Claudia 
Lange, Alexander Becker, Wen Tao, John A. Scherschel, Mark H. Soonpaa, Tao 
Yang, Qiong Lin, Martin Zenke, Dong-Wook Han, Hans R. Schöler, Cornelia 
Rudolph, Doris Steinemann, Brigitte Schlegelberger, Steve Kattman, Alec Witty, 
Gordon Keller, Loren J. Field, and Wolfram-Hubertus Zimmermann. 2013. 
Parthenogenetic stem cells for tissue-engineered heart repair, The Journal of Clinical 
Investigation, 123: 1285-98. 
Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. 
Chaisson, and T. R. Gingeras. 2013. STAR: ultrafast universal RNA-seq aligner, 
Bioinformatics, 29: 15-21. 
Doege, K. J., and J. H. Fessler. 1986. Folding of carboxyl domain and assembly of 
procollagen I, J Biol Chem, 261: 8924-35. 
Domian, I. J., M. Chiravuri, P. van der Meer, A. W. Feinberg, X. Shi, Y. Shao, S. M. 
Wu, K. K. Parker, and K. R. Chien. 2009. Generation of functional ventricular heart 
muscle from mouse ventricular progenitor cells, Science, 326: 426-9. 
Drogemuller, C., D. Becker, A. Brunner, B. Haase, P. Kircher, F. Seeliger, M. Fehr, 
U. Baumann, K. Lindblad-Toh, and T. Leeb. 2009. A missense mutation in the 
SERPINH1 gene in Dachshunds with osteogenesis imperfecta, PLoS Genet, 5: 
e1000579. 
Du, A., J. M. Sanger, and J. W. Sanger. 2008. Cardiac myofibrillogenesis inside intact 
embryonic hearts, Dev Biol, 318: 236-46. 
Durinck, S., P. T. Spellman, E. Birney, and W. Huber. 2009. Mapping identifiers for 
the integration of genomic datasets with the R/Bioconductor package biomaRt, Nat 
Protoc, 4: 1184-91. 
Edmondson, R., J. J. Broglie, A. F. Adcock, and L. Yang. 2014. Three-dimensional 
cell culture systems and their applications in drug discovery and cell-based 
biosensors, Assay Drug Dev Technol, 12: 207-18. 
Eghbali, M., O. O. Blumenfeld, S. Seifter, P. M. Buttrick, L. A. Leinwand, T. F. 
Robinson, M. A. Zern, and M. A. Giambrone. 1989. Localization of types I, III and 
IV collagen mRNAs in rat heart cells by in situ hybridization, J Mol Cell Cardiol, 21: 
103-13. 
Eghbali, Mahboubeh, Mark J. Czaja, Maria Zeydel, Francis R. Weiner, Mark A. Zern, 
Sam Seifter, and Olga O. Blumenfeld. 1988. Collagen chain mRNAs in isolated heart 
cells from young and adult rats, Journal of Molecular and Cellular Cardiology, 20: 
267-76. 
Eghbali, M., and K. T. Weber. 1990. Collagen and the myocardium: fibrillar structure, 
biosynthesis and degradation in relation to hypertrophy and its regression, Mol Cell 
Biochem, 96: 1-14. 
Engler, A. J., C. Carag-Krieger, C. P. Johnson, M. Raab, H. Y. Tang, D. W. Speicher, 
J. W. Sanger, J. M. Sanger, and D. E. Discher. 2008. Embryonic cardiomyocytes beat 




Eschenhagen, T., C. Fink, U. Remmers, H. Scholz, J. Wattchow, J. Weil, W. 
Zimmermann, H. H. Dohmen, H. Schafer, N. Bishopric, T. Wakatsuki, and E. L. 
Elson. 1997. Three-dimensional reconstitution of embryonic cardiomyocytes in a 
collagen matrix: a new heart muscle model system, Faseb j, 11: 683-94. 
Fan, D., A. Takawale, J. Lee, and Z. Kassiri. 2012. Cardiac fibroblasts, fibrosis and 
extracellular matrix remodeling in heart disease, Fibrogenesis Tissue Repair, 5: 15. 
Farhadian, F., F. Contard, A. Corbier, A. Barrieux, L. Rappaport, and J. L. Samuel. 
1995. Fibronectin expression during physiological and pathological cardiac growth, J 
Mol Cell Cardiol, 27: 981-90. 
Fassler, R., and M. Meyer. 1995. Consequences of lack of beta 1 integrin gene 
expression in mice, Genes Dev, 9: 1896-908. 
Fassler, R., J. Rohwedel, V. Maltsev, W. Bloch, S. Lentini, K. Guan, D. Gullberg, J. 
Hescheler, K. Addicks, and A. M. Wobus. 1996. Differentiation and integrity of 
cardiac muscle cells are impaired in the absence of beta 1 integrin, J Cell Sci, 109 ( Pt 
13): 2989-99. 
Favor, J., C. J. Gloeckner, D. Janik, M. Klempt, A. Neuhauser-Klaus, W. Pretsch, W. 
Schmahl, and L. Quintanilla-Fend. 2007. Type IV procollagen missense mutations 
associated with defects of the eye, vascular stability, the brain, kidney function and 
embryonic or postnatal viability in the mouse, Mus musculus: an extension of the 
Col4a1 allelic series and the identification of the first two Col4a2 mutant alleles, 
Genetics, 175: 725-36. 
Feinberg, A. W., P. W. Alford, H. Jin, C. M. Ripplinger, A. A. Werdich, S. P. Sheehy, 
A. Grosberg, and K. K. Parker. 2012. Controlling the contractile strength of 
engineered cardiac muscle by hierarchal tissue architecture, Biomaterials, 33: 5732-
41. 
Fernandes, Hugo, Lorenzo Moroni, Clemens van Blitterswijk, and Jan de Boer. 2009. 
Extracellular matrix and tissue engineering applications, Journal of Materials 
Chemistry, 19: 5474-84. 
Fletcher, D. A., and R. D. Mullins. 2010. Cell mechanics and the cytoskeleton, 
Nature, 463: 485-92. 
Frangogiannis, N. G. 2012. Regulation of the inflammatory response in cardiac repair, 
Circ Res, 110: 159-73. 
Fuegemann, C. J., A. K. Samraj, S. Walsh, B. K. Fleischmann, S. Jovinge, and M. 
Breitbach. 2010. Differentiation of mouse embryonic stem cells into cardiomyocytes 
via the hanging-drop and mass culture methods, Curr Protoc Stem Cell Biol, Chapter 
1: Unit 1F.11. 
Gaudesius, G., M. Miragoli, S. P. Thomas, and S. Rohr. 2003. Coupling of cardiac 




Gelse, K., E. Poschl, and T. Aigner. 2003. Collagens--structure, function, and 
biosynthesis, Adv Drug Deliv Rev, 55: 1531-46. 
Giancotti, F. G., and E. Ruoslahti. 1999. Integrin signaling, Science, 285: 1028-32. 
Gilbert, H. F. 1997. Protein disulfide isomerase and assisted protein folding, J Biol 
Chem, 272: 29399-402. 
Gittenberger-de Groot, A. C., M. P. Vrancken Peeters, M. M. Mentink, R. G. Gourdie, 
and R. E. Poelmann. 1998. Epicardium-derived cells contribute a novel population to 
the myocardial wall and the atrioventricular cushions, Circ Res, 82: 1043-52. 
Goldsmith, E. C., A. D. Bradshaw, and F. G. Spinale. 2013. Cellular mechanisms of 
tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving 
beyond collagen expression, Am J Physiol Cell Physiol, 304: C393-402. 
Gregorio, C. C., and P. B. Antin. 2000. To the heart of myofibril assembly, Trends 
Cell Biol, 10: 355-62. 
Griffith, L. G., and M. A. Swartz. 2006. Capturing complex 3D tissue physiology in 
vitro, Nat Rev Mol Cell Biol, 7: 211-24. 
Grinnell, F. 1994. Fibroblasts, myofibroblasts, and wound contraction, J Cell Biol, 
124: 401-4. 
Grosberg, A., P. W. Alford, M. L. McCain, and K. K. Parker. 2011. Ensembles of 
engineered cardiac tissues for physiological and pharmacological study: heart on a 
chip, Lab Chip, 11: 4165-73. 
Guan, K., D. O. Furst, and A. M. Wobus. 1999. Modulation of sarcomere organization 
during embryonic stem cell-derived cardiomyocyte differentiation, Eur J Cell Biol, 
78: 813-23. 
Gullberg, D., A. Tingstrom, A. C. Thuresson, L. Olsson, L. Terracio, T. K. Borg, and 
K. Rubin. 1990. Beta 1 integrin-mediated collagen gel contraction is stimulated by 
PDGF, Exp Cell Res, 186: 264-72. 
Hagiwara, S., H. Iwasaka, S. Matsumoto, T. Noguchi, and H. Yoshioka. 2007. 
Coexpression of HSP47 gene and type I and type III collagen genes in LPS-induced 
pulmonary fibrosis in rats, Lung, 185: 31-7. 
Hagiwara, S., H. Iwasaka, C. Shingu, S. Matumoto, A. Hasegawa, and T. Noguchi. 
2011. Heat shock protein 47 (HSP47) antisense oligonucleotides reduce cardiac 
remodeling and improve cardiac function in a rat model of myocardial infarction, 
Thorac Cardiovasc Surg, 59: 386-92. 
Harada, M., H. Itoh, O. Nakagawa, Y. Ogawa, Y. Miyamoto, K. Kuwahara, E. 
Ogawa, T. Igaki, J. Yamashita, I. Masuda, T. Yoshimasa, I. Tanaka, Y. Saito, and K. 
Nakao. 1997. Significance of ventricular myocytes and nonmyocytes interaction 
during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic 
factor from cardiac nonmyocytes, Circulation, 96: 3737-44. 
Bibliography 
126 
Harston, R. K., and D. Kuppuswamy. 2011. Integrins are the necessary links to 
hypertrophic growth in cardiomyocytes, J Signal Transduct, 2011: 521742. 
Harvey, Adam, Ten-Yang Yen, Irina Aizman, Ciara Tate, and Casey Case. 2013. 
Proteomic Analysis of the Extracellular Matrix Produced by Mesenchymal Stromal 
Cells: Implications for Cell Therapy Mechanism, PLoS One, 8: e79283. 
Higuchi, S., Q. Lin, J. Wang, T. K. Lim, S. B. Joshi, G. S. Anand, M. C. Chung, M. P. 
Sheetz, and H. Fujita. 2013. Heart extracellular matrix supports cardiomyocyte 
differentiation of mouse embryonic stem cells, J Biosci Bioeng, 115: 320-5. 
Hill, J. A., and E. N. Olson. 2008. Cardiac plasticity, N Engl J Med, 358: 1370-80. 
Hinton, R. B., Jr., J. Lincoln, G. H. Deutsch, H. Osinska, P. B. Manning, D. W. 
Benson, and K. E. Yutzey. 2006. Extracellular matrix remodeling and organization in 
developing and diseased aortic valves, Circ Res, 98: 1431-8. 
Hirayoshi, K., H. Kudo, H. Takechi, A. Nakai, A. Iwamatsu, K. M. Yamada, and K. 
Nagata. 1991. HSP47: a tissue-specific, transformation-sensitive, collagen-binding 
heat shock protein of chicken embryo fibroblasts, Mol Cell Biol, 11: 4036-44. 
Hornberger, L. K., S. Singhroy, T. Cavalle-Garrido, W. Tsang, F. Keeley, and M. 
Rabinovitch. 2000. Synthesis of extracellular matrix and adhesion through beta(1) 
integrins are critical for fetal ventricular myocyte proliferation, Circ Res, 87: 508-15. 
Howard, C. M., and T. A. Baudino. 2014. Dynamic cell-cell and cell-ECM 
interactions in the heart, J Mol Cell Cardiol, 70: 19-26. 
Hudson, J., D. Titmarsh, A. Hidalgo, E. Wolvetang, J. Cooper-White. 2012. Primitive 
cardiac cells from human embryonic stem cells, Stem Cells Dev, 21: 1513-23. 
Hynes, R. O. 1987. Integrins: a family of cell surface receptors, Cell, 48: 549-54. 
Hynes, R. O. 2002. Integrins: bidirectional, allosteric signaling machines, Cell, 110: 
673-87. 
Ieda, M., T. Tsuchihashi, K. N. Ivey, R. S. Ross, T. T. Hong, R. M. Shaw, and D. 
Srivastava. 2009. Cardiac fibroblasts regulate myocardial proliferation through beta1 
integrin signaling, Dev Cell, 16: 233-44. 
Ingber, D. E. 2006. Mechanical control of tissue morphogenesis during embryological 
development, Int J Dev Biol, 50: 255-66. 
Irion, Stefan, Herve Luche, Paul Gadue, Hans Joerg Fehling, Marion Kennedy, and 
Gordon Keller. 2007. Identification and targeting of the ROSA26 locus in human 
embryonic stem cells, Nat Biotech, 25: 1477-82. 
Ishida, Y., H. Kubota, A. Yamamoto, A. Kitamura, H. P. Bachinger, and K. Nagata. 
2006. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and 
deficient in N-propeptide processing and fibrillogenesis, Mol Biol Cell, 17: 2346-55. 
Ishida, Y., and K. Nagata. 2011. Hsp47 as a collagen-specific molecular chaperone, 
Bibliography 
127 
Methods Enzymol, 499: 167-82. 
Ishida, Y., A. Yamamoto, A. Kitamura, S. R. Lamande, T. Yoshimori, J. F. Bateman, 
H. Kubota, and K. Nagata. 2009. Autophagic elimination of misfolded procollagen 
aggregates in the endoplasmic reticulum as a means of cell protection, Mol Biol Cell, 
20: 2744-54. 
Izzard, C. S., and L. R. Lochner. 1976. Cell-to-substrate contacts in living fibroblasts: 
an interference reflexion study with an evaluation of the technique, J Cell Sci, 21: 
129-59. 
Jacot, J. G., J. C. Martin, and D. L. Hunt. 2010. Mechanobiology of cardiomyocyte 
development, J Biomech, 43: 93-8. 
Janicki, J. S., and G. L. Brower. 2002. The role of myocardial fibrillar collagen in 
ventricular remodeling and function, J Card Fail, 8: S319-25. 
Jugdutt, B. I. 2003. Remodeling of the myocardium and potential targets in the 
collagen degradation and synthesis pathways, Curr Drug Targets Cardiovasc 
Haematol Disord, 3: 1-30. 
Jugdutt, B. I. 2003. Ventricular remodeling after infarction and the extracellular 
collagen matrix: when is enough enough?, Circulation, 108: 1395-403. 
Kakkar, R., and R. T. Lee. 2010. Intramyocardial fibroblast myocyte communication, 
Circ Res, 106: 47-57. 
Kakugawa, T., H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, H. Oku, M. 
Miyazaki, J. Kadota, and S. Kohno. 2004. Pirfenidone attenuates expression of HSP47 
in murine bleomycin-induced pulmonary fibrosis, Eur Respir J, 24: 57-65. 
Kakugawa, T., H. Mukae, Y. Hishikawa, H. Ishii, N. Sakamoto, Y. Ishimatsu, T. 
Fujii, T. Koji, and S. Kohno. 2010. Localization of HSP47 mRNA in murine 
bleomycin-induced pulmonary fibrosis, Virchows Arch, 456: 309-15. 
Kambe, K., A. Yamamoto, T. Yoshimori, K. Hirayoshi, R. Ogawa, and Y. Tashiro. 
1994. Preferential localization of heat shock protein 47 in dilated endoplasmic 
reticulum of chicken chondrocytes, J Histochem Cytochem, 42: 833-41. 
Karamifar, H., H. Ilkhanipoor, G. Ajami, Z. Karamizadeh, G. Amirhakimi, and A. M. 
Shakiba. 2013. Cardiovascular involvement in children with osteogenesis imperfecta, 
Iran J Pediatr, 23: 513-8. 
Keller, R. S., S. Y. Shai, C. J. Babbitt, C. G. Pham, R. J. Solaro, M. L. Valencik, J. C. 
Loftus, and R. S. Ross. 2001. Disruption of integrin function in the murine 
myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance, 
Am J Pathol, 158: 1079-90. 
Kirchhofer, D., L. R. Languino, E. Ruoslahti, and M. D. Pierschbacher. 1990. Alpha 2 
beta 1 integrins from different cell types show different binding specificities, J Biol 
Chem, 265: 615-8. 
Bibliography 
128 
Kléber, André G., Michiel J. Janse, and Vladimir G. Fast. 2011. Normal and 
Abnormal Conduction in the Heart. in, Comprehensive Physiology (John Wiley & 
Sons, Inc.). 
Klewer, S. E., S. L. Krob, S. J. Kolker, and G. T. Kitten. 1998. Expression of type VI 
collagen in the developing mouse heart, Dev Dyn, 211: 248-55. 
Klug, M. G., M. H. Soonpaa, G. Y. Koh, and L. J. Field. 1996. Genetically selected 
cardiomyocytes from differentiating embronic stem cells form stable intracardiac 
grafts, J Clin Invest, 98: 216-24. 
Knight, C. G., L. F. Morton, A. R. Peachey, D. S. Tuckwell, R. W. Farndale, and M. 
J. Barnes. 2000. The collagen-binding A-domains of integrins alpha(1)beta(1) and 
alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native 
(triple-helical) collagens, J Biol Chem, 275: 35-40. 
Kofidis, T., P. Akhyari, J. Boublik, P. Theodorou, U. Martin, A. Ruhparwar, S. 
Fischer, T. Eschenhagen, H. P. Kubis, T. Kraft, R. Leyh, and A. Haverich. 2002. In 
vitro engineering of heart muscle: artificial myocardial tissue, J Thorac Cardiovasc 
Surg, 124: 63-9. 
Kohl, P. 2003. Heterogeneous cell coupling in the heart: an electrophysiological role 
for fibroblasts, Circ Res, 93: 381-3. 
Koide, T., S. Asada, Y. Takahara, Y. Nishikawa, K. Nagata, and K. Kitagawa. 2006. 
Specific recognition of the collagen triple helix by chaperone HSP47: minimal 
structural requirement and spatial molecular orientation, J Biol Chem, 281: 3432-8. 
Koivu, J., R. Myllyla, T. Helaakoski, T. Pihlajaniemi, K. Tasanen, and K. I. 
Kivirikko. 1987. A single polypeptide acts both as the beta subunit of prolyl 4-
hydroxylase and as a protein disulfide-isomerase, J Biol Chem, 262: 6447-9. 
Kolditz, D. P., M. C. Wijffels, N. A. Blom, A. van der Laarse, N. D. Hahurij, H. Lie-
Venema, R. R. Markwald, R. E. Poelmann, M. J. Schalij, and A. C. Gittenberger-de 
Groot. 2008. Epicardium-derived cells in development of annulus fibrosis and 
persistence of accessory pathways, Circulation, 117: 1508-17. 
Kolodney, M. S., and E. L. Elson. 1993. Correlation of myosin light chain 
phosphorylation with isometric contraction of fibroblasts, J Biol Chem, 268: 23850-5. 
Kovacic-Milivojevic, B., F. Roediger, E. A. Almeida, C. H. Damsky, D. G. Gardner, 
and D. Ilic. 2001. Focal adhesion kinase and p130Cas mediate both sarcomeric 
organization and activation of genes associated with cardiac myocyte hypertrophy, 
Mol Biol Cell, 12: 2290-307. 
Krenning, G., E. M. Zeisberg, and R. Kalluri. 2010. The origin of fibroblasts and 
mechanism of cardiac fibrosis, J Cell Physiol, 225: 631-7. 
Kruithof, B. P., S. A. Krawitz, and V. Gaussin. 2007. Atrioventricular valve 
development during late embryonic and postnatal stages involves condensation and 
extracellular matrix remodeling, Dev Biol, 302: 208-17. 
Bibliography 
129 
Krupnick, A. S., D. Kreisel, F. H. Engels, W. Y. Szeto, T. Plappert, S. H. Popma, A. 
W. Flake, and B. R. Rosengard. 2002. A novel small animal model of left ventricular 
tissue engineering, J Heart Lung Transplant, 21: 233-43. 
Kuhn, B., F. del Monte, R. J. Hajjar, Y. S. Chang, D. Lebeche, S. Arab, and M. T. 
Keating. 2007. Periostin induces proliferation of differentiated cardiomyocytes and 
promotes cardiac repair, Nat Med, 13: 962-9. 
Lamande, S. R., and J. F. Bateman. 1999. Procollagen folding and assembly: the role 
of endoplasmic reticulum enzymes and molecular chaperones, Semin Cell Dev Biol, 
10: 455-64. 
LaNasa, S. M., and S. J. Bryant. 2009. Influence of ECM proteins and their analogs 
on cells cultured on 2-D hydrogels for cardiac muscle tissue engineering, Acta 
Biomater, 5: 2929-38. 
Lang, K., F. X. Schmid, and G. Fischer. 1987. Catalysis of protein folding by prolyl 
isomerase, Nature, 329: 268-70. 
Langholz, O., D. Rockel, C. Mauch, E. Kozlowska, I. Bank, T. Krieg, and B. Eckes. 
1995. Collagen and collagenase gene expression in three-dimensional collagen lattices 
are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins, J Cell Biol, 
131: 1903-15. 
Larsen, M., V. V. Artym, J. A. Green, and K. M. Yamada. 2006. The matrix 
reorganized: extracellular matrix remodeling and integrin signaling, Curr Opin Cell 
Biol, 18: 463-71. 
Lechat, Philippe, Milton Packer, Stephan Chalon, Michel Cucherat, Tarek Arab, and 
Jean-Pierre Boissel. 1998. Clinical Effects of β-Adrenergic Blockade in Chronic Heart 
Failure: A Meta-Analysis of Double-Blind, Placebo-Controlled, Randomized Trials, 
Circulation, 98: 1184-91. 
Leor, J., S. Aboulafia-Etzion, A. Dar, L. Shapiro, I. M. Barbash, A. Battler, Y. 
Granot, and S. Cohen. 2000. Bioengineered cardiac grafts: A new approach to repair 
the infarcted myocardium?, Circulation, 102: Iii56-61. 
Lesman, A., M. Habib, O. Caspi, A. Gepstein, G. Arbel, S. Levenberg, and L. 
Gepstein. 2010. Transplantation of a tissue-engineered human vascularized cardiac 
muscle, Tissue Eng Part A, 16: 115-25. 
Li, A. H., P. P. Liu, F. J. Villarreal, and R. A. Garcia. 2014. Dynamic changes in 
myocardial matrix and relevance to disease: translational perspectives, Circ Res, 114: 
916-27. 
Li, R. K., Z. Q. Jia, R. D. Weisel, D. A. Mickle, A. Choi, and T. M. Yau. 1999. 
Survival and function of bioengineered cardiac grafts, Circulation, 100: Ii63-9. 
Li, R. K., T. M. Yau, R. D. Weisel, D. A. Mickle, T. Sakai, A. Choi, and Z. Q. Jia. 




Li, S., J. L. Guan, and S. Chien. 2005. Biochemistry and biomechanics of cell 
motility, Annu Rev Biomed Eng, 7: 105-50. 
Liau, B., N. Christoforou, K. W. Leong, and N. Bursac. 2011. Pluripotent stem cell-
derived cardiac tissue patch with advanced structure and function, Biomaterials, 32: 
9180-7. 
Lie-Venema, H., N. M. van den Akker, N. A. Bax, E. M. Winter, S. Maas, T. 
Kekarainen, R. C. Hoeben, M. C. deRuiter, R. E. Poelmann, and A. C. Gittenberger-
de Groot. 2007. Origin, fate, and function of epicardium-derived cells (EPDCs) in 
normal and abnormal cardiac development, ScientificWorldJournal, 7: 1777-98. 
Lincoln, J., C. M. Alfieri, and K. E. Yutzey. 2004. Development of heart valve 
leaflets and supporting apparatus in chicken and mouse embryos, Dev Dyn, 230: 239-
50. 
Lindert, U., M. A. Weis, J. Rai, F. Seeliger, I. Hausser, T. Leeb, D. Eyre, M. 
Rohrbach, and C. Giunta. 2015. Molecular Consequences of the SERPINH1/HSP47 
Mutation in the Dachshund Natural Model of Osteogenesis Imperfecta, J Biol Chem, 
290: 17679-89. 
Liu, B., L. Dhawan, B. C. Blaxall, and M. B. Taubman. 2010. Protein kinase Cdelta 
mediates MCP-1 mRNA stabilization in vascular smooth muscle cells, Mol Cell 
Biochem, 344: 73-9. 
Liu, H., B. Chen, and B. Lilly. 2008. Fibroblasts potentiate blood vessel formation 
partially through secreted factor TIMP-1, Angiogenesis, 11: 223-34. 
Liu, X., H. Wu, M. Byrne, S. Krane, and R. Jaenisch. 1997. Type III collagen is 
crucial for collagen I fibrillogenesis and for normal cardiovascular development, Proc 
Natl Acad Sci U S A, 94: 1852-6. 
Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, 25: 
402-8. 
Lo, S. H. 2006. Focal adhesions: whats new inside, Dev Biol, 294: 280-91. 
Lockhart, M., E. Wirrig, A. Phelps, and A. Wessels. 2011. Extracellular matrix and 
heart development, Birth Defects Res A Clin Mol Teratol, 91: 535-50. 
Lohler, J., R. Timpl, and R. Jaenisch. 1984. Embryonic lethal mutation in mouse 
collagen I gene causes rupture of blood vessels and is associated with erythropoietic 
and mesenchymal cell death, Cell, 38: 597-607. 
Lompre, A. M., B. Nadal-Ginard, and V. Mahdavi. 1984. Expression of the cardiac 
ventricular alpha- and beta-myosin heavy chain genes is developmentally and 
hormonally regulated, J Biol Chem, 259: 6437-46. 
Louault, C., N. Benamer, J. F. Faivre, D. Potreau, and J. Bescond. 2008. Implication 
of connexins 40 and 43 in functional coupling between mouse cardiac fibroblasts in 
primary culture, Biochim Biophys Acta, 1778: 2097-104. 
Bibliography 
131 
MacKenna, D., S. R. Summerour, and F. J. Villarreal. 2000. Role of mechanical 
factors in modulating cardiac fibroblast function and extracellular matrix synthesis, 
Cardiovasc Res, 46: 257-63. 
Maitra, N., I. L. Flink, J. J. Bahl, and E. Morkin. 2000. Expression of alpha and beta 
integrins during terminal differentiation of cardiomyocytes, Cardiovasc Res, 47: 715-
25. 
Majkut, S., T. Idema, J. Swift, C. Krieger, A. Liu, and D. E. Discher. 2013. Heart-
specific stiffening in early embryos parallels matrix and myosin expression to 
optimize beating, Curr Biol, 23: 2434-9. 
Manso, A. M., S. M. Kang, and R. S. Ross. 2009. Integrins, focal adhesions, and 
cardiac fibroblasts, J Investig Med, 57: 856-60. 
Masago, Y., A. Hosoya, K. Kawasaki, S. Kawano, A. Nasu, J. Toguchida, K. Fujita, 
H. Nakamura, G. Kondoh, and K. Nagata. 2012. The molecular chaperone Hsp47 is 
essential for cartilage and endochondral bone formation, J Cell Sci, 125: 1118-28. 
Masuda, H., M. Fukumoto, K. Hirayoshi, and K. Nagata. 1994. Coexpression of the 
collagen-binding stress protein HSP47 gene and the alpha 1(I) and alpha 1(III) 
collagen genes in carbon tetrachloride-induced rat liver fibrosis, J Clin Invest, 94: 
2481-8. 
Matsuoka, Y., H. Kubota, E. Adachi, N. Nagai, T. Marutani, N. Hosokawa, and K. 
Nagata. 2004. Insufficient folding of type IV collagen and formation of abnormal 
basement membrane-like structure in embryoid bodies derived from Hsp47-null 
embryonic stem cells, Mol Biol Cell, 15: 4467-75. 
Matsuura, K., S. Masuda, Y. Haraguchi, N. Yasuda, T. Shimizu, N. Hagiwara, P. W. 
Zandstra, and T. Okano. 2011. Creation of mouse embryonic stem cell-derived 
cardiac cell sheets, Biomaterials, 32: 7355-62. 
Mays, P. K., R. J. McAnulty, J. S. Campa, and G. J. Laurent. 1991. Age-related 
changes in collagen synthesis and degradation in rat tissues. Importance of 
degradation of newly synthesized collagen in regulating collagen production, Biochem 
J, 276 ( Pt 2): 307-13. 
Metsaranta, M., S. Garofalo, G. Decker, M. Rintala, B. de Crombrugghe, and E. 
Vuorio. 1992. Chondrodysplasia in transgenic mice harboring a 15-amino acid 
deletion in the triple helical domain of pro alpha 1(II) collagen chain, J Cell Biol, 118: 
203-12. 
Midwood. K., I. Wierzbicka-Patynowski, J. Schwarzbauer. 2002. Methods in Cell-
Matrix Adhesion (Adams J. ed) pp. 145–161, Academic Press, San Diego. 
Nag, A. C., and R. Zak. 1979. Dissociation of adult mammalian heart into single cell 
suspension: an ultrastructural study, J Anat, 129: 541-59. 
Nagai, N., M. Hosokawa, S. Itohara, E. Adachi, T. Matsushita, N. Hosokawa, and K. 
Nagata. 2000. Embryonic lethality of molecular chaperone hsp47 knockout mice is 
associated with defects in collagen biosynthesis, J Cell Biol, 150: 1499-506. 
Bibliography 
132 
Nagata, K. 1996. Hsp47: a collagen-specific molecular chaperone, Trends Biochem 
Sci, 21: 22-6. 
Nagata, K. 1998. Expression and function of heat shock protein 47: a collagen-
specific molecular chaperone in the endoplasmic reticulum, Matrix Biol, 16: 379-86. 
Nagata, K. 2003. HSP47 as a collagen-specific molecular chaperone: function and 
expression in normal mouse development, Semin Cell Dev Biol, 14: 275-82. 
Nagata, K., and N. Hosokawa. 1996. Regulation and function of collagen-specific 
molecular chaperone, HSP47, Cell Struct Funct, 21: 425-30. 
Nagata, K., S. Saga, and K. M. Yamada. 1986. A major collagen-binding protein of 
chick embryo fibroblasts is a novel heat shock protein, J Cell Biol, 103: 223-9. 
Nagata, K., and K. M. Yamada. 1986. Phosphorylation and transformation sensitivity 
of a major collagen-binding protein of fibroblasts, J Biol Chem, 261: 7531-6. 
Nagy, A., J. Rossant, R. Nagy, W. Abramow-Newerly, and J. C. Roder. 1993. 
Derivation of completely cell culture-derived mice from early-passage embryonic 
stem cells, Proc Natl Acad Sci U S A, 90: 8424-8. 
Naito, H., I. Melnychenko, M. Didie, K. Schneiderbanger, P. Schubert, S. 
Rosenkranz, T. Eschenhagen, and W. H. Zimmermann. 2006. Optimizing engineered 
heart tissue for therapeutic applications as surrogate heart muscle, Circulation, 114: 
I72-8. 
Nakai, A., K. Hirayoshi, and K. Nagata. 1990. Transformation of BALB/3T3 cells by 
simian virus 40 causes a decreased synthesis of a collagen-binding heat-shock protein 
(hsp47), J Biol Chem, 265: 992-9. 
Nelson, C. M., and J. Tien. 2006. Microstructured extracellular matrices in tissue 
engineering and development, Curr Opin Biotechnol, 17: 518-23. 
Nesvizhskii, Alexey I., Andrew Keller, Eugene Kolker, and Ruedi Aebersold. 2003. A 
Statistical Model for Identifying Proteins by Tandem Mass Spectrometry, Analytical 
Chemistry, 75: 4646-58. 
Nichol, J. W., G. C. Engelmayr, Jr., M. Cheng, and L. E. Freed. 2008. Co-culture 
induces alignment in engineered cardiac constructs via MMP-2 expression, Biochem 
Biophys Res Commun, 373: 360-5. 
Niebruegge, S., A. Nehring, H. Bar, M. Schroeder, R. Zweigerdt, and J. Lehmann. 
2008. Cardiomyocyte production in mass suspension culture: embryonic stem cells as 
a source for great amounts of functional cardiomyocytes, Tissue Eng Part A, 14: 
1591-601. 
Norris, R. A., T. K. Borg, J. T. Butcher, T. A. Baudino, I. Banerjee, and R. R. 
Markwald. 2008. Neonatal and adult cardiovascular pathophysiological remodeling 
and repair: developmental role of periostin, Ann N Y Acad Sci, 1123: 30-40. 
Norris, R. A., B. Damon, V. Mironov, V. Kasyanov, A. Ramamurthi, R. Moreno-
Bibliography 
133 
Rodriguez, T. Trusk, J. D. Potts, R. L. Goodwin, J. Davis, S. Hoffman, X. Wen, Y. 
Sugi, C. B. Kern, C. H. Mjaatvedt, D. K. Turner, T. Oka, S. J. Conway, J. D. 
Molkentin, G. Forgacs, and R. R. Markwald. 2007. Periostin regulates collagen 
fibrillogenesis and the biomechanical properties of connective tissues, J Cell 
Biochem, 101: 695-711. 
Oberwallner, B., A. Brodarac, P. Anic, T. Saric, K. Wassilew, K. Neef, Y. H. Choi, 
and C. Stamm. 2015. Human cardiac extracellular matrix supports myocardial lineage 
commitment of pluripotent stem cells, Eur J Cardiothorac Surg, 47: 416-25; 
discussion 25. 
Olivey, H. E., N. A. Mundell, A. F. Austin, and J. V. Barnett. 2006. Transforming 
growth factor-beta stimulates epithelial-mesenchymal transformation in the 
proepicardium, Dev Dyn, 235: 50-9. 
Oslowski, C. M., and F. Urano. 2011. Measuring ER stress and the unfolded protein 
response using mammalian tissue culture system, Methods Enzymol, 490: 71-92. 
Packer, Milton, Michael R. Bristow, Jay N. Cohn, Wilson S. Colucci, Michael B. 
Fowler, Edward M. Gilbert, and Neil H. Shusterman. 1996. The Effect of Carvedilol 
on Morbidity and Mortality in Patients with Chronic Heart Failure, New England 
Journal of Medicine, 334: 1349-55. 
Pampaloni, Francesco, Emmanuel G. Reynaud, and Ernst H. K. Stelzer. 2007. The 
third dimension bridges the gap between cell culture and live tissue, Nat Rev Mol Cell 
Biol, 8: 839-45. 
Parker, K. K., and D. E. Ingber. 2007. Extracellular matrix, mechanotransduction and 
structural hierarchies in heart tissue engineering, Philos Trans R Soc Lond B Biol Sci, 
362: 1267-79. 
Patten, R. D., M. J. Aronovitz, L. Deras-Mejia, N. G. Pandian, G. G. Hanak, J. J. 
Smith, M. E. Mendelsohn, and M. A. Konstam. 1998. Ventricular remodeling in a 
mouse model of myocardial infarction, Am J Physiol, 274: H1812-20. 
Perez-Pomares, J. M., A. Phelps, M. Sedmerova, R. Carmona, M. Gonzalez-Iriarte, R. 
Munoz-Chapuli, and A. Wessels. 2002. Experimental studies on the spatiotemporal 
expression of WT1 and RALDH2 in the embryonic avian heart: a model for the 
regulation of myocardial and valvuloseptal development by epicardially derived cells 
(EPDCs), Dev Biol, 247: 307-26. 
Petit, V., and J. P. Thiery. 2000. Focal adhesions: structure and dynamics, Biol Cell, 
92: 477-94. 
Pfannkuche, K., S. Neuss, F. Pillekamp, L. P. Frenzel, W. Attia, T. Hannes, J. Salber, 
M. Hoss, M. Zenke, B. K. Fleischmann, J. Hescheler, and T. Saric. 2010. Fibroblasts 
facilitate the engraftment of embryonic stem cell-derived cardiomyocytes on three-
dimensional collagen matrices and aggregation in hanging drops, Stem Cells Dev, 19: 
1589-99. 
Pinto, A. R., A. Ilinykh, M. J. Ivey, J. T. Kuwabara, M. L. D'Antoni, R. Debuque, A. 
Chandran, L. Wang, K. Arora, N. A. Rosenthal, and M. D. Tallquist. 2016. Revisiting 
Bibliography 
134 
Cardiac Cellular Composition, Circ Res, 118: 400-9. 
Plotnikov, S. V., and C. M. Waterman. 2013. Guiding cell migration by tugging, Curr 
Opin Cell Biol, 25: 619-26. 
Pong, T., W. J. Adams, M. A. Bray, A. W. Feinberg, S. P. Sheehy, A. A. Werdich, 
and K. K. Parker. 2011. Hierarchical architecture influences calcium dynamics in 
engineered cardiac muscle, Exp Biol Med (Maywood), 236: 366-73. 
Pontes Soares, C., V. Midlej, M. E. de Oliveira, M. Benchimol, M. L. Costa, and C. 
Mermelstein. 2012. 2D and 3D-organized cardiac cells shows differences in cellular 
morphology, adhesion junctions, presence of myofibrils and protein expression, PLoS 
One, 7: e38147. 
Porter, K. E., and N. A. Turner. 2009. Cardiac fibroblasts: at the heart of myocardial 
remodeling, Pharmacol Ther, 123: 255-78. 
Poschl, E., U. Schlotzer-Schrehardt, B. Brachvogel, K. Saito, Y. Ninomiya, and U. 
Mayer. 2004. Collagen IV is essential for basement membrane stability but 
dispensable for initiation of its assembly during early development, Development, 
131: 1619-28. 
Radisic, M., A. Marsano, R. Maidhof, Y. Wang, and G. Vunjak-Novakovic. 2008. 
Cardiac tissue engineering using perfusion bioreactor systems, Nat Protoc, 3: 719-38. 
Radunovic, Z., L. L. Wekre, L. M. Diep, and K. Steine. 2011. Cardiovascular 
abnormalities in adults with osteogenesis imperfecta, Am Heart J, 161: 523-9. 
Rahkonen, O., M. Su, H. Hakovirta, I. Koskivirta, S. G. Hormuzdi, E. Vuorio, P. 
Bornstein, and R. Penttinen. 2004. Mice with a deletion in the first intron of the 
Col1a1 gene develop age-dependent aortic dissection and rupture, Circ Res, 94: 83-
90. 
Ross, R. S., and T. K. Borg. 2001. Integrins and the myocardium, Circ Res, 88: 1112-
9. 
Samarel, A. M. 2005. Costameres, focal adhesions, and cardiomyocyte 
mechanotransduction, Am J Physiol Heart Circ Physiol, 289: H2291-301. 
Sasaki, H., T. Sato, N. Yamauchi, T. Okamoto, D. Kobayashi, S. Iyama, J. Kato, T. 
Matsunaga, R. Takimoto, T. Takayama, K. Kogawa, N. Watanabe, and Y. Niitsu. 
2002. Induction of heat shock protein 47 synthesis by TGF-beta and IL-1 beta via 
enhancement of the heat shock element binding activity of heat shock transcription 
factor 1, J Immunol, 168: 5178-83. 
Sastry, S. K., and K. Burridge. 2000. Focal adhesions: a nexus for intracellular 
signaling and cytoskeletal dynamics, Exp Cell Res, 261: 25-36. 
Satoh, M., K. Hirayoshi, S. Yokota, N. Hosokawa, and K. Nagata. 1996. Intracellular 
interaction of collagen-specific stress protein HSP47 with newly synthesized 
procollagen, J Cell Biol, 133: 469-83. 
Bibliography 
135 
Sauk, J. J., N. Nikitakis, and H. Siavash. 2005. Hsp47 a novel collagen binding serpin 
chaperone, autoantigen and therapeutic target, Front Biosci, 10: 107-18. 
Sauk, J. J., T. Smith, K. Norris, and L. Ferreira. 1994. Hsp47 and the translation-
translocation machinery cooperate in the production of alpha 1(I) chains of type I 
procollagen, J Biol Chem, 269: 3941-6. 
Schiro, J. A., B. M. Chan, W. T. Roswit, P. D. Kassner, A. P. Pentland, M. E. Hemler, 
A. Z. Eisen, and T. S. Kupper. 1991. Integrin alpha 2 beta 1 (VLA-2) mediates 
reorganization and contraction of collagen matrices by human cells, Cell, 67: 403-10. 
Schwartz, M. A., and M. H. Ginsberg. 2002. Networks and crosstalk: integrin 
signalling spreads, Nat Cell Biol, 4: E65-8. 
Schwartz, M. A., M. D. Schaller, and M. H. Ginsberg. 1995. Integrins: emerging 
paradigms of signal transduction, Annu Rev Cell Dev Biol, 11: 549-99. 
Sengbusch, J. K., W. He, K. A. Pinco, and J. T. Yang. 2002. Dual functions of 
[alpha]4[beta]1 integrin in epicardial development: initial migration and long-term 
attachment, J Cell Biol, 157: 873-82. 
Shai, S. Y., A. E. Harpf, C. J. Babbitt, M. C. Jordan, M. C. Fishbein, J. Chen, M. 
Omura, T. A. Leil, K. D. Becker, M. Jiang, D. J. Smith, S. R. Cherry, J. C. Loftus, and 
R. S. Ross. 2002. Cardiac myocyte-specific excision of the beta1 integrin gene results 
in myocardial fibrosis and cardiac failure, Circ Res, 90: 458-64. 
Sheehy, S. P., A. Grosberg, and K. K. Parker. 2012. The contribution of cellular 
mechanotransduction to cardiomyocyte form and function, Biomech Model 
Mechanobiol, 11: 1227-39. 
Shimazaki, M., K. Nakamura, I. Kii, T. Kashima, N. Amizuka, M. Li, M. Saito, K. 
Fukuda, T. Nishiyama, S. Kitajima, Y. Saga, M. Fukayama, M. Sata, and A. Kudo. 
2008. Periostin is essential for cardiac healing after acute myocardial infarction, J Exp 
Med, 205: 295-303. 
Shimizu, T., M. Yamato, Y. Isoi, T. Akutsu, T. Setomaru, K. Abe, A. Kikuchi, M. 
Umezu, and T. Okano. 2002. Fabrication of pulsatile cardiac tissue grafts using a 
novel 3-dimensional cell sheet manipulation technique and temperature-responsive 
cell culture surfaces, Circ Res, 90: e40. 
Simpson, D. G., M. Majeski, T. K. Borg, and L. Terracio. 1999. Regulation of cardiac 
myocyte protein turnover and myofibrillar structure in vitro by specific directions of 
stretch, Circ Res, 85: e59-69. 
Simpson, P., and S. Savion. 1982. Differentiation of rat myocytes in single cell 
cultures with and without proliferating nonmyocardial cells. Cross-striations, 
ultrastructure, and chronotropic response to isoproterenol, Circ Res, 50: 101-16. 
Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. 
Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. 
Measurement of protein using bicinchoninic acid, Anal Biochem, 150: 76-85. 
Bibliography 
136 
Snider, P., K. N. Standley, J. Wang, M. Azhar, T. Doetschman, and S. J. Conway. 
2009. Origin of cardiac fibroblasts and the role of periostin, Circ Res, 105: 934-47. 
Soong, P. L., M. Tiburcy, and W. H. Zimmermann. 2012. Cardiac differentiation of 
human embryonic stem cells and their assembly into engineered heart muscle, Curr 
Protoc Cell Biol, Chapter 23: Unit23.8. 
Souders, C. A., S. L. Bowers, and T. A. Baudino. 2009. Cardiac fibroblast: the 
renaissance cell, Circ Res, 105: 1164-76. 
Stevens, K. R., K. L. Kreutziger, S. K. Dupras, F. S. Korte, M. Regnier, V. Muskheli, 
M. B. Nourse, K. Bendixen, H. Reinecke, and C. E. Murry. 2009. Physiological 
function and transplantation of scaffold-free and vascularized human cardiac muscle 
tissue, Proceedings of the National Academy of Sciences of the United States of 
America, 106: 16568-73. 
Sussman, M. A., S. Welch, A. Walker, R. Klevitsky, T. E. Hewett, R. L. Price, E. 
Schaefer, and K. Yager. 2000. Altered focal adhesion regulation correlates with 
cardiomyopathy in mice expressing constitutively active rac1, J Clin Invest, 105: 875-
86. 
Swynghedauw, B. 1999. Molecular mechanisms of myocardial remodeling, Physiol 
Rev, 79: 215-62. 
Taber, L. A. 2001. Biomechanics of cardiovascular development, Annu Rev Biomed 
Eng, 3: 1-25. 
Taguchi, T., and M. S. Razzaque. 2007. The collagen-specific molecular chaperone 
HSP47: is there a role in fibrosis?, Trends Mol Med, 13: 45-53. 
Takechi, H., K. Hirayoshi, A. Nakai, H. Kudo, S. Saga, and K. Nagata. 1992. 
Molecular cloning of a mouse 47-kDa heat-shock protein (HSP47), a collagen-binding 
stress protein, and its expression during the differentiation of F9 teratocarcinoma 
cells, Eur J Biochem, 206: 323-9. 
Takeda, N., and I. Manabe. 2011. Cellular Interplay between Cardiomyocytes and 
Nonmyocytes in Cardiac Remodeling, Int J Inflam, 2011: 535241. 
Tasab, M., M. R. Batten, and N. J. Bulleid. 2000. Hsp47: a molecular chaperone that 
interacts with and stabilizes correctly-folded procollagen, EMBO J, 19: 2204-11. 
Tasab, M., L. Jenkinson, and N. J. Bulleid. 2002. Sequence-specific recognition of 
collagen triple helices by the collagen-specific molecular chaperone HSP47, J Biol 
Chem, 277: 35007-12. 
Terracio, L., D. Gullberg, K. Rubin, S. Craig, and T. K. Borg. 1989. Expression of 
collagen adhesion proteins and their association with the cytoskeleton in cardiac 
myocytes, Anat Rec, 223: 62-71. 
Terracio, L., K. Rubin, D. Gullberg, E. Balog, W. Carver, R. Jyring, and T. K. Borg. 
1991. Expression of collagen binding integrins during cardiac development and 
hypertrophy, Circ Res, 68: 734-44. 
Bibliography 
137 
Thomson, C. A., R. Tenni, and V. S. Ananthanarayanan. 2003. Mapping Hsp47 
binding site(s) using CNBr peptides derived from type I and type II collagen, Protein 
Sci, 12: 1792-800. 
Tiburcy, M., M. Didie, O. Boy, P. Christalla, S. Doker, H. Naito, B. C. Karikkineth, 
A. El-Armouche, M. Grimm, M. Nose, T. Eschenhagen, A. Zieseniss, D. M. 
Katschinksi, N. Hamdani, W. A. Linke, X. Yin, M. Mayr, and W. H. Zimmermann. 
2011. Terminal differentiation, advanced organotypic maturation, and modeling of 
hypertrophic growth in engineered heart tissue, Circ Res, 109: 1105-14. 
Tiburcy, M., T. Meyer, P. L. Soong, and W. H. Zimmermann. 2014. Collagen-based 
engineered heart muscle, Methods Mol Biol, 1181: 167-76. 
Tobita, K., E. A. Schroder, J. P. Tinney, J. B. Garrison, and B. B. Keller. 2002. 
Regional passive ventricular stress-strain relations during development of altered 
loads in chick embryo, Am J Physiol Heart Circ Physiol, 282: H2386-96. 
Tohyama, S., F. Hattori, M. Sano, T. Hishiki, Y. Nagahata, T. Matsuura, H. 
Hashimoto, T. Suzuki, H. Yamashita, Y. Satoh, T. Egashira, T. Seki, N. Muraoka, H. 
Yamakawa, Y. Ohgino, T. Tanaka, M. Yoichi, S. Yuasa, M. Murata, M. Suematsu, 
and K. Fukuda. 2013. Distinct metabolic flow enables large-scale purification of 
mouse and human pluripotent stem cell-derived cardiomyocytes, Cell Stem Cell, 12: 
127-37. 
Tulloch, N. L., V. Muskheli, M. V. Razumova, F. S. Korte, M. Regnier, K. D. Hauch, 
L. Pabon, H. Reinecke, and C. E. Murry. 2011. Growth of engineered human 
myocardium with mechanical loading and vascular coculture, Circ Res, 109: 47-59. 
Turoverova, L. V., M. G. Khotin, N. M. Yudintseva, K. E. Magnusson, M. I. Blinova, 
G. P. Pinaev, and D. G. Tentler. 2009. Analysis of extracellular matrix proteins 
produced by cultured cells, Cell and Tissue Biology, 3: 497-502. 
Uzawa, K., W. J. Grzesik, T. Nishiura, S. A. Kuznetsov, P. G. Robey, D. A. Brenner, 
and M. Yamauchi. 1999. Differential expression of human lysyl hydroxylase genes, 
lysine hydroxylation, and cross-linking of type I collagen during osteoblastic 
differentiation in vitro, J Bone Miner Res, 14: 1272-80. 
Van der Loop, F. T., G. J. Van Eys, G. Schaart, and F. C. Ramaekers. 1996. Titin 
expression as an early indication of heart and skeletal muscle differentiation in vitro. 
Developmental re-organisation in relation to cytoskeletal constituents, J Muscle Res 
Cell Motil, 17: 23-36. 
Van Duyn Graham, L., M. T. Sweetwyne, M. A. Pallero, and J. E. Murphy-Ullrich. 
2010. Intracellular calreticulin regulates multiple steps in fibrillar collagen expression, 
trafficking, and processing into the extracellular matrix, J Biol Chem, 285: 7067-78. 
van Rooij, E., L. B. Sutherland, J. E. Thatcher, J. M. DiMaio, R. H. Naseem, W. S. 
Marshall, J. A. Hill, and E. N. Olson. 2008. Dysregulation of microRNAs after 
myocardial infarction reveals a role of miR-29 in cardiac fibrosis, Proc Natl Acad Sci 
U S A, 105: 13027-32. 
Bibliography 
138 
van Spreeuwel, A. C. C, N. A. M. Bax, C. V. C.Bouten. 2014. The relevance of 
extracellular matrix structure and composition in engineering the diseased cardiac 
microenvironment, OA Tissue Engineering, 18; 2(1):2. 
Vandenburgh, H. H., and P. Karlisch. 1989. Longitudinal growth of skeletal myotubes 
in vitro in a new horizontal mechanical cell stimulator, In Vitro Cell Dev Biol, 25: 
607-16. 
Von der Mark, K. 1981. Localization of collagen types in tissues, Int Rev Connect 
Tissue Res, 9: 265-324. 
Wang, Chih-Chen, and Chen-Lu Tsou. 1998. Enzymes as chaperones and chaperones 
as enzymes, FEBS Letters, 425: 382-84. 
Warnes, Gregory R, Ben Bolker, L Bonebakker, R Gentleman, W Huber, A Liaw, T 
Lumley, M Maechler, A Magnusson, and S Moeller. 2009. gplots: Various R 
programming tools for plotting data, R package version, 2. 
Weber, K. T. 1989. Cardiac interstitium in health and disease: the fibrillar collagen 
network, J Am Coll Cardiol, 13: 1637-52. 
Wells, R. G. 2008. The role of matrix stiffness in regulating cell behavior, 
Hepatology, 47: 1394-400. 
Wenstrup, R. J., J. B. Florer, E. W. Brunskill, S. M. Bell, I. Chervoneva, and D. E. 
Birk. 2004. Type V collagen controls the initiation of collagen fibril assembly, J Biol 
Chem, 279: 53331-7. 
Widmer, C., J. M. Gebauer, E. Brunstein, S. Rosenbaum, F. Zaucke, C. Drogemuller, 
T. Leeb, and U. Baumann. 2012. Molecular basis for the action of the collagen-
specific chaperone Hsp47/SERPINH1 and its structure-specific client recognition, 
Proc Natl Acad Sci U S A, 109: 13243-7. 
Wobus, A. M., G. Wallukat, and J. Hescheler. 1991. Pluripotent mouse embryonic 
stem cells are able to differentiate into cardiomyocytes expressing chronotropic 
responses to adrenergic and cholinergic agents and Ca2+ channel blockers, 
Differentiation, 48: 173-82. 
Xin, M., E. N. Olson, and R. Bassel-Duby. 2013. Mending broken hearts: cardiac 
development as a basis for adult heart regeneration and repair, Nat Rev Mol Cell Biol, 
14: 529-41. 
Yamamoto, N., T. Kinoshita, N. Nohata, H. Yoshino, T. Itesako, L. Fujimura, A. 
Mitsuhashi, H. Usui, H. Enokida, M. Nakagawa, M. Shozu, and N. Seki. 2013. 
Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via 
targeting HSP47 in cervical squamous cell carcinoma, Int J Oncol, 43: 1855-63. 
Yin, L., H. Bien, and E. Entcheva. 2004. Scaffold topography alters intracellular 
calcium dynamics in cultured cardiomyocyte networks, Am J Physiol Heart Circ 
Physiol, 287: H1276-85. 
Young, J. L., and A. J. Engler. 2011. Hydrogels with time-dependent material 
Bibliography 
139 
properties enhance cardiomyocyte differentiation in vitro, Biomaterials, 32: 1002-9. 
Zeisberg, E. M., and R. Kalluri. 2010. Origins of cardiac fibroblasts, Circ Res, 107: 
1304-12. 
Zeisberg, E. M., O. Tarnavski, M. Zeisberg, A. L. Dorfman, J. R. McMullen, E. 
Gustafsson, A. Chandraker, X. Yuan, W. T. Pu, A. B. Roberts, E. G. Neilson, M. H. 
Sayegh, S. Izumo, and R. Kalluri. 2007. Endothelial-to-mesenchymal transition 
contributes to cardiac fibrosis, Nat Med, 13: 952-61. 
Zhang, D., I. Y. Shadrin, J. Lam, H. Q. Xian, H. R. Snodgrass, and N. Bursac. 2013. 
Tissue-engineered cardiac patch for advanced functional maturation of human ESC-
derived cardiomyocytes, Biomaterials, 34: 5813-20. 
Zhu, J., G. Xiong, H. Fu, B. M. Evers, B. P. Zhou, and R. Xu. 2015. Chaperone 
Hsp47 Drives Malignant Growth and Invasion by Modulating an ECM Gene 
Network, Cancer Res, 75: 1580-91. 
Zimmermann, W. H., C. Fink, D. Kralisch, U. Remmers, J. Weil, and T. 
Eschenhagen. 2000. Three-dimensional engineered heart tissue from neonatal rat 
cardiac myocytes, Biotechnol Bioeng, 68: 106-14. 
Zimmermann, W. H., Didie, M., Wasmeier, G.H., Nixdorff, U., Hess, A., 
Melnychenko, I., Boy, O., Neuhuber, W.L., Weyand, M., and Eschenhagen, T. 
Cardiac grafting of engineered heart tissue in syngenic 
rats. Circulation. 2002;106:I151–157. 
Zimmermann, W.H., J. Hudson, and M. Tiburcy. 2015. "A method to direct 
differentiation of pluripotent stem cells into functional heart muscle." In.: Google 
Patents. 




A1. Supplement data 
mCM  (only) EHM-formation (days)























































Figure S1. Advanced mCM maturation in cFB-supplemented EHMs. (A) EHMs generated with 
mCMs formed a spongy-like tissue with immature mCMs (n=35 in total). Single CMs stayed isolated 
with no tendency to form a functional syncytium, as indicated by the rounded shaped CMs (α-actinin: 
green). (B) The lack of tissue formation could not be rescued by using FB-conditioned medium or 
additional supplementation of growth factors and matrix components via Matrigel (n=8). (C) 
Supplementation of cFBs (25 % of total EHM composition) facilitated the formation of the typical 
EHM ring structure (n=67 in total). mCMs developed into tightly packed and longitudinally orientated 
muscle bundles. (D) Forces of contraction from cFB-supplemented EHMs, analysed by concentration 
response measurements under increasing extracellular Ca
2+
 (n=4). (E) qPCR analysis of α-MHC to β-
MHC transcript ratio in 2D differentiated and 3D (EHM) matured mCMs of the same age (day 22). In 
addition, heart samples from fetal (f), neonatal (n) and adult (a) mice were analysed. *p<0.05 EHM (3D 
matured) vs. (2D matured; n=4/group). Green: F-Actin; Scale bars: 20 µm. (Data taken from Christalla 





































Figure S2. Validation of Anti-Integrin alpha 1 antibody for immunoblotting analysis in human 
samples. The Rabbit Polyclonal Anti-Integrin alpha 1 antibody (ab106267; Abcam) was tested on 
human FB populations (hcFB and hFFB) and purely enriched hCM populations (15ug sample; 
n=3/group), according to the manufacturer‟s recommended concentration and conditions. The predicted 
molecular weight band size of ITGA1 is 131 kDa (according to the manufacturer‟s information), 
however immunoblotting analysis revealed non-specific bands in all samples. Strong signals were 
detected at around 40 kDa, in addition to fainter bands between; 100-125 kDa, around 180 kDa, and 
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A2. Reagents and medium 
 
Buffers for neonatal rat heart isolation: 
 
For making CBFHH solution, the following stock solutions were prepared:   
 
NaCl    200 g/L autoclaved 58.44 g/mol  
KCl    40 g/L  autoclaved 74.56 g/mol 
MgSO4xH2O   20 g/L  autoclaved 246.48 g/mol 
KH2PO4   6 g/L  autoclaved 136.09 g/mol 
Na2HPO4x2H2O  5.97 g/L autoclaved 177.99 g/mol 
Glucose (dehydrated)  100 g/L filtered  180.16 g/mol 
HEPES (Sigma)  47.66 g/L filtered  238.3 g/mol 
 
 
Calcium and Bicarbonate-free Hanks with HEPES (CBFHH)-buffer solution 
 
810 ml  H20 (sterile) 
40 ml  NaCl (stock)  
10 ml  KCl (stock) 
10 ml  MgSO4xH2O (stock)  
10 ml  KH2PO4 (stock)  
10 ml  Na2HPO4x2H2O (stock) 
10 ml  Glucose (stock)  
100 ml  HEPES (stock)  
 
The pH was adjusted to 7.4 with 1 mol/L NaOH, sterile filtered (0,22 µm) and stored 
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Trypsin-stock solution (50X) 
 
Dissolve trypsin (Trypsin certified 1:250 crude, Difco
TM
, BD Biosciences, #0153-15-
9; 100 g) in CBFHH (100 mg/ml). Concentrated stocks were sterile filtered (0.22 
µm), aliquoted and stored at -20 °C. 
 
DNase I-stock solution 
 
DNase I,type V (from bovine spleen, Sigma #D8764) was dissolved in sterile H20 (1 
mg/ml). Concentrated stocks were sterile filtered (0.22 µm), aliquoted and stored at -




0.5 ml   P/S (100X ; Gibco) 
1.3 ml   Trypsin stock (50X) 
0.2 ml   DNase I stock  
 




0.5 ml   P/S (100X; Gibco) 
1.7 ml   Fetal Bovine Serum (FBS) (Gibco, 10270) 
0.2 ml   DNase I stock 
0.5 ml   Trypsin stock (50X)  
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Reagents and medium for cell culture: 
 
Accutase digestion solution 
Accutase solution (Millipore, SCR005) 
0.125 % Trypsin (1:20 dilution from Trypsin 2.5 % stock [Gibco, 15090-046]) 
20 µg/ml DNase I 
 
Activin A stock solution 
Dissolve Activin A (338‐AC, R&D systems) according to manufactures protocol to 
obtain a stock concentration of 10 µg/ml. 
 
bFGF stock solution 
Dissolve bFGF (130‐093‐841; Stemgent) according to manufacturer‟s protocol to 
obtain a stock concentration of 10 μg/ml. Aliquot into sterile microfuge tubes and 
store at -20 °C. 
 
BMP4 stock solution 
Dissolve BMP4 (314‐BP, R&D systems) according to manufactures protocol to 
obtain a stock concentration of 10 µg/ml. 
 
Cardiac Specification medium  
Serum free monolayer differentiation medium 
5 µmol/L IWP4 
Medium containing grow factor supplements are prepared fresh, prior to use.  
 
CHIR stock solution 
Dissolve CHIR (04‐0004, Stemgent) in DMSO to obtain a stock concentration of 10 
mmol/L. 
 
Collagenase I solution 




)  and 
10 ml FBS (10270 Gibco) . Stock solution was sterile filtered, aliquoted and store at -
20 °C. 
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Differentiation medium 
500 ml Iscove‟s MEM (F0465, Biochrom) 
120 ml FBS 
6 ml L-Glutamine 
6 ml MEM-NEAA  
6 ml P/S 
4.34 μl 2-ß-Mercaptoethanol 
0.2 mM (43 mg) L-ascorbic acid 2-phosphate salt (Sigma, A8960). 
 
EDTA Solution (0.5 mmol/L) 
Add 500 μl of the 0.5 mol/L EDTA stock solution (pH 8.0), to 500 ml of 1X PBS 
14190; Invitrogen), containing 0.45 g NaCl. Sterile filter (0.22um), aliquot and store 
at 4 °C for 6 months. 
 
Freezing medium 
90 % FBS 
10 % DMSO (276855, Sigma Aldrich) 
Cell pellets were resuspended in FBS, followed by the addition of DMSO. Cell 
suspensions were distributed into cryovial (ml/vial and transferred into a isopropanol 
insulated container, prior to cryopreservation at either -80 or -152 °C. 
 
HFF medium 
500 ml DMEM (42430, Invitrogen) 
88.8 ml FBS 
3 ml P/S 
 
hESC medium 
500 ml KO-DMEM (10829-018, Invitrogen) 
128.2 ml KOSR (10828028, Invitrogen) 
6.4 ml L-glutamine  
6.4 ml MEM NEAA  
Add 10 μl of bFGF stock solution into 10 ml of hESC medium (final bFGF 
concentration: 10 ng/ml) per 100 mm hESC culture plate.  
 
 
Appendix (A2. Reagents and medium) 
146 
IWR1 stock solution 
Dissolve IWR1 (I0161, Sigma) in DMSO to obtain a stock concentration of 5 
mmol/L. 
 
IWP4 stock solution 
Dissolve IWP4 (04‐0036, Stemgent) in DMSO to obtain a stock concentration of 5 
mmol/L. 
 
Maturation medium  
Serum free monolayer differentiation medium 
 
MEF medium 
500 ml DMEM (high glucose, GlutaMAX
TM
) (61965026, Gibco) 
120 ml FBS 
6 ml MEM NEAA  
6 ml P/S 
 
mESC medium 
500 ml DMEM (high glucose, no pyruvate, 25 mmol/l HEPES) (42430025, Gibco)  
92 ml FBS  
6.2 ml L-Glutamine (200 mmol/L; 25030-024, Invitrogen) 
6.2 ml MEM-NEAA (10 mmol/L; 11140-050, Invitrogen) 
6.2 ml Nucleoside mix (100X)* 
5 ml Sodium Pyruvate (100 mmol/L; 11360-039, Invitrogen) 
6.2 ml Penicillin and Streptomycin (P/S: 5.000 U/ml and 5 mg/ml; 
15070-063, Invitrogen) 
4.34 μl 2-ß-Mercaptoethanol (31350-010, Sigma) 
62 μl Leukemia inhibitory factor (LIF) 10
7
 U/ml  
 
*Nucleoside mix (100X) 
Adenosine 30 μmol/L 
Guanosine 30 μmol/L 
Cytidine 30 μmol/L 
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Uridine 30 μmol/L 
Thymidine 10 μmol/L 
 
Mesoderm Induction medium  
Serum free monolayer differentiation medium 
5 ng/ml BMP4 
9 ng/ml Activin A 
5 ng/ml bFGF  
1 µmol/L CHIR  
Medium containing grow factor supplements are prepared fresh, prior to use.  
 
Serum free monolayer differentiation medium 
500 ml RPMI 1640 with GlutaMAX™ (61870, Invitrogen) 
5 ml Sodium Pyruvate  
5 ml P/S 
All reagents are thoroughly mixed and stored at 4 °C for 2 weeks. 2% B27 
supplement (17504‐044, Invitrogen) is added prior to use. 
 
Selection medium  
49.15 ml RPMI 1640 [-glucose, -glutamine] (01-101-1A; Biological Industries/WKS 
Labordiagnostik,) 
0.25 ml sodium lactate (71723, Sigma) [Final concentration: 2.2 mmol/L] 
0.5 ml P/S 




Make up TeSR™-E8 medium (05940, StemCell Technologies) according to 
manufacturers protocol, including 1% P/S. 
 
10X DMEM 
669 mg DMEM powder (52100-039,Invitrogen) dissolved in 5 ml sterile H20. 
Filter the solution through a 0.22 μm syringe filter. Stored at 4 °C for 1-2 months. 
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2X DMEM 
1 ml   10X DMEM 
120 ml  FBS 
100 μl   L-glutamine  
100 μl   P/S  
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Reagents and solutions for isometric force measurements: 
 
For making Tyrode‟s working solution, the following stock solutions were prepared:   
 
CaCl2 stock (2.25M) 
165.57 g  CaCl2 x 2H2O (MW = 147.02) 
500 ml  ddH2O 
 
MgCl2 stock (1.05M) 
106.83 g  MgCl2x6H2O (MW = 203.01) 








]:   1.8 mM  0.4 mM  0.2 mM 
 
NaCl (MW=58.44):   175 g   175 g   175 g 
KCl (MW=74.56):   10 g  10 g  10 g 
CaCl2 stock (2.25 M):  20 ml  4.44 ml  2.22 ml 
MgCl2 stock (1.05 M):  25 ml   25 ml  25 ml 
Fill with ddH2O:   1000 ml 1000 ml  1000 ml 
 
Stock II 
50 g   NaHCO3 (MW=84.01) 
1000 ml  ddH2O  
 
Stock III 
5.8 g   NaH2PO4 (MW=137.99)  
1000 ml  ddH2O  





Appendix (A2. Reagents and medium) 
150 
Tyrode‟s Working Solution 
 
Stock I:   40 ml  80 ml  120 ml  200 ml 
Stock II:   38 ml  76 ml  114 ml  140 ml 
Stock III:   10 ml  20 ml  30 ml  50 ml 
Glucose:   1 g   2 g   3 g   5 g 
Ascorbic acid:  50 mg  100 mg  150 mg  250 mg 
ddH2O:   1 L   2 L  3 L  5 L 
 
Prior to isometric force measurements, Tyrode‟s working solutions were mixed (as 
indicated above), dissolved thoroughly and poured into thermostatted force transducer 





6X Laemmli loading buffer 
3 ml  Tris-HCL 0.5 M (pH 6.8)     
0.75 ml Bromophenol blue  (0.5 %)        
1.2 g  SDS                                          
1.5 ml  Glycerin (100 %)                      
Fill to 9 ml ddH2O    
Aliqout 900 µl into tubes. Add 150 µl 2-ß-Mercaptoethanol  and store at -20 °C until 
use.  
 
0.5 M Tris-HCL pH 6.8 
30.28 g  Tris-HCl 
400 ml  H2O 
Adjusted to pH 6.8 and topped up to 500 ml ddH2O. 
 
1.5 M Tris-HCL pH 8.8 
90.85 g  Tris-HCl 
400 ml  ddH2O 
Adjusted to pH 8.8 and topped up to 500 ml H2O. 
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SDS-PAGE gel preparation 
 
Separating gel  
 
Volume (ml)  
(2 Gels) 
5% 6% 8% 10% 12% 15% 18% 
 KDa 220-60 150-50 105-40 90-25 60-20 45-10 40-4 
H2O 5,6 5,3 4,6 4,0 3,3 2,3 1,3 
30 % Acrylamide 1,7 2,0 2,7 3,3 4,0 5,0 6,0 
1,5 M Tris pH 8,8 2,5 2,5 2,5 2,5 2,5 2,5 2,5 
10 % SDS 0,1 0,1 0,1 0,1 0,1 0,1 0,1 
10 % APS 0,1 0,1 0,1 0,1 0,1 0,1 0,1 





ml 4 gels 2 gels 
H2O 5,6 2,8 
30 % Acrylamid 0,85 1,7 
0,5 M Tris pH 6,8 2,5 1,25 
10 % SDS 0,1 0,05 (50ul) 
10 % APS 0,1 0,05 (50ul) 
TEMED 0,01 0,005 (5ul) 
 
 
PVDF membrane preparation 
 
PVDF membranes were immersed in 100 % Methanol for 10 seconds. Next, 
membranes were washed in ddH2O for 5 minutes and placed in transfer buffer and 
allowed to equilibrate for 10 minutes. Thereafter, PVDF membranes were activated 
for SDS gel blot transfers. 
 
10X Transfer Buffer 
60.5 g  Tris-Base 
288 g   Glycine 
Dissolve thoroughly in 2 L ddH2O. 
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1X Transfer Buffer  
200 ml  10x Buffer 
400 ml  Methanol 
Adjusted to 2 L ddH2O. 
 
Ponceau S Solution  
Ponceau S-solution (Applichem) is used neat for staining of western blot membranes. 
Membranes were incubated in Ponceau-S solution for 1-5 minutes in RT and then 
rinsed with ddH2O until the membrane background turned white and the stained 
bands were clearly contrasted. After image documentation, the ponceau S stains were 
rinsed away in TBST. 
 
10X TBS stock solution 
121.14 g  Tris-Base 
175.32 g NaCl 
Add all reagents and 1.5 L of ddH2O in a suitable glass beaker and mix until all 
reagents were dissolved. Equilibrate the solution with fuming HCl till pH 7.5, then fill 
up to 2 L with ddH2O. 
 
1X TBS solution 
100 ml  10x TBS 
900 ml  H2O 
1 ml   Tween 20 
Mix all reagents until they dissolve. Tween 20 is extremely viscous and requires 
approximately 10 – 15 minutes to dissolve completely. 
 
10X Electrophoresis (Running) Buffer (pH 8.3 -8.7) 
60.6 g   Tris- Base 
288 g   Glycine 
20 g   SDS 
Dissolve all reagents in 1 L ddH2O and topped up to 2 L ddH2O and mix thoroughly. 
During gel electrophoresis, 1: 10 ml dilution with ddH2O is prepared fresh, to obtain 
1X running buffer. 
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DNA Gel Electrophoresis: 
 
50X TAE 
242 g   Tris-Base 
100 ml  EDTA (0.5M pH 8.0) 
57.1 ml  Glacial Acetic Acid 
Dissolve first in 800 ml, pH 8.5 adjusted and fill up to 1 L H2O. Gel electrophoresis 
run is diluted 1 : 50 to obtain 1X TAE gel running buffer prior to use. 
 
1.5 % Agarose gel 
1.5 g of agarose powder (Applichem) is dissolved in 100 ml 1XTAE buffer and 
boiled to obtain a 1 % agarose gel solution. Following cooling of the solution, 0.2 
μg/ml ethidium bromide (EtBR) is added and swirled to obtain a homogenous 
solution. The solution is then poured into a casting tray with appropriate combs and 
allowed to solidify. 
 
6X DNA loading buffer (2 coloured) 
75 mg   Bromophenol-Blue 
25 mg  Xylene cyanol 
100 ml  Glycerol (30 %) 
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Reagents for Immunohistochemistry/Flow cytometry: 
 
Blocking (permeabilization) Buffer 
500 ml 1X PBS (0.05 M, pH 7.4, Invitrogen) 
25 ml FBS 
5 g Bovine Serum Albumin (BSA) (Sigma, A3311) 
2.5 ml Triton X-100 (Sigma, T8787) 
All reagents are mixed together thoroughly. Triton X-100 is viscous and 
requires constant stirring to dissolve. Blocking buffer can be aliquoted and 
stored at -20 °C. 
 
 
